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Abstract 
The genus Streptomyces is known to be responsible for the production of more than 
two-thirds of the world’s antibiotics, through complex specialised metabolic 
pathways. However, given the high frequency of rediscovery of known antibiotics and 
the challenge of producing novel analogues via chemical synthesis, biosynthetic 
engineering has emerged as an attractive approach to optimising antibiotic natural 
products for clinical use. This technique utilises enzymes from antibiotic biosynthetic 
pathways to create novel antibiotic derivatives. However, its application requires an 
understanding of how antibiotics are biosynthesised.  
This work is focused on the methylenomycin antibiotics produced by Streptomyces 
coelicolor A 3 (2), a model Actinobacterium. The cluster of genes directing 
methylenomycin production and its regulation are carried on the giant linear plasmid 
SCP1. The sequencing of the entire 356-kb SCP1 plasmid allowed bioinformatics 
analyses to be applied to the assignment of putative roles in methylenomycin 
biosynthesis for several of the enzymes encoded within the methylenomycin 
biosynthetic gene cluster. However, experimental evidence to support the proposed 
roles of several of these enzymes has yet to be obtained, while the roles of some of 
the proteins encoded by the cluster remain unclear.  
Here, work towards understanding the biosynthesis as well as the mode of action of 
the methylenomycin antibiotics is reported. In particular, the roles of MmyO and 
MmyF in the epoxidation of methylenomycin C to produce methylenomycin A are 
demonstrated via feeding of methylenomycin C to a methylenomycin-resistant 
derivative of S. coelicolor M145 expressing mmyO and mmyF. A putative butenolide 
intermediate in the pathway, believed to derive from a MmyD-catalysed condensation 
of acetoacetyl-MmyA with a pentulose, was identified in S. coelicolor strains 
expressing the methylenomycin biosynthetic gene cluster. The pattern of 
incorporation of [U-13C]-D-ribose into the putative butenolide intermediate was 
similar to that observed for methylenomycin C, indicating the former could indeed be 
a precursor to the latter.  
A putative intermediate of the pathway, pre-methylenomycin C, accumulating in a 
mmyE mutant strain, and its lactone form, pre-methylenomycin C lactone, were shown 
to be 16 and 256 times, respectively, more potent than methylenomycin A, against 
methicillin-resistant Staphylococcus aureus (MRSA). Expression of the 
methylenomycin resistance determinant (mmr) in Streptomyces species also confers 
no resistance against these two putative intermediates unlike methylenomycin A, the 
final antibiotic product of the pathway. Investigations into the mechanism of action 
of methylenomycin antibiotics with luciferase and β-galactosidase pathway-specific 
promoter-reporter fusion strains strongly suggest that the methylenomycins exert their 
antibiotic effects in bacteria primarily by targeting the biosynthesis of cell wall 
peptidoglycan, consistent with their activities mainly against Gram-positive strains. 
This is the first report of the mode of action of methylenomycin family of antibiotics. 
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CHAPTER ONE 
1. INTRODUCTION  
1.1 Antibiotics and their importance in medicine 
The term antibiotic literally means ‘against life’. It was first employed in biological 
abstracts in 1943 shortly after it was defined by Selman Waksman as a chemical 
substance produced by a microorganism and which, in dilute solutions, has the 
capacity to kill or inhibit the growth of other microorganisms.1 This definition, 
although originally intended for substances isolated directly from microbial sources, 
is now also commonly used to refer to antimicrobial products of plant origin, those 
modified chemically after being isolated from microorganisms, and those produced 
via total chemical synthesis. 
The first true antibiotic, penicillin (1) from Penicillium notatum (Fig.1.1), was 
discovered by Alexander Fleming in 1928, and was subsequently developed into a 
drug in the 1940s by Chain and co-workers.2-4  That development revolutionised the  
 
           
                                                 
 Fig.1.1: Structure of penicillin G (1) and some of its derivatives.  
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practice of medicine as many hitherto untreatable and deadly infectious diseases 
caused by Streptococcus and Staphylococcus strains were rapidly and effectively 
treated. Since then, the use of antibiotics in medicine has become widespread and 
almost indispensable. An estimated 100,000 to 200,000 tons of antibiotics are 
believed to be consumed world-wide on an annual basis.5 A significant portion of 
these are used in veterinary medicine and agriculture for the treatment and prevention 
of infectious diseases, and as growth-promoting agents.6,7 
The success and the excitement elicited by the introduction of penicillin prompted the 
search for substances with similar properties from a variety of sources. 
1.2 Antibiotic producers 
1.2.1 Actinobacteria are prolific producers of antibiotics and other bioactive 
compounds 
Bacteria are broadly classified into two groups based on their response to a staining 
procedure developed by Christian Gram over a hundred years ago. The response 
reveals an underlying structural difference in the cell envelope of the two groups, with 
those retaining Gram’s stain classified as Gram-positive while those that do not are 
termed Gram-negative.8 The Gram-positive bacteria further include two major 
branches- those whose genomes contain a low percentage of Guanine and Cytosine 
(G + C), including the Staphyloccocus, Bacillus and Streptococcus genera; and those 
with a high G + C content, referred to as the Actinobacteria.9  
Actinobacteria have been a very important source of bioactive natural products, 
including antibacterial, antifungal, antiviral, anti-hypertensive, antitumor, and 
immunosuppressant drugs.10-12  This class of bacteria comprises a wide range of 
organisms, differing considerably in physiology, biochemistry, morphology and 
phylogeny. They range in morphological appearance from unicellular spheres, rods 
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and coccoids; to those with fragmenting hyphae and highly differentiated branched 
mycelium.13-15 Actinobacteria consists of five orders: Actinomycetales, 
Bifidobacteriales, Acidimicrobiales, Coriobacteriales, and Rubrobacterales, based on 
16S rRNA gene sequence comparisons.35 The Actinomycetales order is further 
divided into 13 suborders of Actinomycineae, Actinopolysporineae, Streptomycineae, 
Micromonosporineae, Catenulisporineae, Corynebacterineae, Frankineae, 
Glycomycineae, Kineosporineae, Micrococcineae, Propionibacterineae, 
Pseudonocardineae, and Streptosporangineae.16,35  
Of particular relevance to the current study is the suborder Streptomycineae which 
has only one family (Streptomycetaceae), subdivided into ten genera: Streptomyces, 
Streptoverticillium, Actinopycnidium, Actinosporangium, Chainia, 
Elytrosporangium, Kitasatoa, Kitasatospora, Microellobosporia, and 
Streptacidiphilus.35, 36 Of the genera under the Streptomycetaceae family, and in fact 
the entire Actinobacteria class, the contribution of the Streptomyces genus to the 
discovery of antibiotics cannot be over-emphasized. Streptomyces produce over 70% 
of antibiotics in clinical use today, either directly or as structurally – modified 
derivatives.12,17-19 This productively unique group of bacteria mostly inhabit the soil 
and possess a characteristic earthy smell. Some species have also been found to exist 
in symbiotic relationships with plants, a situation where the antibiotics produced by 
Streptomyces protect the plant against invasion by disease agents while the 
Streptomyces benefit from nutrients coming from the plant’s exudates.9, 12, 26 
Streptomyces exhibit a complex life cycle which reflects their adaptation to the soil 
and other environments. Single spores often germinate and grow into vegetative 
mycelium which further develops into branched aerial hyphae in a manner similar to 
moulds.20-23 This enhances their ability to attach to, penetrate, and feed on plant and 
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invertebrate tissues in the soil via the secretion of cellulase and xylanase enzymes.20 
Depletion of nutrients within a given growth area leads to the formation of spores, 
enabling survival outside of the dead tissues and also serving as a means of dispersal 
or reproduction.20, 22, 23 The onset of spores formation is also believed to coincide with 
specialised metabolite (e.g. antibiotic) production in many species of Streptomyces 
(Fig. 1.2).24, 25 
 
(A)  
                                 
 
 
 
 
 
 
 
 
 
 
Fig. 1.2 (A): Aerial hyphae growth in Streptomyces species is temporally coupled to antibiotic 
production (Chater 20). The antibiotic (in pink) protects the nutrients underneath from invasion 
by other microbes while ensuring a continued supply of the nutrients to the producer (B) 
Streptomyces coelicolor M145 sporulating on soya flour mannitol medium, SFM (Image 
obtained from the present study). 
The first antibiotic to be isolated from Streptomyces, streptomycin (2) from S. griseus, 
was discovered by Selman Waksman in 1943, 27, 28 and soon became an effective drug 
for the treatment of tuberculosis. Researchers in the field of natural product discovery 
thus developed an interest in Streptomyces as sources of bioactive compounds and 
their efforts were handsomely rewarded with the discovery and introduction of many 
more antibiotic compounds with wide-ranging structural                
(B) 
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Fig. 1.3: Representative specialised metabolites produced by Streptomyces species. 
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Fig. 1.4: Timeline of bioactive natural products discovery. The list (although not exhaustive) 
is intended to show the frequency of antibiotics discovery from Streptomyces species (in blue) 
compared to other sources. Cephalosporins were first discovered from Acremonium 
chrysogenum (formerly classified as Cephalosporium)44,45; penicillin was also first obtained 
from Penicillium notatum in 1928.2,3  
 
features. Notable among the clinically used antibiotics produced by Streptomyces 
species are chloramphenicol (3) from S. venezuelae, chlortetracycline (4) from S. 
aureofaciens and daptomycin (5) from S. roseosporus.29-34 Streptomyces species also 
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produce cephalosporins, noviobiocin, kanamycin (6), avermectin (7), fosfomycin (8), 
and lincomycin (9) (see Figs 1.3 and 1.4). It is noteworthy that Satoshi Omura and 
William Campbell were jointly awarded half the 2015 Nobel prize in medicine for 
their roles in the discovery and development of avermectin/ ivermectin, an important 
antiparasitic agent.271 
Despite numerous modern genome-driven and molecular biology-inspired approaches 
for the discovery of novel Streptomyces specialised metabolites (section 1.5), new 
isolates of the genus from the environment also continue to contribute to the discovery 
of new antibiotics. Particularly noteworthy is the isolation of two antibiotic-producing 
endophytic Streptomyces spp. NRRL 30562 and NRRL 30566 in the Northern part of 
Australia. The former produces a family of antibiotics called the munumbicins while 
the later produces a quinoxaline group of antibiotics with highly potent activity 
against Gram-positive strains as well as the malarial parasite (Plasmodium 
falciparum). 37,38  These findings suggest that endophytic Streptomyces, and indeed 
other as yet unisolated Streptomyces species from various underexplored 
environmental niches, still offer some promise for the discovery of novel antibiotic 
scaffolds with potential therapeutic applications. This view is further underscored by 
the discovery of platensimycin (produced by Streptomyces platensis isolated from 
South Africa), introducing a unique structural class of antibiotics possessing an amino 
– dihydroxyl - benzoic acid moiety joined via an amide bond to a pentacylic terpenoid 
(Fig. 1.5). 39, 40 
                                 
 Fig.1.5: Structure of platensimycin (10), an antibiotic discovered in 2006 from S. platensis.  
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1.2.2 Other sources of antibiotics  
The accidental discovery of penicillin from Penicillium notatum by Fleming did not 
mark the end of the road for fungi in terms of the discovery of antibacterial and other 
therapeutic natural products. Indeed, fungi account for an estimated 38 % of all 
bioactive compounds derived from microbial sources (unicellular bacteria, 
filamentous Actinomycetales and eukaryotic fungi).41 Cephalosporins are another 
important group of antibiotics obtained from fungi (Fig.1.6). They were originally 
found to be produced by the fungus Acremonium chrysogenum (formerly called 
Cephalosporium acremonium)  and are structurally related to penicillin due to the 
presence of a beta-lactam ring.42-45 Fusidic acid, which has broad-spectrum activity 
against Gram – positive bacteria, was also obtained from a fungus (Fusidium 
coccineum) and has activity against most Gram-positive strains.46, 47 It has been 
widely used topically in creams and dermatological products,48, 49 as well as in the 
clinic for the treatment of systemic infections caused by methicillin-resistant 
Staphylococcus aureus (MRSA).50 
  
Fig 1.6: Structures of cephalosporin C and fusidic acid, antibiotics produced by fungi that 
were discovered after penicillin.  
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Apart from the prolific Actinobacteria, other groups of bacteria, especially 
Pseudomonas, Cyanobacteria and Bacillus, are known to produce an estimated 3,800 
bioactive compounds, representing 17% of the bioactive natural products obtained so 
far from microbial origin (Table 1.1).41  Mupirocin,51 noscomin,52 and bacitracin 53 are 
notable examples of antibiotics produced by these three groups respectively.  
 
Table 1.1: Estimated number of antibiotics and other bioactive specialised metabolites 
from microbial origin (Adapted from Berdy 41) 
          
Source Antibiotics 
Other 
bioactive Total bioactive     Used in 
    metabolites metabolites human therapy 
Other bacteria 2900 900 3800 8 - 10 
Actinobacteria 8700 1400 10100 70 - 75 
Fungi 4900 3700 8600 13 - 15 
     
Total 16500 6000 22500 91 - 100 
     
 
Interestingly, antibiotic production is not restricted to microorganisms. Almost all 
forms of life have been reported to produce antimicrobials and other bioactive 
compounds. These include higher plants, invertebrates, worms, insects, fishes, 
reptiles, birds and mammals.41 Unlike the compounds from bacteria and fungi, many 
of the products from the higher life forms have, however, not found applications in 
human or veterinary medicine.  
1.3 Antibiotic classes and modes of action  
Antibiotics exert their bacteriostatic or bactericidal effects on pathogens through a 
wide range of mechanisms. Antibiotics target and disrupt essential functions in 
bacterial cells. However, in order to be useful in the clinic, they must have no adverse 
effect on humans. Thus, based partly on their sources and chemical structures, and 
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more importantly, on the cellular functions which they disrupt, antibiotics can be 
classified as highlighted below. 
1.3.1 Antibiotics inhibiting bacterial cell wall biosynthesis  
Antibiotics in this class disrupt different stages of the biosynthesis of peptidoglycan, 
a key component of the bacterial cell wall otherwise known as murein (Mur). 
Peptidoglycan is a polymer consisting of repeating disaccharide units comprising N-
acetyl-glucosamine (GlcNAc) and N-acetyl muramic acid (MurNAc), which are 
cross-linked by short peptides.54,55 The initial step in peptidoglycan biosynthesis is the 
conversion of UDP-GlcNAc to UDP-MurNAc through the actions of MurA and 
MurB. The UDP-MurNAc is then modified with a pentapeptide through the activities 
of the ligase enzymes (MurC,D,E,F) which sequentially add L-Ala, D-Glu, Dmp 
(diamino-pimelic acid), and D-Ala-D-Ala to give the hydrophilic product UDP-
MurNAc pentapeptide.56,57 This intermediate is linked by MraY to a poly-isoprenoid 
lipid carrier (undecaprenyl phosphate; C55-P) to form lipid I, facilitating its export 
from the cytoplasm.56,57  
Once lipid I is associated with the membrane, MurG (a membrane-associated glycosyl 
transferase) adds GlcNAc derived from UDP-GlcNAc to the developing precursor and 
leads to the formation of lipid II, regarded as the full monomer of peptidoglycan.54,56 
The lipid II is then translocated across the membrane to the extracellular surface where 
it serves as substrate for enzymes that polymerise it to form a linear peptidoglycan 
chain via transglycosylation, and cross-link adjacent polymers through the 
pentapeptide chains, thus incorporating newly biosynthesized polymers into the 
existing murein network (transpeptidation).57-59  
Beta-lactam antibiotics, such as penicillins, cephalosporins and carbapenems, disrupt 
cell wall biosynthesis by irreversibly inhibiting the enzymes involved in 
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transpeptidation, the so-called penicillin binding proteins (PBPs), thereby preventing 
cross-linking of peptide side chains, ultimately leading to cell lysis.60-62 Resistance to 
these antibiotics involves enzymatic cleavage of the beta-lactam by beta-lactamases.63 
Resistance to beta-lactam antibiotics may also occur by modification of the active site 
of the PBPs.61 
The glycopeptide antibiotics (vancomycin and teicoplanin) exert their antibacterial 
action at the point of transglycosylation (scheme 1.1). Once the lipid II is translocated 
to the extracytoplasmic membrane, these compounds bind to its D-Ala- 
 
 
 
 
Scheme 1.1: Overview of the steps in peptidoglycan biosynthesis. The point of action of 
tunicamycin 67, ramoplanin 68, bacitracin 69, glycopeptides and beta-lactams are indicated.  
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D-Ala terminus forming a stable and non-covalent complex. This sterically hinders 
the action of the peptidoglycan polymerases which are not able to transglycosylate the 
bulky antibiotic-substrate complex.64-66 
Other antibiotics exist which interfere with earlier stages of peptidoglycan 
biosynthesis. The points of action of some of these antibiotics are also illustrated in 
scheme 1.1. 
 
1.3.2 Antibiotics inhibiting DNA replication 
Notable antibiotics inhibiting DNA replication in bacteria include the quinolones 
(particularly norfloxacin and ciprofloxacin, the clinically used fluorinated quinolone 
derivatives) and metronidazole. The quinolones act by inhibiting DNA gyrase and 
DNA topoisomerase IV, two enzymes essential for DNA replication. DNA gyrase 
controls DNA supercoiling, while topoisomerase IV functions in the separation of 
interlinked daughter chromosomes following DNA replication.70 Normally, DNA 
gyrase functions by introducing a double-strand break into a region of duplex DNA 
and passing another region of duplex DNA through the break before rejoining the 
broken strands.70,71  However, in the presence of a quinolone antibiotic, the DNA-
bound gyrase is trapped as soon as the double strand break is generated, thereby 
preventing it from resealing the broken strands (Fig. 1.7). This causes damage to DNA 
by generating permanent double strand breaks, ultimately leading to cell death.70,71 
Topoisomerae IV is a homologue of DNA gyrase and uses a similar mechanism of 
double-strand breaking and passing of duplex DNA.72,73 Resistance to quinolone 
antibiotics is associated with mutations in the gyrA and gyrB subunits of the DNA 
gyrase,70 thereby preventing interaction with quinolones. 
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Fig. 1.7: Schematic representation of the interruption of gyrase action by a quinolone 
antibiotic: (a) DNA gyrase (in blue) binds DNA before strand passage (b) Gyrase undergoes 
a conformational change and DNA gate is opened via double-strand break. Another region of 
the same DNA molecule (shown in cross section as DNA strand) moves close to the DNA 
gate (c) Quinolone traps DNA gyrase and disrupt strand passage. This prevents the resealing 
and repair of the broken DNA that should occur at (d). Redrawn from Drlica and Zhao.70 
 
In the case of metronidazole (a prodrug), the nitro-group of the compound is first 
reduced by an electron-transport ferredoxin pathway in anaerobic bacteria and 
protozoa. The reduced drug (a nitroso free radical) then binds non-specifically to 
bacterial DNA and causes high level DNA breakage and degradation (Fig. 1.8).74,75  
                                
Fig. 1.8: Schematic depicting the mode of action of metronidazole, an antibiotic inhibiting 
replication. Redrawn from Neu and Gootz.76 
  Chapter One - Introduction 
14 
 
1.3.3 Antibiotics inhibiting transcription 
There are many antibiotics that inhibit transcription in bacteria, including rifampicin, 
fidaxomicin, streptoglydigin, and myxopyronin.79 However, only rifampicin and 
fidaxomicin (Fig. 1.9) are used in the clinic. Rifampicin belongs to the rifamycin 
group of antibiotics produced by Amycolatopsis mediterranei.77 Like other 
rifamycins, it disrupts transcription by binding strongly to the DNA-dependent RNA 
polymerase, a complex enzyme with an α2, β, β’, ω subunit structure.77 Rifampicin 
acts at the transcription initiation stage by binding to the β subunit (Fig. 1.10), causing 
a conformational change that prevents the formation of phosphodiester bond, thereby 
blocking initiation of transcription or extension of a nascent RNA chain.77,78 
Resistance develops mainly due to mutation in the target polymerase and to a lesser 
extent by inactivation of the antibiotic.77  
Fidaxomicin was recently approved for the treatment of Clostridium difficile 
infections. It inhibits RNA synthesis by binding to the DNA template-RNA 
polymerase complex, thereby preventing the separation of template DNA strands,79 
an essential prerequisite for transcription initiation. 
 
 
 
Fig. 1.9: Structures of rifampicin and fidaxomicin. 
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Fig. 1.10: (A) Schematic showing the point of action of rifampicin (R) at the start of RNA 
synthesis, after the separation of template DNA strands (B) Representation of the Thermus 
aquaticus RNA polymerase-rifampicin complex (PDB 1I6V), showing interaction of the 
antibiotic with amino acids in the β-subunit.77,78 Residues depicted in dark ball and stick form 
interact with the antibiotic via hydrogen bonds (dashed lines); other residues interact via Van 
der Waals forces. 
 
1.3.4 Antibiotics inhibiting translation 
Many antibiotics target translation, owing to the nature and importance of this process 
in bacteria.80,81 Translation is catalysed by ribosome and involves four key steps: 
initiation, elongation, termination and recycling.82 Initiation step involves the 
R 
NTP-NTP-(NTP) 
nascent RNA 
DNA template 
(B) 
RNA polymerase 
(A) 
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formation of 70S ribosome from small (30S) and large (50S) ribosomal subunits, and 
the positioning of an mRNA start codon and an initiator tRNA at the P-site in the 70S 
ribosome. The elongation cycle is the most common stage of translation inhibited by 
antibiotics. This involves the delivery of an aminoacylated tRNA (aa-tRNA) to the A-
site of the ribosome by elongation factor Tu (EF-Tu). Peptide bond formation then 
occurs between the amino acid residues attached to tRNAs at the A and P-sites, 
causing the residue of peptide chain attached to the latter to be transferred to the 
former.82 The tRNAs in the P and A sites of the ribosome are then translocated into  
 
       
Fig. 1.11: Schematic depicting translation by the ribosome and the point at which various 
antibiotics disrupt the process. Ery (erythromycin), SB (streptogramin B), Tel 
(telithromycin), Stp (streptomycin), Tet (tetracyclines), Tig (tigecycline), Bls (blasticidin), 
Cam (chloramphenicol), Cln (clindamycin), Lnz (linezolid), Plu (pleuromutilins), Pmn 
(puromycin), SA (streptogramin A), Spr (sparsomycin), Cap (capreomycin), Vio (viomycin, 
41), HygB (hygromycin B), Neo (neomycin), Par (paromomycin), Fus (fusidic acid) and Spt 
(spectinomycin). Adapted from Wilson 2014.82  E-, P-, and A- sites refer to exit, peptidyl, 
and aminoacyl sites respectively. 
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Fig. 1.12: Structures of some antibiotics inhibiting translation.  
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the E and P sites, respectively, to provide room in the A-site for a new incoming aa-
tRNA, which is required for the next round of chain elongation.83 The mRNA is 
recycled, while the nascent polypeptide chain is released into the cytoplasm at 
termination. 
The points of action of various antibiotics targeting the elongation cycle during 
translation are illustrated in Fig. 1.11; the structures of some of these compounds are 
shown in Fig.1.12. As a specific example, viomycin (41) acts by stabilising the tRNA 
at the A-site in the ribosome, thereby preventing its translocation into the P-site and 
hindering the incoming aa-tRNA (i.e. blockage of translocation).84  
1.3.5 Antibiotics inhibiting fatty acid biosynthesis 
Fatty acids are important for the construction of bacterial membranes, and as 
component of the phospholipid bilayer.85 They are biosynthesised on an acyl carrier 
protein (ACP) by the successive action of discrete components enzyme of the fatty 
acid synthase (FAS): ketoacyl synthase (KS), ketoreductase (KR), dehydratase (DH), 
enoyl reductase (ER) and thioesterase (TE). In the first step of the biosynthesis, the 
ketoacyl synthase catalyses a decarboxylative condensation of a malonate with a 
starter acyl unit (usually an acetyl-CoA) to give an acetoacetyl-ACP (scheme 1.2). 
The β-keto group in this product is reduced by the ketoreductase, dehydrated by the 
dehydratase and finally reduced by the enoyl reductase to give a saturated chain longer 
than the starter acyl unit by two carbons. The cycle is repeated after the saturated chain 
is transferred to the ketosynthase, eventually leading to a chain of required length (14, 
16, or 18 carbons),118 which is finally hydrolysed by the thioesterase to give the free 
acid.  
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Notable antibiotics that inhibit fatty acid biosynthesis are thiolactomycin, triclosan 
and cerulenin, and the recently-discovered platencin (Fig. 1.13). Thiolactomycin 
mimics the malonate by forming strong hydrogen bond with histidine residues in the 
 
 
Scheme 1.2: Fatty acid biosynthetic cycle. ACP: acyl carrier protein; KS: ketoacyl synthase; 
KR: ketoreductase; DH: dehydratase; ER: enoyl reductase; TE: thioesterase. n is number of 
cycles. 
 
 
    
Fig. 1.13: Structures of some antibiotics inhibiting fatty acid biosynthesis in bacteria. 
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active site of the KS, FabB, thereby preventing the loading of malonate onto the 
enzyme.86 Triclosan similarly binds to the active site of enoyl-(ACP) reductase in the 
fatty acid synthase.87,88 Cerulenin inhibits the condensation step in fatty acid 
biosynthesis by reacting irreversibly with the active site cysteine residue in ketoacyl 
synthases.89,90 Platencin uniquely inhibit both FabF and FabH, respectively beta-
ketoacyl-ACP synthase II and III, thereby blocking chain elongation in fatty acid 
biosynthesis.91 
 
1.4 The need to discover and develop new antibiotics  
New antibiotics are required to find agents with improved pharmacological 
properties such as reduced toxicity, protection from rapid metabolism and 
excretion, and increased solubility and permeability.93,94 Of greater urgency, 
however, is the need to find antibiotics to combat the currently high incidence of 
resistance by disease-causing pathogens to almost all classes of antibiotics. 
Recently, the world health organisation (WHO) published a list of bacterial strains 
which pose the greatest threat to human health and for which antibiotics are 
urgently required. Top on this priority list are carbapenem-resistant Acinetobacter 
baumannii,  Pseudomonas aeruginosa and Enterobacteriaceae (e.g. Escherichia 
coli and klebsiella pneumonia); vancomycin-resistant Enterococcus faecium; and 
methicillin-resistant Staphylococcus aureus.92 These strains are collectively 
termed the ESKAPE pathogens. Also infamous in terms of antibiotic resistance is 
Mycobacterium tuberculosis.95, 96 
The traditional approach to discovering new antibiotics involves screening 
organisms from underexplored ecological niches for antimicrobial activity. 
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However, in recent years, this approach has frequently rediscovered known 
antibiotics rather than unveiling new ones.97 While it is not impossible that novel 
antibiotic scaffolds could still be discovered by exploring unusual ecological 
niches (for example, the growing interests in endophytic and marine 
actinomycetes),98-100 the techniques described in the following section are being 
proactively deployed to generate new antibiotics and other therapeutic agents. 
1.5 Approaches for generating new antibiotics and other bioactive compounds 
1.5.1 Exploitation of pathogen genomics to discover new antibiotic targets  
The sequencing of the genomes of many pathogenic organisms has made a wealth of 
information available about them which is being exploited to identify novel targets 
for antibiotics.113 Potential antibacterial targets are identified by bioinformatics and 
expression profiling of putative protein coding sequences. The essentiality of such 
coding sequences for cell survival is established via molecular genetic manipulation. 
Targets identified in this way are expressed and used in high-throughput screens for 
inhibitors, which are then tested for biological activity.114-116 Such target-based 
screening has been used by Pfizer to discover three novel antibacterial leads which 
progressed into clinical trials.117  
However, most of the compounds screened using this approach are often generated 
by total synthesis and very few antimicrobial leads are identified out of several 
thousands from library of compounds typically screened. Given that the majority of 
antibiotics which have found applications in the clinic are naturally-derived (see, for 
example,  Fig. 1.4), many other biological approaches are focused on generating 
analogues of natural antibiotics via rational manipulation of the producing strains, and 
by chemical modifications. 
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1.5.2 Biosynthetic engineering 
In biosynthetic engineering, enzymes from natural product biosynthetic pathways are 
harnessed to create novel antibiotic derivatives. For example, by developing an 
understanding of the enzymatic machinery for an antibiotic of interest,  it is possible 
to exploit the substrate promiscuity of certain biosynthetic enzymes to produce 
antibiotic derivatives via feeding of substrate analogues to the producing organism.105, 
106 The production of penicillin V by addition of phenoxyacetate to penicillin 
producing fermentations 107-109 is a classic example of this approach (Fig.1.14). It is 
also possible to purify key enzymes in a biosynthetic pathway, and use them to 
produce new antibiotic derivatives by incubation with analogues of  
 
 
 
Fig.1.14:(A) Isopenicillin-N-acyltransferase (IAT)-catalysed coupling of phenylacetyl-CoA 
with 6-aminopenicillinic acid to give penicillin G (1), the natural antibiotic (B) Production of 
penicillin V, an industrially important analogue of 1, by feeding phenoxyacetate as 
replacement for phenylacetyl-CoA during Penicillium chrysogenum fermentation. 
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intermediates in the pathway.110 Isopenicillin-N-synthase (IPNS) was used in this 
manner to generate a variety of penicillin analogues via incubation with various 
derivatives of the natural substrate, L-amino adipyl-L-cysteine-D-valine.110  
The technique of mutasynthesis is closely-related to the precursor-directed approach 
described above. In this case, the gene cluster for an antibiotic of interest is 
manipulated to block its biosynthesis. This may lead to the accumulation of 
biosynthetic intermediates which may possess antibiotic activity.  Synthetic analogues 
of early biosynthetic intermediates can also be fed to the blocked mutants, resulting 
in novel antibiotic analogues.111 Many applications of this approach, including to the 
vancomycin-type glycopeptides, have been reported.112 
Polyketides are another group of natural products whose analogues have been 
generated by biosynthetic engineering. They include erythromycin A (36), 
amphotericin B, lovastatin and rapamycin (Fig. 1.15). Polyketides are assembled by 
large multi-domain enzymes, the polyketide synthases (PKSs),  via condensation of 
simple precursors such as malonyl-CoA, propionyl-CoA and methylmalonyl-CoA, in 
a manner similar to the biosynthesis of fatty acids.248 
One of the most studied polyketide natural product is the antibiotic erythromycin A, 
whose polyketide backbone, 6-deoxyerythronolide B (6-DEB), is assembled by 6-
DEB synthase (DEBS). DEBS contains three bimodular polypeptides (DEBS 1, 
DEBS 2, and DEBS 3) which catalyse the biosynthesis of 6-DEB via stepwise 
decarboxylative Claisen condensation of a propionyl starter unit with six methyl-
malonyl extender units (as illustrated in Fig. 1.16A).249,269 A thioesterase domain at 
the C-terminal end of DEBS 3 then catalyses the release of the polyketide chain, with 
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concomitant macrolactone formation to give 6-DEB.249 This is then hydroxylated at 
C-6 position by a P450 hydroxylase to give erythronolide B, followed by attachment 
 
 
Fig. 1.15: Structures of some polyketide natural products. 
of sugar moieties (L-mycarose to C-3 hyrodxyl group and D-desosamine to C-5 
hydroxyl group). Further hydroxylation at C-12 and SAM-dependent methylation of 
the C-3 hydroxyl group of the mycarose unit will afford erythromycin A.250, 270  
Organisation of many PKSs into domains and modules has made them particularly 
amenable to genetic manipulations via domain inactivation or replacement with 
domains from other PKSs, leading to the generation of novel analogues of polyketide 
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natural products.248,267-268 This is exemplified by the substitution of the 
methylmalonyl-specific acyl transferase (AT) domain in DEBS module 2 with malo- 
 
Fig. 1.16: (A) Biosynthesis of 6-DEB, the polyketide backbone of erythromycin A (B) 
Representative analogues of 6-DEB generated by biosynthetic engineering: 37 was 
generated by replacing the AT2 domain in DEBS with rapamycin AT2; 38 was generated by 
replacing KR2 of DEBS with (KR and DH) from rapamycin module 4. 
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nyl-specific AT domain from rapamycin PKS, leading to 10-desmethyl-6DEB (37, 
Fig. 1.16B). Similarly, 10,11-anhydro-6-DEB (38) was generated by replacing the 
ketoreductase in DEBS module 2 with ketoreductase plus dehydratase from the 
rapamycin cluster.251 Loading modules may also be swapped between different  PKSs 
to alter the selectivity of the starter acyl units.250 These strategies have been used to 
generate numerous analogues of 6-DEB (and subsequently erythromycin), as well as 
analogues of many other polyketide natural products. 
1.5.3 Activation of silent biosynthetic gene clusters 
Microbial genome sequencing projects have led to the hypothesis that antibiotic-
producing organisms have the capability to biosynthesize more bioactive products 
than they are currently known to produce.122-124 For example, the S. coelicolor, S. 
avermitilis, S. venezuelae and  S. griseus genome sequences contain, respectively, 25, 
34, 31 and 34 specialised metabolite biosynthetic gene clusters, suggesting that they 
have the potential to assemble a significantly greater number of specialised 
metabolites than they have been shown to produce to date.128-131 Methods are, 
therefore, being developed to identify the products of these so-called cryptic 
biosynthetic gene clusters, which have the potential to direct the production of novel 
specialised metabolites in antibiotic-producing organisms.132  
Several of such strategies have been reported to yield novel natural compounds. The 
first is heterologous gene expression and comparative metabolite profiling, which 
involves the cloning of an entire cryptic biosynthetic gene cluster in a single cosmid 
or BAC vector, followed by expression in a heterologous host. LC-MS analysis is then 
used to identify metabolites present in the strain containing the cloned gene cluster 
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that are absent from the wild type organism (Fig.1.17).133, 134 An example of a novel 
compound discovered using this strategy is CBS40 (Fig. 1.19).135  
                 
Fig. 1.17: Identification of the product of a cryptic biosynthetic gene cluster via expression in 
a heterologous host and comparative metabolite profiling. X is the likely product. 
The second approach is gene knock out/comparative metabolic profiling. One or more 
genes believed to encode essential biosynthetic enzymes in a cryptic biosynthetic gene 
cluster are inactivated, and culture extracts from the wild type strain and the non-
producing mutants are compared (Fig. 1.18). Metabolites present in the wild-type but 
absent in the mutant are likely products of the gene cluster, which can be purified and 
characterised.134 This strategy was used to discover coelichelin in Streptomyces 
coelicolor.136 
                                          
Fig. 1.18: Identification of the product of a cryptic biosynthetic gene cluster via gene knock 
out and comparative metabolite profiling. Y is the likely product. 
The third approach involves manipulating the expression of putative pathway-specific 
activator genes within cryptic biosynthetic gene clusters. The activator gene is 
typically put under the control of a constitutive promoter, with the expectation that 
forcing expression of the activator will induce the expression of the biosynthetic 
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genes, thus trigerring metabolite production.137 This strategy was used to discover the 
aspyridones in Aspergillus nidulans,138 and the stambomycins in S. ambofaciens.125 
Closely related to the use pathway-specific activator is the deletion of pathway-
specific transcriptional repressor genes.  Such genes encode DNA-binding proteins 
which repress the expression of biosynthetic genes in a cluster. Thus, by identifying 
and inactivating a pathway-specific repressor gene, it is possible to turn on the 
production of metabolites encoded in a biosynthetic gene cluster. This approach was 
first successfully demonstrated with the discovery of gaburedins in S. venezuelae, by 
Fig. 1.19: Structures of some novel compounds discovered through activation of silent 
biosynthetic gene clusters.  
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inactivating gbnR, which encodes an ArpA – like transcriptional repressor.126 
Two or more of the above approaches can also be combined, as exemplified by the 
discovery of venemycin via expression of the gene cluster in a heterologous host and 
manipulation of the pathway specific activator. The venemycin cluster, originally 
from S. venezuelae, was constitutively expressed in S. coelicolor host, together with 
vemR, the pathway-specific activator gene, leading to the production of venemycin 
and a monohalogenated derivative.127 
1.5.4 Metagenomics-guided discovery 
Metagenomics refers to the direct isolation and analysis of genetic material from 
natural microbial communities, bypassing the need to isolate microbes using 
traditional culturing methods.139, 140 Antibiotic discovery using metagenomics-based 
approaches was inspired by the observation that only a small proportion of microbes 
can be cultivated in the laboratory; the vast majority in the environment (potentially 
harbouring novel antibiotic scaffolds) remain uncultivated.141, 142   
DNA isolated from the environment is typically used for metagenomic library 
construction in a suitable host such as E. coli. Genes or gene clusters encoding 
enzymes potentially involved in antibiotic biosynthesis can then be identified either 
by homology-based screening, or phenotype/activity guided screening approaches, 
such as the appearance of zone of growth inhibition around clones, or the production 
of a coloured metabolite.140, 143 Gene clusters identified by homology-based screening 
can be expressed in a heterologous host to identify the metabolic 
product.144Antibiotics discovered using metagenomics approaches include 
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turbomycins A and B,145 and fasamycins A and B.146 The unusual structures of the 
turbomycins (Fig. 1.20) were confirmed by synthesis and by single crystal X-ray diff- 
                
Fig.1.20: Structures of turbomycins and fasamycins, antibiotics discovered via metagenomics 
approach. X is counter ion. 
raction experiments.145 While isolation of DNA from the environment continues to 
show huge promise for the discovery of antibiotics from uncultivable bacteria, 
strategies are also being deployed to grow these bacteria and to uncover potential 
antimicrobial compounds encoded in their genomes. An interesting example was 
exemplified by the discovery of teixobactin, a non-ribosomal peptide synthetase 
(NRPS) - derived compound (Fig. 1.21). Teixobactin was produced by Gram-  
 
Fig. 1.21: Structure of teixobactin.  
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negative bacteria (Eleftheria terrae), cultured on a multi-channel chip device within 
the natural soil environment. This compound uniquely binds to both lipid II and lipid 
III (a precursor of cell wall teichoic acid).101 
1.5.5 Semisynthesis 
Semisynthetic antibiotics are developed via extensive studies of the chemistry, 
biochemistry, and pharmacology of naturally-derived antibiotics with a view to 
determining their structure-activity relationships. Chemical modifications are then 
applied to produce analogues with improved properties.102  
Recently, the antimalarial drug artemether was developed by semi-synthetic 
modification of artemisinin, an unstable natural product, by conversion of its lactone 
to an acetal via reduction and subsequent methylation (Scheme 1. 3).104 Artemisinin 
was originally discovered from extract of a plant, Artemesia annua, by Youyou Tu in 
1985.264,265 Tu was awarded half the 2015 Nobel prize in medicine for this discovery. 
However, artemisinin is only produced in low yield by Artemesia annua. Yo and co-
workers subsequently engineered the production of artemisinin in yeast, Saccharomy-                   
                  
Scheme 1.3: Route for semisynthesis of artemether, an important antimalarial drug, from the 
natural product artemisinin.  
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yces cerevisiae, leading to high titres of up to 100 mg/L, and paving the way for a 
large-scale industrial production of this important antimalarial agent.266  
Another good example is in the development of cephalosporins into drugs. Whereas 
the natural product, cephalosporin C (11), has weak antibiotic activity against Gram-
positive strains (MIC 25 to 100 µg/ml) and no activity against Gram-negative bacteria, 
several analogues with improved potency against Gram-positive bacteria and 
significant activity towards Gram-negative strains have been generated via chemical 
modification of the cephalosporin core structure.44,103 This has culminated in the 
development of first, second, third, fourth and fifth generation cephalosporin antibio- 
 
Table 1.2: Generations of cephalosporin antibiotics and their antimicrobial activity  
Generation Members Active against 
  
cephalotin, cephaloridine, 
cephaloglycine, cephazoline, Gram-positive bacteria, especially  
1st cephaprin, cefazolin and  Staphylococci and Streptococci species 
  cephalexin  
      
  cefamandole, cefoxitin, cefuroxime, Gram-negative Bacilli 
2nd 
cefaclor, cefadroxil, cefotetan, 
cefprozil and Slightly less active against Gram-positive  
  cefmetazole cocci compared to the 1st generation 
      
  cefotaxime, cefoperazone, ceftazidime,  Gram-positive cocci and Gram-negative   
3rd ceftizoxime, cefsulodin, ceftriaxone, Haemophilus influenza, Enterobacteria  
   cefdinir, cefditoren, cefixime and (e.g. E. coli, K. pneumoniae) that do not  
  cefpodoxime 
 produce betalactamase. Ceftazidime is 
active against Pseudomonas  
    aeruginosa 
      
    Gram-positive and Gram-negative strains  
4th notably cefepime and cefpirome 
(including Pseudomonas and 
betalactamase-producing  
    bacteria) 
   
    methicillin-resistant S. aureus (MRSA),   
5th notably ceftaroline and ceftobiprole K. pneumoniae, E. faecalis. Also Gram- 
    positive cocci and Gram-negative Bacilli.  
    Not active against Pseudomonas species 
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Fig. 1.22: Structures of selected 1st, 2nd, 3rd , 4th and 5th generation cephalosporin 
antibiotics. The common core structure derived from the natural product, cephalosporin C 
(11) is shown in blue. 
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tics (Table 1.2 and Figure 1.22) 
1.5.6 Targeting non-multiplying bacteria 
Non-multiplying and multiplying bacterial cells often exist simultaneously in a 
clinical infection.119 However, most antibiotics in clinical use kill only multiplying 
cells, leaving behind the non-multiplying cells which serve as a pool from which 
multiplying bacteria can emerge again to cause recurrent disease.113, 120-121 Thus, one 
strategy being pursued to combat antibiotic resistance in disease-causing pathogens is 
to develop drugs that can kill non-multiplying bacterial cells, in addition to inhibiting 
the growth of actively-dividing cells. HT61, developed by Helperby Therapeutics and 
currently in clinical trials, is an example of an antibiotic that kills non-multiplying 
bacteria, in particular Staphylococcus aureus.119  
1.6 Antibiotics produced by Streptomyces coelicolor A 3(2) 
Streptomyces coelicolor A 3(2) is a model Actinobacterium, widely used to study the 
genetic and biochemical basis for specialised metabolite production in 
Streptomycetes.147-149  It was the first member of the genus to have its genome 
completely sequenced.128 It produces many structurally-diverse antibiotics, including 
undecylprodigiosin (13) and streptorubin B (35), coelimycin A (39) and coelimycin P 
(40), actinorhodin (14), and calcium-dependent antibiotics (CDA, 15) (Fig. 1.23), all 
of which are chromosomally determined. The biosynthesis of these antibiotics has 
been recently reviewed by Challis,150 Hu et al,151 and Okamoto et al.152  S. coelicolor 
A 3(2) also produces the epoxy-cylcopentanone antibiotics: methylenomycin A 
(MmA, 16) and methylenomycin B (MmB, 24),  as well as methylenomycin C (MmC, 
17), a common precursor to the two methylenomycin antibiotics.150 MmA (16) and 
MmB (24) were first isolated from an Actinobacterium called Streptomyces violaceo-  
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Fig. 1.23: Structures of representatives of the main groups of antibiotics produced by 
Streptomyces coelicolor A 3(2). Methylenomycins are shown in Fig. 1.24. 
ruber in 1974 and were shown to exhibit a wide range of activity against many Gram-
positive bacteria and some Gram-negative ones, with 16 being more potent.261 
Structure-activity study had revealed that the α,β – unsaturated ketone was the most 
essential feature for antibacterial activity in this compound, while the ketonic group 
at C-3 was a basic requirement for antifungal activity.261 
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In contrast to the chemical name of 16, which is (1S,5S)-1,5-dimethyl-3-methylene-
4-oxo-6-oxabicyclo[3.1.0]hexane-2-carboxylic acid, the compound was assigned a 
numbering scheme as shown in Fig. 1.24(A).172, 262-263  The highly-functionalised 
nature of 16 was previously explored to generate semisynthetic derivatives (42 – 49, 
Fig. 1.24B), with consequent impact on its biological activity and toxicity. The 
dibrominated derivative (43) showed stronger antibacterial activity than MmA (16). 
The methyl ester derivatives (42 and 44) also showed stronger antibacterial and 
antifungal activities than 16.263 Substituting the methyl group of the ester with longer 
 
Fig. 1.24: (A) Structures of methylenomycin A (16), methylenomycin B (24) and their 
putative precursor, methylenomycin C (17). (B) Structures of some derivatives of methyle-
nomycin A generated by chemical modifications. 
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alkyl chain significantly reduced the antimicrobial activity. Similarly, aromatic esters 
generated were not biologically active, except the dibromo - methylenomycin A - 
diphenyl ester (45).263 
Replacing the C-2 double bond led to a complete loss of antibacterial activity in the 
semi-synthetic analogues, with the exception of the brominated derivatives and the 2-
ethylidene derivative (48).263 All of the semi-synthetic analogues with stronger 
antimicrobial activity than MmA (16) also had greater toxicity. Only the methyl ester 
(42) was slightly less toxic and had an improved antimicrobial activity.263 
1.7 Regulation of methylenomycin production in S. coelicolor A 3(2) 
All of the genetic elements required for the biosynthesis of the methylenomycin 
antibiotics and regulation are present within the 23kb mmy gene cluster, carried on a 
giant linear plasmid SCP1 of S. coelicolor (Fig. 1.25).153 - 155 The complete sequence 
of the mmy cluster became available when the SCP1 plasmid was sequenced as part 
of the S. coelicolor genome sequencing project.156 The cluster contains twenty-one 
genes, including seven (coloured in blue and green), encoding proteins that play 
various roles in transcriptional regulation.  
The mmr gene encodes an efflux/export protein that confers methylenomycin 
resistance by exporting the antibiotics from the cell. To the left of this gene is mmyJ, 
which encodes a protein belonging to the ArsR family of transcriptional repressors 
that sense metal ions.157 Recently, it was shown that MmyJ binds specifically to the 
intergenic region between mmr and mmyJ (containing the promoters for the two 
genes) and that binding of methylenomycin A to MmyJ causes it to be released from 
this operator.158 This confirmed a previous suggestion that MmyJ controls its own 
expression, as well as that of the methylenomycin resistance determinant, mmr, prov- 
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Fig. 1.25: Organisation of the methylenomycin biosynthetic gene cluster on SCP1 of 
Streptomyces coelicolor A 3(2). mmfLHP genes encoding the methylenomycin furan (MMF) 
biosynthetic enzymes are in green; Genes involved in regulation are in blue; the 
methylenomycin resistance gene, mmr, is in pink. Genes involved  in methylenomycins 
biosynthesis are in red. 
iding a mechanism for triggering mmr expression upon production of 
methylenomycin A.159 The mmyB gene, located towards the right end of the cluster, 
encodes a transcription factor that activates expression of the methylenomycin 
biosynthetic genes.  
At the left hand end of the cluster are five genes: mmyR, mmfR, and mmfLHP. Both 
mmyR and mmfR encode proteins belonging to the TetR superfamily of transcriptional 
repressors.160, 161 Indeed, deletion of mmyR leads to methylenomycin overproduction, 
confirming that MmyR represses Mm biosynthesis.161,162 Both MmyR and MmfR are 
similar in sequence to the Streptomyces griseus DNA-binding protein, ArpA (MmyR: 
43% identity and 65% similarity; MmfR: 32% identity and 58% similarity).167 ArpA 
binds to the promoter region of adpA which encodes the pathway-specific activator 
for streptomycin biosynthesis. Binding of A-factor (18), a gamma-butyrolactone 
signalling molecule, to ArpA causes it to be released from the adpA promoter, leading 
to expression of the streptomycin gene cluster.163,164 Similar to ArpA, both MmyR and 
MmfR have been shown to bind to the promoter region of mmyB, the pathway 
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activator gene for methylenomycin production. These two transcription factors also 
bind to the mmyR promoter and the intergenic region between mmfL and mmfR.165  
Like ArpA, MmfR (but not MmyR) is released from the mmyR and mmyB promoters, 
as well as the mmfL-mmfR intergenic region upon binding to diffusible signalling 
molecules.168 These have been identified as a group of five 2- alkyl-4-
hydroxymethylfuran-3-carboxylic acids, termed the methylenomycin furans (MMFs 
1-5, 19-23) (Fig. 1.26) and are the metabolic products of the enzymes encoded by the 
mmfLHP operon.155 MMF biosynthesis involves MmfL-catalysed condensation of β-
ketoacyl-ACP intermediates in fatty acid assembly with dihydroxyacetone phosphate, 
an intermediate in glycolysis. MmfP has been shown to catalyse dephosphorylation 
of the resulting phosphorylated butenolides, and MmfH is proposed to catalyse the 
rearrangement of the butenolides to give the MMFs (Sceheme 1.4).150,166,167 
 
 
Fig. 1.26: Structures of A-factor (18), the signalling molecule that induces streptomycin 
production in S. griseus, and the methylenomycin furans (MMFs, 19-23), which induce 
methylenomycin production in S. coelicolor A 3(2). 
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Scheme 1.4: Proposed pathway for methylenomycin furans (MMF) biosynthesis in S. 
coelicolor.150 FabC is the acyl carrier protein from the fatty acid biosynthetic pathway. MMF1 
(X=Me, Y=Z=H); MMF2 (X=Y=Z=H); MMF3 (X=H, Y=Z=Me); MMF4 (X=Y=H, Z=Me); 
MMF5 (X=Y=H, M=Et). 
In the early stages of growth, the MmfR/MmyR repressor complex is proposed to bind 
to the operators upstream of mmyB and mmyR, and in the intergenic region of mmfL 
and mmfR. The expression of mmyB is proposed to be fully repressed, whereas the 
expression of mmyR, mmfR and mmfL is only partially blocked. This permits low 
levels of the MMFs to be produced and gradually accumulate.165,167 As the 
extracellular, and subsequently, the intracellular levels of the MMFs increase, they 
begin to bind to MmfR, causing its release from the operators. This permits express-    
                                               
Fig. 1.27: Crystal structure of MmfR showing interaction with MMF2, 20. Such interaction 
causes the protein to be released from the promoter region of mmyB, thereby switching on 
methylenomycins biosynthesis. 
MMF2 
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ion of mmyB, thereby switching on the expression of the genes involved in 
methylenomycin biosynthesis.165 The X-ray crystal structure of MmfR bound to 
methylenomycin furan 2 (MMF2) has recently been solved (Fig. 1.27).169 
1.8 Previous investigations into the biosynthesis of methylenomycin antibiotics  
1.8.1 Incorporation of labelled putative precursors 
Efforts to elucidate the biosynthetic pathway to methylenomycin A (16 ) began over 
three decades ago with incorporation experiments involving precursors. Intact 
incorporation of [1,2-13C2]acetate into C-4, C-8 and C-1, C-6 of 16 was reported 
(scheme 1.5A).170 Moreover, radiolabelled methylenomycin C (17, also known as des-
epoxy-4,5-didehydromethylenomycin A) was incorporated into methylenomycin A 
(16),171 indicating that epoxidation of 17 is the final step in methylenomycin A 
biosynthesis. Methylenomycin B (24) appears to derive from decarboxylation of 
methylenomycin A (16).  
In a reinvestigation of the metabolic origins of the carbon atoms in the 
methylenomycins, Challis and Chater examined the incorporation of  [U-13C]glycerol 
in S. coelicolor. Using a combination 1H, 13C and HMBC NMR experiments, they 
were able to confirm the intact incorporation of the [U- 13C]glycerol into C-3, C-4, 
and C-8 of 16, as  well as an indirect incorporation of a 2-carbon unit into the C-5, C-
9 and C-1, C-6 portions of the molecule via catabolism of  [U-13C]glycerol  to [1,2-
13C]acetyl-CoA (scheme 1.5B).172 
A major advance towards understanding the biosynthesis of the methylenomycins was 
made when Corre and Challis 173 established the metabolic origin of C-2 and C-7 
which was hitherto unknown. Feeding of [U- 13C]glycerol to Streptomyces lividans 
1326, with a cosmid containing the entire methylenomycin biosynthetic gene cluster 
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integrated into its chromosome, led to the labelling of 16 and 17. Analysis of coupling 
data in the 13C NMR spectra of these compounds confirmed that a 3-carbon precursor 
derived from a molecule of [U- 13C]glycerol was incorporated intact into C-3, C-4, C-
8 as observed previously. Interestingly, intact incorporation of a 5-carbon precursor 
derived from 2 molecules of [U- 13C]glycerol into C-2, C-3, C-4, C-7 and C-8 was 
also observed. The incorporation of a 5-carbon precursor is explained based on the 
metabolism of [U-13C]glycerol to [U-13C]glyceraldehyde-3-phosphate (G3P), which 
is then converted through the pentose phosphate pathway to one or more of the 
following: [U-13C]Xylulose-5-phosphate (Xu5P), [U-13C]Ribulose -5-phosphate 
(Ru5P), and  [U-13C]Ribose-5-phosphate (R5P).173 The intact incorporation of a 
pentulose into C-2, C-3, C-4, C-7 and C-8 of 16 and 17 was confirmed by feeding [U-
13C]-D-ribose (scheme 1.5C).173  
                        
Scheme 1.5: Pattern of incorporation of labelled precursors into methylenomycin A (16), 
observed following the feeding of : (A) [U- 13C]acetate 170   (B) [U- 13C]glycerol 172  (C) [U- 
13C]D-ribose,173 to Streptomyces spp. expressing the mmy cluster. The same incorporation 
pattern was observed for methylenomycin C (17). 
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1.8.2 Proposed biosynthetic pathway for methylenomycin A (16) 
Since the complete sequence of the mmy gene cluster became available,156 attempts to 
further elucidate the biosynthetic pathway to the methylenomycins have focused on 
the assignment of plausible biosynthetic roles for the proteins encoded by each of the 
genes in the cluster. Comparison of the amino acid sequences of the proteins encoded 
by the genes in the cluster with proteins of known function have allowed plausible 
biosynthetic roles to be assigned to the majority of them (Table 1.3). 
The mmyD gene within the methylenomycin cluster encodes a protein with 28% 
identity and 47% similarity over 333 amino acids to AvrD in Pseudomonas  
Table.1.3: Putative functions of the proteins encoded by the methylenomycin gene cluster 
    
Protein (aa) UNIPROT  Homologue (% Identity) Proposed function 
MmyA (82) Q7API2 RedQ S. coelicolor (33) Acyl carrier protein 
MmyB (313) Q9ACS4 TR:Q9RDF4 S. coelicolor(43) Mm pathway transcriptional activator 
MmyC (332) Q9JN82 FabH E. coli (39) β-ketoacyl synthase III 
MmyD (339) Q7API4 AvrD P. syringae (28) Butenolide synthase 
MmyE (387) Q7API5 PlmM S. sp. HK803 (32) Flavin-dependent enoyl reductase 
MmyF (174) Q7API8 NtaB C. heintzii (40) Flavin reductase, partner to monooxygenase 
MmyG (393) Q9ACS3 JadP S. venezuelae (29) NAD(P)-dependent dehydrogenase 
MmyJ (111) Q7APH9 TR:O31480  B. subtilis(45) AsR-type DNA-binding transcription factor 
MmyK (206) Q7API0 Adk E. coli (30) Kinase 
MmyO (373) Q7APH8 LimB R. erythropolis (43) Flavin-dependent monooxygenase 
MmyP (232) Q7API1 SsgB S. griseus (30) Phosphatase 
MmyQ (217) Q7API6 NdpG R. opacus (30) Coenzyme F-420-dependent reductase 
MmyR (203) Q7APH3 ArpA S. griseus (43) DNA-binding receptor protein 
MmyT (269) Q9ACS2 MtmZ S. argillaceus (31) Thioesterase 
MmyX (234) Q7API3 MmyK S. coelicolor (42) Kinase 
MmyY (153) Q9JN76 JadX S. venezuelae (27) Belongs to NTF2-like superfamily 
MmfH (400) Q7APH5 LndZ5 S. globisporus (42) Flavin-dependent dehydrogenase 
MmfL (353) Q7APH6 BarX S. virginiae (34) Butenolide synthase 
MmfP (265) Q7APH4 SsgB S.griseus (30) Phosphatase 
MmfR (214) Q7APH7 ArpA S. griseus (32) DNA-binding receptor protein 
Mmr (475) P11545 SW:P39886 S. glaucescens (32) Methylenomycin resistance protein 
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Scheme 1.6: AvrD-initiated condensation of β-ketooctanoyl CoA with xylulose to give 
syringolide 1 (33). Syringolide 2 has the alkyl side chain increased by 2 carbon units and is 
derived from β-ketodecanoyl CoA. 
syringae.173 AvrD catalyses the production of a group of compounds called 
syringolides, elicitors of plant hypersensitive response.188,189 The biosynthesis of these 
compounds proceeds via AvrD-catalysed condensation of β-ketooctanoyl CoA or β-
ketodecanoyl CoA with xylulose to form a key butenolide intermediate (32), which 
then rearranges to give the tricyclic ring system characteristic of the syringolides 
(scheme 1.6).189 
Based on the similarity between MmyD and AvrD, it was proposed that MmyD could 
catalyse a similar condensation of a β-ketothioester ACP  with a pentulose to give a 
butenolide intermediate (25) in methylenomycin pathway.173 This hypothesis is 
consistent with the encoding, within the mmy cluster, of a ketoacyl synthase III, 
MmyC, and an acyl carrier protein, MmyA. MmyC could catalyse the decarboxylative 
condensation of malonyl-MmyA with acetyl-CoA to give the β- ketothioester ACP 
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(acetoacetyl-MmyA), required by MmyD for condensation with a pentulose (Scheme 
1.7).173  
 
Scheme 1.7: Proposed pathway for methylenomycin A (16) biosynthesis in S. coelicolor.  
A post doc in the group, Christophe Corre, had previously generated S. coelicolor 
M145 strains in which putative methylenomycin biosynthetic genes have been 
individually deleted from the mmy cluster, carried on an integrative cosmid 
C73_787.174 The transcriptional repressor, mmyR, was also disrupted in each of the 
constructs in order to obtain high titers of methylenomycin-related metabolites.159  LC-
MS analysis was carried out to examine the metabolite profiles of some of the 
transconjugant strains. Production of methylenomycin antibiotics was completely 
abolished in a mutant strain lacking mmyD, corroborating the hypothesis that MmyD 
catalyses a crucial early step leading to the butenolide intermediate (25) in the 
methylenomycin pathway.174 A possible role for MmyE in forming the exomethylene 
function of the methylenomycins via dehydration of a recently-discovered putative 
intermediate, the pre-methylenomycin C (26), has also been proposed.174  This 
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metabolite accumulates in a mmyE mutant and converts to pre-methylenomycin C 
lactone (27) under acidic conditions (scheme 1.8). 
                           
Scheme 1.8: Formation of pre-methlenomycin C lactone (27) from pre-methylenomycin C 
(26).  
 Abolition of the production of 16, but not 17, in mutants lacking mmyO or mmyF 
suggested the possible involvement of the enzymes encoded by these genes in the 
epoxidation of 17 to form 16. MmyO shows similarity to FADH2-dependent 
monooxygenases while MmyF is similar to NADH-dependent flavin reductases 
required for the supply of FADH2 to flavin-dependent monooxygenases (Table 1.3).
 
The involvement of molecular oxygen in formation of the epoxide group of 16 has 
also been demonstrated via incorporation of isotopically-labelled molecular oxygen 
(18O2).174 In both mmyO and mmyF mutant, methylenomycin C (17) is metabolised to a 
mixture of diastereoisomers, methylenomycin D1 (28) and methylenomycin D2 (29), 
via the saturation of the C-2 double bond (scheme 1.9). 
                          
Scheme 1.9: Saturation of the exomethylene function at C-2 in methylenomycin C (17) leads 
to methylenomycin D1 (28) and methylenomycin D2 (29).  
The function of MmyY, a nuclear transport factor (NTF2) encoded within the 
methylenomycin cluster, was investigated to some extent by O’ Rourke et al.155 In 
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this study, mmyY was replaced with an apramycin resistance cassette, and the resulting 
strain (J3994) was assessed for methylenomycin production on the basis of whether a 
zone of inhibition was visible when an agar plug inoculated with the strain was placed 
on a plate inoculated with a methylenomycin-sensitive S. coelicolor strain, J1501 
(SCP1-, SCP2-). The absence of a zone of inhibition in the experiment (presumably 
due to the lack of methylenomycin production) led to the conclusion that MmyY 
probably plays role in methylenomycin biosynthesis.155 However, the bioassay-based 
approach used in the study to evaluate the production of methylenomycins by the 
mmyY mutant did not provide the opportunity to detect levels of production below that 
required to inhibit growth of the indicator strain. It also did not provide an opportunity 
to identify any intermediates that might accumulate in the mutant that lack 
antimicrobial activity.  
Of the 21 genes in the mmy cluster, eight have been shown to be involved in the 
regulation of methylenomycin production and biosynthesis of the MMF signalling 
molecules.156, 165 A further seven genes have been assigned plausible roles in 
methylenomycin biosynthesis (Scheme 1.7), although direct evidence to support these 
roles is, in most cases, lacking. The functions of the remaining mmy genes (T, G, X, 
K, Q, Y) have yet to be unambiguously assigned. Experimental evidence is also 
lacking for the proposed butenolide intermediate (25) in methylenomycin 
biosynthesis. 
1.9 Aims and objectives of this study 
The aim of this PhD project was to investigate the biosynthesis and mode of action of 
methylenomycin antibiotics produced by S. coelicolor A 3(2). Elucidating the 
biosynthetic pathway to the methylenomycins could pave the way for a 
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bioengineering strategy to produce novel analogues, as well as providing insight into 
the biosynthesis of other structurally-related biologically-active compounds e.g. 
xanthocidin.  The project builds on previous work in the group and seeks to achieve 
the following objectives:  
• To obtain further evidence for the proposed role of MmyF and MmyO in the 
epoxidation of methylenomycin C to form methylenomycin A 
• To identify and characterise biosynthetic intermediates accumulating in 
mmyP, mmyT, mmyG, mmyX, mmyK, mmyQ, and mmyY deletion mutants 
• To investigate the role of a putative butenolide intermediate in 
methylenomycin biosynthesis 
• To investigate the biological activity of biosynthetic intermediates and shunt 
metabolites in the methylenomycin pathway 
• To investigate the mode of action of the methylenomycins
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CHAPTER TWO 
2. BIOSYNTHESIS OF METHYLENOMYCIN ANTIBIOTICS 
2.1 Investigations into the roles of MmyO and MmyF 
Early investigations into the biosynthesis of methylenomycin A (16) has suggested 
that epoxidation of methylenomycin C (17) is the last step in the biosynthesis.170 As 
discussed in chapter one (section 1.8.2), deletion of mmyF or mmyO from the 
methylenomycin biosynthetic gene cluster led to accumulation of 16 in the 
corresponding S. coelicolor transconjugant strains, indicating that MmyF and MmyO 
both play roles in the epoxidation of 17 to form 16. However, direct evidence for the 
roles of these proteins has not been obtained. 
As a starting point for further investigations into the roles of MmyF and MmyO in the 
current study, the experiment showing accumulation of 16 in mmyF and mmyO 
mutants was repeated. The S. coelicolor strains W108 (M145/C73_787/∆mmyF/ 
mmyR::apr) and W100 (M145/C73_787/∆mmyO/mmyR::apr) were grown on 
supplemented minimal medium solid (SMMS) for two days and the culture extracts 
were analysed by LC-ESI-MS. Figure 2.1 shows data from the analyses, confirming 
accumulation of 17 in the two mutant strains.  
Previous attempts to obtain soluble recombinant MmyO and MmyF were 
unsuccessful, making it impossible to do an in vitro assay with the putative substrate, 
17. Thus, an in vivo alternative is considered which would involve feeding of 17 to an 
S. coelicolor W110 strain, in which both mmyO and mmyF are heterologously 
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expressed  expressed under a strong constitutive promoter ermE* in a pOSV556 (A) 
    
 
 
 
 
 
expressed under a strong constitutive promoter ermE* in a pOSV556 vector. 
Compound 17 has not previously been shown to have antimicrobial activity. However, 
direct feeding of 17 to W110 strain results in cell death, presumably because the onset 
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Figure 2.1: (A) Total ion chromatogram (TIC) showing methylenomycin C (17) and other 
metabolites present in S. coelicolor W108 crude extract (B) Extracted ion chromatograms 
(EICs) at m/z = 167.0700, corresponding to [M + H+] for 17 following LC-MS analysis of  
extracts of S. coelicolor W108 and W100, and the heterologous host, S. coelicolor M145 (C) 
HR-MS data at 13.7 minutes showing m/z = 167.0705 and 123.0807, corresponding to [M + H+] 
and [M + H+ - CO2] respectively for 17.  
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of the conversion of 17 to methylenomycin A (16) was suicidal to the heterologous S. 
coelicolor strain, which is susceptible to 16. Thus, it was considered necessary to first 
generate a derivative of S. coelicolor W110 strain which is resistant to 16 . The 
construction of this strain is discussed in the next section. 
2.1.1 Introduction of the methylenomycin resistance gene (mmr) into W110 and 
M145  
S. coelicolor M145 is a derivative of the wild type strain A 3(2) which lacks the 
naturally occurring plasmids SCP2 and SCP1(containing the entire methylenomycin 
gene cluster).9 S. coelicolor strain W110 (M145 carrying mmyO and mmyF genes) 
was constructed previously in the group and was kindly provided by Dr. C. Corre.  
The methylenomycin resistance gene, mmr, was previously cloned into a multicopy 
plasmid, pIJ86, under the control of a strong constitutive ermE* promoter (Fig. 2.2). 
pIJ86 contains an oriT (for conjugal transfer) and origins of replication in E. coli and  
                   
Fig. 2.2: Map of pIJ86 carrying the methylenomycin resistance gene, mmr. 
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Streptomyces species.9  E. coli TOP10 carrying the pIJ86/mmr construct was provided 
by Dr. C. Corre. The construct pIJ86/mmr was purified from E. coli following 
standard procedures and the presence of the resistance gene was confirmed by 
polymerase chain reaction (PCR) (Figure 2.3). 
                                              
Figure 2.3: 1% gel from agarose electrophoresis separation following PCR amplification of 
mmr. 1- plasmid pIJ86, 2 & 3 - pIJ86/mmr, M- middle range DNA Ladder (bp). Expected 
size = 1.43 kb. 
The purified pIJ86/mmr was used to transform a non-methylating E. coli ET12567/ 
pUZ8002. The plasmid DNA was then transferred into S. coelicolor W110 strain via 
conjugation with the transformed E. coli ET12567/pUZ8002, and apramycin-resistant 
colonies were selected to give strain W301 (M145/pOSV556/mmyOF/ pIJ86mmr) 
(methods section 5.11.3). Since control assays would require feeding of 17 to S. 
coelicolor M145, which also lacks SCP1 and is therefore sensitive to methylenomycin 
antibiotics, but does not contain mmyO and mmyF; the resistance gene was also 
introduced into M145 by conjugation, to give strain W302 (M145/pIJ86mmr).  
2.1.2 Confirming methylenomycin resistance phenotype in W301 and W302 
The newly generated Streptomyces strains W301 and W302 were both expected to 
have increased resistance to methylenomycin A (16), relative to their respective parent 
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strains W110 and M145. Firstly, the presence of mmr in the new strains was confirmed 
by PCR analysis. The strains were grown on SFM plates for four days and the colonies 
were treated with lysis buffer (section 5.11.4). The lysed colonies were then analysed 
by PCR using the same primers and conditions employed to confirm the presence of 
mmr DNA in the purified construct. Colonies of the parent strains W110 and M145 
were also lysed and analysed simultaneously (Figure 2.4). As expected, a positive 
amplification band corresponding to the mmr gene (1.43 kb) was seen in colonies from 
the two new derivative strains, while the band was absent in the lysed samples from 
M145 and W110, thereby confirming the successful introduction of the mmr gene into 
the two strains.        
                                  
Figure 2.4: Gel from agarose electrophoresis separation following PCR amplification of mmr 
from lysed colonies of W110 (1), M145 (2), W301 (3 & 4), and W302 (5 & 6). L – middle 
range FastRulerTM DNA Ladder. Expected size = 1.43 kb. 
Following these results, bioassay experiments were conducted to demonstrate the 
methylenomycin-resistance phenotypes of the new strains. This was carried out by 
saturating filters with a concentrated solution of 16 (purified as discussed in section 
2.1.4) and placing the filters in the centre of AlaMM pH 5 plates inoculated separately 
with spore suspensions of W301, W302, W110 and M145. Following incubation at 
30 oC for four days, a zone of inhibition was visible in the region immediately 
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surrounding the filters in plates inoculated with M145 and W110, indicating 
sensitivity to 16, while no zone of inhibition was seen in the plates inoculated with 
the derivative strains carrying the methylenomycin resistance gene, mmr (Figure 2.5). 
The experiments confirmed that the Mmr was produced in the derivative strains, 
thereby conferring resistance against methylenomycin A, 16. The construction of 
these resistant derivatives, as well as the purification of 16 and 17 (discussed in the 
next sections) paved the way for feeding experiments to demonstrate the roles of 
MmyO and MmyF in the epoxidation of 17 to give 16. 
 
         
Figure 2.5: Growth inhibition of S. coelicolor strains W110 and M145 revealed sensitivity to 
methylenomycin A (left plates on each image). Introduction of methylenomycin resistance 
determinant, mmr, conferred resistance seen in W301 and W302 (Right plates on each image). 
2.1.3 Purification of methylenomycin C (17) 
The putative substrate for MmyO, methylenomycin C (17), accumulates in two mutant 
strains: S. coelicolor W108 (M145 with C73_787/∆mmyF/mmyR::apr) and W100 
(M145 with C73_787/∆mmyO/mmyR::apr) (see Fig. 2.1). A litre of supplemented 
minimal medium solid (SMMS) was inoculated with spore suspension of strain W108 
and incubated for 36 hours. Methylenomycin C (17) was purified from acidified ethyl 
acetate extract of this culture by preparative HPLC as detailed in the methods section 
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(5.14.1). The purified compound was subjected to 1H, 13C and 2D-NMR analyses and 
data obtained were consistent with the structure of 17, as reported previously.173  
2.1.4 Expression of the entire mmy gene cluster in heterologous hosts and 
purification of methylenomycin A (16)  
An authentic standard of methylenomycin A (16) was also required. S. coelicolor 
strain W89 contains all the genes required for the regulation and production of 
methylenomycin antibiotics carried on the cosmid C73_787, except the transcriptional 
repressor, mmyR, which had been replaced with an apramycin resistance cassette.174 
This strain was expected to overproduce 16 and 17. Although LC-MS analysis of 
supernatant and acidified culture extracts of W89 revealed that the strain indeed 
produced 16, attempts to purify it from large cultures of this strain grown on SMMS 
were unsuccessful. This is because germicidins, another set of metabolites produced 
by the parent strain M145 under the same fermentation conditions,136 were produced 
in much higher titers (Fig. 2.6) and completely obscured 16 in HPLC purification 
attempts. Thus, other heterologous hosts were considered for the expression of the 
methylenomycin gene cluster.  
Two Streptomyces species were used as alternative hosts for the mmy cluster: S. 
lividans, a close genetic relation of S. coelicolor 176 and S. albus, widely used as 
heterologous host for the expression of secondary metabolite biosynthetic gene 
clusters.177,178 E. coli ET12567/pUZ8002 was therefore transformed by the construct 
C73_787/mmyR::apr and subsequently conjugated with S. lividans TK24 and S. albus 
J1074 as detailed in the experimental section (5.11.3).  The resultant strains, named 
W303 and W304 respectively for S. albus J1074 and S. lividans TK24 host strains, 
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Fig. 2.6: LC-MS analysis of extract of S. coelicolor W89 (M145/C73_787/mmyR::apr), 
comparing EIC at m/z = 183.1181, corresponding to [M+H+] for germicidin B (blue traces) 
with EIC at m/z = 183.0650 corresponding to [M+H+] for methylenomycin A (16) (red traces).  
were fermented on SMMS and their metabolic profile was examined. As expected, 
LC-ESI-HRMS of the acidified culture extracts of these strains revealed the presence 
of a peak at 14.5 minutes with m/z [M + H]+ = 167.0705 corresponding to M = 
[C9H11O3]
+, consistent with the protonated form of 17, and a small peak at 15.1 
minutes with m/z [M + H]+ = 183.0654, corresponding to M = [C9H11O4]
+ for 16 (Fig. 
2.7). Compounds with m/z [M + H]+ = 123.0807 corresponding to [C8H11O]
+ and [M 
+ H]+ = 139.0755 corresponding to [C8H11O2]
+, resulting from spontaneous 
decarboxylation of 17 and 16 respectively were also observed.   
In addition to the peaks corresponding to 16 and 17 in the transformed host strains, 
two prominent peaks were also found in W304 (S. lividans TK24/ C73_787/mmyR:: 
apr) at 16.7 and 17.3 minutes. These peaks had m/z values [M + H]+ = 197.1172 and 
183.1181 respectively, corresponding to molecular formulae of C11H17O3 and 
C10H15O3, previously assigned to germicidins A and B respectively.
136 Given that a 
germicidin B 
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germicidin synthase (Gcs) with 99% identity to the S. coelicolor Gcs has been 
identified in Streptomyces lividans,179,180 the additional metabolites produced by  
 
 
 
Fig. 2.7: LC-ESI-HRMS showing the production of 16 and 17 by S.albus and S. lividans 
transformed with the construct C73_787/mmyR::apr (A) TIC following extraction of W304 
(S. lividans TK24/C73_787/mmyR::apr) and W303 (S. albus J1074/C73_787/mmyR::apr). 
Peaks labelled A and B gave exact m/z values and molecular formulae corresponding to 
germicidins A and B respectively (B) HR-MS data at 15.1 minutes showing m/z = 183.0654 
and 139.0755 corresponding to [M + H+] and [M + H+ - CO2] respectively for 16.  
W304 are proposed to be germicidins. Thus, to avoid similar challenges posed by the 
presence of germicidins in the attempted purification of 16 from S. coelicolor 
strainW89, W303 was chosen as the preferred strain for the purification. W303 was 
therefore fermented on SMMS and 16 (20 mg) was purified from acidified ethyl 
acetate extract of a litre culture as detailed in the methods section (5.14.2). The 
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compound was confirmed by 1H and COSY NMR analysis and data obtained were 
consistent with those reported previously for 16.173  
2.1.5 Feeding of methylenomycin C (17) to S. coelicolor W301 confirms the roles 
of MmyO and MmyF in epoxide formation in methylenomycin A (16) 
Strains W301 and W302 were inoculated over a semi-permeable membrane supported 
by Alamm medium (pH 5.0, allowing for better diffusion of methylenomycin 
metabolites). A solution of methylenomycin C (17) in DMSO was fed at low 
concentrations to W301 and W302 after an initial incubation at 30 oC for 2 days. 
Following a further incubation for 4 days and extraction with methanol, LC-ESI-
HRMS analyses of the W301 culture extract revealed the presence of a compound 
with the same m/z value (183.0652) and retention time (14.7 minutes) as the authentic 
standard of 16 (Fig. 2.8).  Absence of this peak in the culture extract of W302 fed with 
 
 
 
 
 
W301 fed 17 
W302 fed 17 
16 authentic standard 
Figure 2.8: Extracted ion chromatograms (EIC) for m/z = 183.0650 ± 0.005 corresponding 
to [M + H+] for 16 from LC-ESI-HRMS analysis of extracts of  S. coelicolor W301 
(M145/ pOSV556/mmyOF/pIJ86mmr) and W302 (M145/pIJ86mmr) fed with 
methylenomycin C, 17. 
16 
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17 clearly indicates that the presence of 16 in the W301 extract resulted from the 
activity of MmyO and MmyF. Feeding high concentrations of 17 (10x) to both strains 
resulted in cell death and no turnover was observed.  
Based on the above results and on a previous experiment which has demonstrated the 
involvement of molecular oxygen in forming the epoxide function of 16, a detailed 
mechanism may be proposed for the epoxidation of 17 to 16 (Scheme 2.1).  
 
 
 
 
 
 
 
 
 
Scheme 2.1: Proposed mechanism for the epoxidation of methylenomycin C (17) to 
give methylenomycin A (16).  
From bioinformatic analyses, MmyF is similar to NADPH- dependent flavin 
reductases known to be required for the supply of reduced flavin, FADH2, to flavin-
dependent monooxygenases.181,182 MmyO shows a significant sequence similarity to 
LimB, a monooxygenase which catalyses FADH2 –dependent epoxidation of the 1,2-
double bond of limonene in Rhodococcus erythropolis using molecular oxygen as co-
substrate (Scheme 2.2A).183  We therefore propose that MmyO carries out the 
epoxidation of 17 to 16 using reduced flavin (FADH2) generated by the proposed 
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flavin reductase, MmyF. The strict requirement for MmyF to supply the FADH2 is 
evidenced by the fact that strain W108, although containing mmyO and all other genes 
coding for enzymes required to biosynthesize the methylenomycin compounds, but 
does not contain mmyF, could not produce 16, leading to the accumulation of 17 (see 
Fig. 2.1).  
The mechanism is likely analogous to other flavin-dependent reactions and 
monooxygenases in which FADH2 is generated via a hydride transfer from NAD(P)H 
to FAD. The reduced flavin then reacts with molecular oxygen via two one-electron 
transfers to generate a flavin hydroperoxide, via a semiquinone radical 
intermediate.184, 204 Deprotonation of the hydroperoxide adduct by a base in the active 
site of the monooxygenase then produces a nucleophilic peroxide which can attack 
the β- Carbon in 17 to generate an enolate (scheme 2.1). The enolate then collapses to 
furnish 16 and a flavin hydroxide. Loss of a water molecule regenerates the oxidised 
flavin (FAD) which is again reduced by MmyF to continue the reaction cycle. 
Although MmyO directly bears homology to the limonene-1,2-monooxygenase in 
Rhodococcus erythropolis, a mechanism similar to the one shown in scheme 2.1 for 
the epoxidation of 17 has also been proposed for the last step in the biosynthesis of 
the 2,3-epoxyhexanoyl side chain of the calcium-dependent antibiotics (CDA), 
produced by Streptomyces coelicolor. HcmO, a flavin-dependent monooxygenase 
encoded within the CDA cluster, catalyses epoxidation of the trans-hexenoyl-CoA 
intermediate in the pathway to give the 2,3-epoxyhexanoyl moiety.185,150 (Scheme 2.2 
B). Thus, the result obtained herein for MmyO is consistent with the reactions 
catalysed by similar monooxygenases in other pathways. 
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(A)  
                                                                      
(B) 
                
Scheme 2.2: Epoxidation of double bonds catalysed by monooxygenases similar to MmyO: 
(A) Conversion of limonene to limonene-1,2-epoxide (B) Formation of the epoxyhexanoyl 
moiety of calcium-dependent antibiotics. 
 
2.2 Putative intermediates and shunt products of the methylenomycin pathway 
considered as substrate for MmyO 
As discussed in the introduction (section 1.8.2), a putative intermediate of the 
methylenomycin pathway, pre-methylenomycin C (26), accumulates in a mmyE 
mutant strain. In addition to 26, another metabolite, 31, was also purified from the 
strain. This compound had the same m/z value and molecular formula as an epoxidized 
form of pre-methylenomycin C (30), but has a different structure. It was proposed that 
26 could possibly be epoxidized by MmyF and MmyO to give 30, which might then 
form 31 via a series of rearrangement steps (scheme 2. 3).174 However, it has yet to be 
demonstrated that MmyF and MmyO are able to catalyse the epoxidation of 26 to 
form 30. Indeed, 26 possesses the core cyclopentenone structure which appears crucial 
to the epoxidation mechanism proposed for methylenomycin C (17), and could 
potentially be a substrate for the monooxygenase (MmyO). 
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Scheme 2.3: Epoxidation of pre-methylenomycin C (26) by MmyO and MmyF is 
hypothesised to form 30, which then undergoes a series of proposed rearrangement steps 
leading to 31 (scheme proposed by G. L. Challis 174). 
 
Pre-methylenomycin C lactone (27), methylenomycin D1 (28) and methylenomycin 
D2 (29), also possess the same cylopentenone structure as methylenomycin C (17) 
and are all used to probe the substrate promiscuity of MmyO in the current study. 
Likely products that may be formed if these compounds are epoxidised are shown in 
Fig. 2.9.  Pre-methylenomycin C (26) and pre-methylenomycin C lactone (27) were 
purified from S. coelicolor W86 (M145/C73_787/∆mmyE/mmyR::apr) as detailed in 
the methods section (5.14.3). Methylenomycin D1 (28) and methylenomycin D2 (29) 
were purified from S. coelicolor W108 (M145/C73_787/∆mmyF/mmyR::apr) as 
detailed in the method section (5.14.4). 
The compounds were fed to strain W301, and following extraction with methanol, all 
the extracts were analysed by LC-MS. The only potential substrate which resulted in 
an altered chromatogram when fed to W301 compared to W302 is pre-
methylenomycin C (26) (Fig. 2.10). The new peak appearing at 14.2 minutes had an 
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Fig. 2.9: Likely products of the epoxidation of 26, 27, 28 and 29. 
 
m/z [M + Na] = 223.0577 corresponding to C9H12O5Na and consistent with the 
sodiated form of 30. This result suggests that MmyO and MmyF are also able to carry 
out the epoxidation of 26, but not 27, 28, and 29. Indeed, the new peak gave the same 
retention time and m/z value 223.0577 as compound 31, present in the culture extract 
of S. coelicolor W86, carrying the cosmid C73_ 787, but with mmyE deleted (Fig. 
2.11). The result indicates that 31 is indeed an an artefact of 30, and it is formed 
spontaneously following the epoxidation of 26 to 30 by the joint actions of MmyF and 
MmyO in the W301 strain. Since 26 accumulates in the S. coelicolor W86, and both 
mmyO and mmyF are present in this strain; it follows that 26 is carried on to 30 
following its formation in the strain, explaining why its artefact, 31, was detectable in 
the culture extract.  
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Fig. 2.10: Extracted ion chromatograms (EIC) from LC-MS analyses of extracts of  W301 
and W302 fed with 26, 27, 28 and 29. Yellow: EIC at m/z = 201.07 and 223.07 corresponding 
to [M + H+] and [M + Na+] for possible epoxidized product of 26. Blue: EIC at m/z = 183.06 
and 205.06 corresponding to [M + H+] and [M + Na+] for possible epoxidized product of 27. 
Green and Purple: EIC at m/z = 185.07 and 207.07 corresponding to [M + H+] and [M + Na+] 
for possible epoxidized product of 28 and 29.   
 
The inability of MmyF and MmyO to epoxidise 27, 28 and 29 suggests that the 
monooxygenase (MmyO) is highly specific for methylenomycin C (17) and its 
putative precursor, pre-methylenomycin C (26). Simple synthetic analogues of 
methylenomycin C such as 2-cyclopentenone and 2-cyclohexenone were obtained 
commercially and also fed to W301, but no epoxidation of these compounds was 
observed. Rather, the compounds were likely degraded as they could not be detected 
in the culture extracts of the strain following incubation.  
W301 fed 26 
W302 fed 26 
W301 fed 27 
W302 fed 27 
W301 fed 28 
W302 fed 28 
W301 fed 29 
W302 fed 29 
new peak resulting from feeding 
of 26 to W301 
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Fig. 2.11: (A) EICs for m/z = 223.0577 corresponding to [M + Na+] for 31 from LC-MS 
analyses of extracts of S. coelicolor W86 (red traces) and W301 fed with 26 (blue traces) (B) 
HR-MS data at 14.3 minutes showing m/z = 223.0577 corresponding to [M + Na+] for 31, 
following LC-MS analysis of extracts from W301 fed 26. 
 
2.3 Metabolites profiling of S. coelicolor transconjugant strains lacking the 
genes: mmyP, mmyG, mmyT, mmyK or mmyX 
As noted in the introduction, various S. coelicolor transconjugant strains lacking 
individual putative biosynthetic genes, and the transcriptional repressor, mmyR 
(replaced with an apramycin resistance gene), were previously constructed using the 
cosmid C73_787 which contains the entire methylenomycin biosynthetic gene 
cluster.174 However, the metabolic profiles of double mutant strains: (∆mmyP/ 
mmyR::apr), (∆mmyG/mmyR::apr), (∆mmyT/mmyR::apr), (∆mmyK/mmyR::apr) and 
(∆mmyX/mmyR::apr) were not previously examined to assess the involvement of the 
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enzymes encoded by each of these mmy genes in the biosynthesis, and to characterise 
any intermediates which may accumulate in the double mutants. 
Thus, the strains were fermented on SMMS and the culture extracts were analysed by 
LC-ESI-HRMS. Fig. 2.12 shows the metabolic profiles of the transconjugant strains, 
compared with those of the mmyR mutant and the heterologous host M145 fermented 
and analysed under the same conditions. Since the cosmid C73_787 includes the 
mmfLHP which code for the biosynthesis of the methylenomycin furan signalling 
molecules (and these genes have not been deleted in each of the mutant strains), they 
provide an opportunity, in the first instance, to confirm the integration of each of the 
mutated constructs into the M145 genome. Thus, each of the strains was expected to 
produce the methylenomycin furans. Indeed, methylenomycin furans (MMF1 and 
MMF4) were detected in all the double mutant strains as well as the mmyR only 
mutant.  
More importantly, the data show that the production of methylenomycin antibiotics is 
completely abolished in the ∆mmyX/mmyR::apr double mutant strain, indicating that 
MmyX is essential for their biosynthesis. Since MmyX shows sequence similarity to 
a kinase, the result strongly points to a need for some intermediates in the 
methylenomycin pathway to be phosphorylated.  
The data also show that methylenomycin production is not abolished in each of 
mmyG/mmyR::apr, mmyK/mmyR::apr, mmyP/mmyR::apr, and mmyT/mmyR:: 
apr transconjugant strains, although the level of production is greatly reduced in the 
mmyP/mmyR::apr and the mmyT/mmyR::apr transconjugant strains. 
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mmyG, mmyK, mmyP and mmyT respectively code for enzymes which have sequence 
homologies to a dehydrogenase/ketoreductase, kinase, phosphatase and a thioesterase. 
The results suggest that these enzymes are either not essential for the biosynthesis of 
methylenomycin antibiotics or that they are not very specific, in which case, enzymes 
with similar functions in the parent strain may perform their functions in their absence, 
accounting for why methylenomycins production is not aborted in the mutant strains.  
The medium used for the production, SMMS, contains a high phosphate 
concentration, which has been reported to favour the production of methylenomycin 
compounds over the other antibiotics (prodiginnes, actinorhodins and CDAs) 
 17 19 22 
S. coelicolor M145 
∆mmyP/mmyR::apr 
∆mmyG/mmyR::apr 
∆mmyT/mmyR::apr 
∆mmyX/mmyR::apr 
∆mmyK/mmyR::apr 
mmyR::apr 
Fig. 2.12: EICs from LC-MS analyses of extracts of S. coelicolor transconjugants for m/z = 
167.0700, corresponding to [M + H+] for methylenomycin C (17), and m/z = 181.0850 
corresponding to [M + H+ - H2O] for MMF1 (19) and MMF4 (22). Each strain contains the cosmid 
C73_787 with mmyR replaced with an apramycin resistance gene/ plus a putative methylenomycin 
biosynthetic gene deleted. 
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produced by Streptomyces coelicolor.159 None of these other antibiotics was detected 
in the LC-ESI-HRMS analysis of the culture extracts. It is therefore very unlikely that 
a “cross talk” between methylenomycin pathway and the pathways of these other 
antibiotics was responsible for sustaining methylenomycin production in the mutant 
strains. Rather, a set of compounds produced under the same fermentation conditions, 
and which were consistently detected in these transconjugant strains, are germicidins 
A and B7, biosynthesized by a type III polyketide synthase.136 While bioinformatic 
analysis did not reveal homology between any of MmyG, MmyK, MmyP and MmyT 
and the enzymes encoded in the S. coelicolor M145 Gcs, responsible for germicidins 
production; the possibility of interactions between such a pathway and the 
methylenomycin pathway may not be completely ruled out. 
The other possible reason for why methylenomycin production is not abolished in the 
mutant strains is that the pathway benefits from activity of enzymes involved in 
primary metabolism of the host strain. It has been noted that the pathway to many 
specialised metabolites of S. coelicolor (including CDAs, prodiginine and 
actinorhodin) rely on the fatty acid synthase (FAS) enzymes for some key steps in 
their biosynthesis.186,187 A good example is the recruitment of the ketoreductase, 
dehydratase, and enoyl reductase from FAS to carry out the full reduction of a β,δ-
diketo hexanoyl ACP intermediate of the CDA epoxyhexanoyl side chain, initially 
produced by FabF3, a ketoacyl synthase II encoded in the CDA cluster (Scheme 
2.4).185  The hexanoyl ACP generated is subsequently hydrolysed to an acid by a 
thioesterase from FAS, and converted to an hexanoyl CoA by an acyl-CoA synthase, 
also from FAS. The hexanoyl CoA is then desaturated by HxcO (a FAD-dependent  
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Scheme 2.4: Biosynthesis of the epoxyhexanoyl side chain of CDA initiated by SC03249 (an 
ACP), FabH4 (a KAS III) and FabF3 (a KAS II) encoded in the CDA cluster. Enzymes from 
primary metabolic fatty acid synthase (FAS) are employed to generate the fully reduced 
hexanoyl-CoA. The last step in this pathway (epoxidation) has been shown in scheme 2.2(B). 
acyl-CoA oxidase/dehydrogenase) and epoxidized by HcmO (a flavin-dependent 
monooxygenase), both enzymes encoded in the CDA cluster. The biosynthesis of this 
moiety of the CDA thus reveal an interplay between enzymes encoded in the CDA 
cluter and those of the primary metabolic fatty acid synthase.  
The pathway proposed for the biosynthesis of methylenomycin antibiotics already 
suggests that a malonyl-CoA acyl carrier protein transacylase (MCAT) derived from 
a primary metabolic FAS would catalyse the loading of a malonyl group onto MmyA, 
the ACP encoded in the methylenomycin gene cluster (see scheme 1.3). It is therefore 
possible that some FAS enzymes could also intervene downstream along the pathway 
in the absence of a mmy enzyme. The fact that the thioesterase, MmyT, is encoded in 
the methylenomycin cluster suggests a need for the MmyA-bound diketide in the 
methylenomycin pathway to first be hydrolysed prior to undergoing condensation 
with a pentulose. Thus, a thioesterase from a FAS may be responsible for this reaction 
in the absence of MmyT, explaining why methylenomycins were not completely 
abolished in the mmyT mutant strain. A ketoreductase encoded within a FAS may also 
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be acting in lieu of MmyG in the mmyG/mmyR::apr double mutant strain, accounting 
for why methylenomycin production is fully retained in the strain.  
The phosphatase, MmyP, might also be complemented by MmfP, another phosphatase 
encoded in the methylenomycin gene cluster. mmfP belongs to the operon of three 
genes required to biosynthesize the methylenomycin furans and has not been deleted 
in all the mutant strains. Similarly, the retainment of methylenomycin production in 
the mmyK/mmyR::apr double mutant strain could be due to the presence of mmyX,  
whose product bears a 42% identity to MmyK (both kinases). As discussed earlier, 
methylenomycin production was abolished in the ∆mmyX/mmyR::apr double mutant 
strain, indicating that MmyX is essential for methylenomycins biosynthesis (Fig. 
2.10). Thus, it appears MmyX may be sufficient for all the phosphorylation steps in 
the pathway. 
However, no new methylenomycin-related intermediates were found in the 
transconjugant strains, except the ∆mmyG/mmyR::apr double mutant. This newly-
identified compound is the focus of the next section. 
2.4 Identification of a putative butenolide intermediate in the methylenomycin 
biosynthetic pathway 
As noted in the introduction (section 1.8.2), the biosynthesis of the methylenomycins 
is proposed to proceed via a butenolide intermediate (25) formed by mmyD, a 
homologue of the avrD in Pseudomonas syringae. However, experimental evidence 
was lacking for this proposed intermediate. 
In the LC-MS analysis of S.coelicolor transconjugants containing the mmy gene 
cluster, a compound was identified in the (∆mmyG/mmyR::apr), (∆mmyO/ 
  Chapter Two – Biosynthesis studies 
71 
 
mmyR::apr) and (∆mmyF/mmyR::apr) strains. This compound eluted at ca. 15 mins 
and it is absent in the heterologous host, S. coelicolor M145 (Fig. 2.13). HR-MS data 
revealed that the compound shows an m/z [M + Na]+ value of 239.0877 and molecular 
formula C
9
H
12
O
6
Na (4.2 ppm error), consistent with the sodiated form of the proposed 
butenolide intermediate.  The compound fragments under the mass spectrometric 
conditions, losing a molecule of water to give m/z = 221.0416 corresponding to 
C9H10O5Na and m/z = 199.0595 corresponding to C9H11O5. This in turn loses a 
molecule of water to give the prominent peak with m/z = 181.0493 corresponding to 
C9H9O4 as shown in the figure. Fragmentation of the putative butenolide intermediate 
via the serial loss of water molecules is consistent with the proposed structure which 
has many easily-cleaved hydroxyl groups. 
 Interestingly, these ions were also detected in S. albus J1074 transformed with the 
cosmid containing the entire mmy gene cluster (except mmyR) but absent in wild type 
S. albus J1074 strain, indicating that the metabolite is a product of the mmy gene 
cluster. However, attempts to purify the compound from scaled-up cultures of the 
producing transconjugant strains was unsuccessful, due to the fact that the compound 
was present in much lower titers compared to other methylenomycin compounds 
produced by the strains. 
Thus, in an effort to further investigate whether the compound is indeed related to the 
methylenomycins, [U-13C]-D-ribose was fed to strain W108 (M145/C73_787/ 
∆mmyF/mmyR::apr) grown in SMM liquid as detailed in the methods section (5.15.2). 
The heterologous host (M145), without methylenomycin gene cluster, was also grown 
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Fig. 2.13: LC-ESI-HRMS analyses showing the putative butenolide intermediate and its 
proposed fragment ions from extracts of S. coelicolor transconjugant strains lacking mmyG, 
mmyO or mmyF (A) EICs for m/z = 181.0493, corresponding to C9H9O4 for 34 (B) HR-MS 
data showing m/z = 239.0877, the sodiated adduct of the proposed butenolide (25), and 
fragment ions resulting from loss of water molecules. 
and fed in parallel. If the proposed butenolide (25) is a precursor of methylenomycin 
C (17), a similar pattern of incorporation of the labelled precursor would be expected 
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into 25 and 17. Fig. 2.14 shows mass spectra data obtained from analysis of the culture 
extracts from the feeding experiments. The data revealed, in addition to m/z 167.07 
normally obtained for 17, the presence of peaks representing increases in m/z units of 
2, 3, 4, 5, and 7. Similarly, a series of peaks with an increase in m/z of 2, 3, 4, 5 and 7 
were also obtained for the m/z of 181.049, derived from the putative butenolide. These 
ions were completely absent when S. coelicolor M145 was fed with the 13C-labelled 
D-ribose (bottom spectra Fig. 2.14).  
The increases in m/z values observed for the putative butenolide (25) can be explained 
based, partly on the incorporation of various intermediates or combination of 
intermediates of the primary metabolic pentose-phosphate pathway and the 
interconnected glycolytic pathway, and on previous studies which have confirmed the 
positions of  labelled 3-, 4-, and 5-carbon units into 16 and 17.172,173  The fed 13C – 
labelled D-ribose is rapidly converted in the cytosol to [U-13C]- ribose-5-phosphate, 
which is then isomerised via the pentose-phosphate pathway to [U-13C]- ribulose-5-
phosphate, itself in constant equilibrium with its epimer, [U-13C]-xylulose-5-
phosphate. Thus, the observed intact incorporation of a labelled 5-carbon precursor 
could have emanated from any of these three intermediates (Scheme 2.5, pink arrows).   
Since the butenolide intermediate (25) is proposed to derive from a MmyD-catalysed 
condensation of a pentulose with acetoacetyl-MmyA,173 it follows that the labelled 4-
, 3-, and 2-carbon units incorporated separately into 25 must proceed via incorporation 
into a pentulose or the diketide, acetoacetate. Each of the transketolase steps in the 
pentose-phosphate pathway (the transfer of a 2-carbon fragment from [U-13C]-
xylulose-5-phosphate to [U-13C]-ribose-5-phosphate and erythrose-4- phosphate) 
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Fig. 2.14: H-MS data following LC-MS analyses of extracts of S. coelicolor W108 and 
M145 fed with [U-13C]-D-ribose. Similar increases of m/z values by 2, 3, 4, 5, and 7 units 
were obtained with respect to methylenomycin C (167.07, top spectra) and the putative 
butenolide derivative (181.049, middle spectra). The ions were absent in the wild type M145 
fed in parallel (bottom spectra). Peak with m/z 185.114 present in the bottom and the middle 
spectra is a metabolite of the wild type M145 and is unrelated to the methylenomycins. Results 
were reproducible in S. coelicolor W100 (M145/C73_787/∆mmyO/mmyR::apr). 
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Scheme.2.5: Pathways for the incorporation of 13C-labelled 5-carbon unit (pink arrows), 3-
carbon unit (brown arrows), and 2- and 4-carbon units (red arrows) derived from [U-13C]-D-
ribose into the butenolide (25) and methylenomycin C (17). R5P: ribose-5-phosphate, Ru5P: 
ribulose-5-phosphate, Xu5P: xylulose-5-phosphate, G3P: glyceraldehyde-3-phosphate, E4P: 
erythrose-4-phosphate, 6FP: fructose-6-phosphate, S7P: seduheptulose-7-phosphate, aa-
MmyA: unlabelled acetoacetyl-MmyA. 13C labelling are denoted with bold blue 
bonds/atoms.* indicates the labelled compounds observed in the HR-MS analysis. 
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phosphate) will generate a molecule of [U-13C]-glyceraldehyde-3-phosphate. This 
may then be combined with an unlabelled fructose-6-phosphate in a reverse 
transketolase step to give erythrose-4-phosphate and xylulose-5-phosphate, labelled 
only at C-3, C-4 and C-5 positions. MmyD-catalysed condensation of this partially-
labelled xylulose-5-phosphate with unlabelled acetoacetyl-MmyA will afford 25 
labelled only at C-3’, C-4’ and C-5’, subsequently leading to methylenomycin C (17) 
labelled at C-3, C-4 and C-8 (scheme 2.5, brown arrows). This accounts for the 
observed incorporation of labelled 3-carbon unit into the putative butenolide (25). 
 [U-13C]glyceraldehyde-3-phosphate is oxidised in the glycolytic pathway to [U-13C]-
pyruvate, which is further broken down under aerobic conditions to [U-13C]-acetyl-
CoA, with the release of 13CO2. To account for the incorporation of a labelled 2-carbon 
unit into 25, the [U-13C]-acetyl-CoA would undergo a MmyC (KAS III) – catalysed 
Claisen condensation with an unlabelled malonyl-MmyA, giving acetoacetyl-MmyA 
that is labelled only at two carbon positions. This partly-labelled acetoacetyl-MmyA 
may then be condensed with a pentulose to give 25 labelled at C-3 and C-4, and 
subsequently 17 labelled at C-5 and C-9 (scheme 2.5 red arrows and top branching).  
Increases in m/z values by 4 units observed in the metabolites correspond to the 
incorporation of 2 units of [U-13C]-acetyl CoA. In this case, one unit of the [U-13C]-
acetyl CoA is first converted to [U-13C]-malonyl CoA by acetyl CoA carboxylase, 
using the 13CO2 released from pyruvate catabolism to form H2
13CO3 that provides the 
source of the carbon. The [U-13C]-malonyl CoA formed is then loaded onto the ACP, 
MmyA, and condensed with [U-13C]-acetyl CoA to give [U-13C]-acetoacetyl-MmyA, 
a step catalysed by MmyC. The fully labelled acetoacetyl-MmyA may then be 
combined with a pentulose to give 25, labelled at C-4, C-3 and C-2, C-1. This would 
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subsequently give 17 labelled at C-5, C-9 and C-1, C-6 (scheme 2.5, red arrows and 
downward branch).  The observed increase in m/z values of the two metabolites by 7 
units may result from the incorporation of a unit of [U-13C]-glyceraldehyde 3-
phosphate (via the partly labelled xylulose-5-phosphate route) plus 2 units of [U-13C]-
acetyl CoA as detailed above.  
Similar incorporation patterns observed for methylenomycin C (17) and the putative 
butenolide fragment, coupled with the fact that the identified putative butenolide 
compound is absent in the heterologous host, strongly suggest that 17 (and other 
methylenomycin compounds) could indeed derive from this compound. 
2.5 Overproduction of mmyD in E. coli  
Cloning of the mmyD homologue, avrD, and overproduction in E. coli or P. syringae 
has been shown to lead to the production of syringolides 1 and 2. 188,189 To investigate 
whether overproduction of mmyD could also lead to the production of the butenolide 
intermediate (25) or other advanced intermediate of the methylenomycin pathway, the 
gene was amplified from the construct C73_787/mmyR::apr  and cloned into pET151 
under the control of an IPTG-inducible T7 promoter. The resulting construct, pGI003, 
was sequenced to confirm the presence of the mmyD gene in the right orientation, and 
was subsequently used to transform E. coli BL21*. The wild-type E. coli BL21* and 
the E. coli BL21* carrying pGI003 were then grown in M9 medium at 37 oC to an 
O.D600nm of 0.7, before IPTG was added to a final concentration of 0.5mM. The 
cultures were incubated overnight at 15 oC, followed by extraction with ethyl acetate. 
An additional control experiment in which E. coli BL21*/pIG003 was grown in 
parallel but without IPTG induction was also carried out. 
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Fig. 2.15: LC-ESI-HRMS analyses of extracts from cultures of wild-type E. coli BL21* and 
E. coli BL21*/pGI003 strains (A) EICs at m/z = 205.0699 corresponding to [C8H13O6]+, 
produced only in the culture of E. coli BL21*/pGI003 to which IPTG was added (B) HR-MS 
data at 13.9 minutes showing the peak m/z 205.0699 and fragment ions resulting from loss of 
water molecules.  
LC-MS analysis of the culture extracts revealed a compound with m/z [M + H]+ of 
205.0699, corresponding to C8H13O6
+, produced in the presence of IPTG in the culture 
of BL21*/pGI003 (Fig. 2.15). The compound was absent in the induced culture of the 
wild-type E. coli BL21*, indicating that it forms due to mmyD overproduction in the 
strain carrying pGI003. The compound shows a serial loss of water molecules, similar 
to the putative butenolide (25) produced by the S. coelicolor transconjugant strains. 
E. coli BL21* + IPTG 
E. coli BL21*/pGI003 + IPTG 
BL21*/pGI003 (No IPTG)  
compound m/z = 205.0699 
(A) 
(B) 
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However, upon feeding of [U-13C]D-ribose to a culture of BL21*/pGI003 containing 
IPTG and analysis of the extract by LC-ESI-MS, the result revealed increases in m/z 
value of the compound by only 2 and 6 mass units (Fig. 2.16), suggesting that the 8-
carbon metabolite is derived from a 2-carbon and a 6-carbon precursor, in contrast to 
the incorporation patterns observed for the butenolide intermediate (25) and 
methylenomycin C (17). 
      
Fig. 2.16: HRMS data at 13.9 minutes following LC-MS analysis of extract of E. coli 
BL21*/pGI003 fed with [U-13C]D-ribose. Two peaks representing increases in m/z value by 
approximately 2 and 6 units are seen in addition to the peak m/z 205.0698. 
The results indicate that mmyD expression alone is not sufficient to produce 25 in E. 
coli, unlike its homologue, avrD, whose sole expression directly led to the production 
of the syringolides.189 The results also suggest that the ketoacyl synthase III, MmyC 
(encoded in the methylenomycin cluster and required for the production of 
acetoacetyl-MmyA) is essential to the pathway and its action may not be substituted 
by KAS III from primary metabolic fatty acid synthase of E. coli, explaining why the 
butenolide (25) or other methylenomyin-related compound could not be detected in 
205.0698
207.0769
211.1433
sample 3_RA4_01_11878.d: +MS, 13.9min #1665
0.0
0.5
1.0
1.5
2.0
5x10
Intens.
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this experiment. This may also account for why singular expression of mmyD in S. 
coelicolor (strain W117) or S. albus (strain W305) under the control of a strong 
constitutive promoter ermE* did not lead to the production of any methylenomycin-
related metabolite.  
2.6 Construction of ∆mmyQ and ∆mmyY transconjugant strains via In vitro 
CRISPR-Cas9 
In addition to the mmy enzymes discussed in the above sections, the cluster also 
encodes MmyQ, a coenzyme F420-dependent reductase, and MmyY, belonging to the 
superfamily of nuclear transport factor 2 (NTF2). S. coelicolor mutant strains lacking 
these individual genes were not previously constructed and it has not been 
investigated whether any methylenomycin intermediates accumulate in such mutants. 
These genes were therefore deleted to pave the way for metabolic profiling of the 
respective S. coelicolor transconjugant strains. 
2.6.1 Principle of CRISPR-Cas9 
The clustered regularly interspaced short palindromic repeats/CRISPR assisted 
protein (CRISPR/Cas) is a relatively new technique that exploits the innate immune 
abilities of bacteria to cleave foreign plasmids and viruses. This protective system has 
been reportedly found in about 40% of sequenced bacteria, with some having more 
than one CRISPR locus in their genome.190,191  
Invading plasmids and DNA are first captured and integrated into the CRISPR locus 
as spacer sequences, separated by some repeat sequences which are highly conserved 
in the bacteria. These spacer sequences then function as templates to generate short 
CRISPR RNAs (crRNAs) which can pair with complementary DNA strand in the 
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invading molecule.192 The CRISPR locus contains sequences for trans-activating 
RNAs (tracrRNAs) which forms a complex with the crRNAs and recruits it onto the 
Cas9 nuclease enzyme (Fig. 2.17).192 The crRNA-tracrRNA complex then serves as a 
guide to direct the Cas9 nuclease to the target site on the foreign DNA where cleavage 
 
 
 
Fig. 2.17: Schematic depicting the mechanism of DNA cleavage by CRISPR/Cas9. CRISPR 
RNA (crRNA) generated using spacers from captured foreign DNA is combined with 
transactivating RNA (tracrRNA) from the CRISPR locus. The resulting hybrid associates with 
Cas9 nuclease and guides it to the target site on the invading DNA. Modified from Sander 
and Joung.194 
spacers tracrRNA 
CRISPR 
repeats 
crRNAs tracrRNA 
crRNA-tracrRNA 
       hybrids 
 
Cas9-crRNA-tracrRNA 
       complex 
 
Cleavage of target DNA 
   site by the complex 
 
Target DNA 
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occurs 3 or 4 base pairs upstream of a protospacer adjacent motif (PAM) sequence to 
give a double strand break.193,194   
While the CRISPR/Cas system has been studied in a wide range of bacteria including 
Escherichia coli, Solfolobus solfataricus, Haloquadratum walsbyi, Pseudomonas 
aeruginosa, and many Streptococcus species,195,196 the most widely used is the Cas9 
nuclease derived from Streptococcus pyogenes (SpCas9). This cas9 nuclease has been 
shown to contain two catalytic domains, HNH and RuvC, for cleaving intruding DNA 
on the strand complementary to the crRNA and on the non-complementary strand 
respectively.190,194 These nuclease domains are activated by the sequence: 5’-NGG-
3’, which is the PAM for the SpCas9 system and also provides a way to distinguish 
self from foreign DNA, preventing the cas9 from cutting within the Streptococcus 
pyogenes’ CRISPR locus.194  
The fact that Streptomyces genomes are rich in G and C nucleotides makes them 
particularly amenable to editing by SpCas9, as an ‘NGG’ sequence can be easily found 
near almost any region of interest.192 ‘N’ in ‘NGG’ refers to any of the four nucleotide 
bases while ‘G’ is guanine.  
In addition to its demonstrated use for targeting individual genes and genomic loci on 
bacterial chromosomes,192,197 the Cas9 system of Streptococcus pyogenes has been 
used successfully to delete genes located on plasmids/cosmids in a variant of the 
technique regarded as in vitro CRISPR/Cas9-mediated editing (ICE).198 This 
approach was employed in this study to delete mmyQ and mmyY from the cosmid 
C73_787/mmyR::apr. 
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2.6.2 sgRNA design and excision of mmyQ and mmyY by Cas9 
Jinek and co-workers in 2012 made a major advance in CRISPR/Cas9 use when 
they showed that, instead of separate crRNAs and tracrRNA used naturally by 
bacteria, it is possible to fuse these two component RNA molecules into a single 
synthetic guide RNA (sgRNA), while still achieving excellent specificity of the 
target site.199 Thus, with careful design of an approximately 20 nucleotide sequence 
upstream of an ‘NGG’ on a targeted sequence, it is possible to generate the required 
synthetic guide RNA (sgRNA) by extension PCR with the plasmid pCRISPomyces 
2 as template.192,203 Using the CRISPR design tool at (http://crispr.mit.edu), a pair 
of ca. 20 nucleotide sequences were selected to delete each of mmyQ and mmyY to 
generate in frame deletions. Fig. 2.18 shows the sequence of the primers designed 
and PCR amplification of the sgRNA first as DNA templates. 
The generated DNA templates were transcribed to RNA (the actual sgRNAs) which 
were subsequently used to guide the Cas9 nuclease to delete mmyQ and mmyY on 
the C73_787/mmyR::apr cosmid (as detailed in the methods section 5.12.4). The 
Cas9 enzyme, in addition to its endonuclease activities, possesses exonuclease 
activity which trims the double strand break at the end without PAM of the non-
complementary strand to give a sticky end, with up to 14 nucleotides randomly 
missing beginning from the cut site.198, 200 This is undesirable as it may lead to 
unintended loss of sequences immediately 5’ of the cut site in the cosmid and may 
affect the expression of elements encoded by the flanking sequences. Thus, the 
mmyQ-mutated and mmyY-mutated cosmids were repaired by treatment with T4 
DNA polymerase to give blunt ends, which were subsequently self-ligated (as 
detailed in the methods section 5.12.5). 
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Fig. 2.18: Synthetic guide RNA (sgRNA) design and generation by extension PCR: (A) 
Sequences of the forward primers used to delete mmyQ and mmyY. Black: a protective 
sequence for the T7 promoter sequence (yellow). Green: the first and most essential half of 
the 6 nucleotide consensus initiation sequence for T7 promoter,201, 202 the first base of which 
is the transcription start point. Blue: the 20 nucleotides crRNA sequence specific for each 
primer. Red: the sequence matching the plasmid (pCRISPomyces-2) segment flanking the 
trans-activating crRNA (tracrRNA) sequence. The reverse primer, sgRNA-rev, was the same 
for all the reactions (see methods section 5.12.1) (B) Gel from agarose electrophoresis 
separation following PCR amplification of the synthetic guide RNA (sgRNA) sequences as 
double–stranded DNA templates (Q1 and Q2 for mmyQ-sgRNA-1 and mmyQ-sgRNA-2 
respectively, and Y1 and Y2 for mmyY-sgRNA-1 and mmyY-sgRNA-2 respectively).  
Editing of cosmids by CRISPR/Cas9 would normally generate one or more copies 
of the mutated cosmid, in a mixture with many copies of the original cosmid. Thus, 
in order to identify the ∆mmyQ and ∆mmyY cosmids, aliquot from the ligation 
mixture was used to transform chemically-competent TOP10 E. coli cells, and 
colonies were selected on LB plates supplemented with apramycin. The colonies 
were passed through LB broth supplemented with apramycin at 37 oC overnight, 
and then served as templates in a PCR screening reaction with primers mmyQ-scrn-
(A) 
(B) 
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fwd/mmyQ-scrn-rev and mmyY-scrn-fwd/mmyY-scrn-rev, annealing approximately 
200 bp from the mmyQ and mmyY cut sites respectively (methods section 5.12.6). 
Fig. 2.19 shows the gel from electrophoretic separation of the PCR products, and 
the bands identifying the colonies containing the ∆mmyQ and ∆mmyY cosmids. 
 The mutated cosmids were purified by standard procedure from overnight cultures 
of the identified colonies and sequenced with the same pair of primers used for the 
screening in each case. Results from sequencing (shown in appendix 1) confirmed  
 
(A) 
          
(B) 
           
Fig. 2.19: gel from agarose electrophoresis separation following PCR amplification of mmyQ 
and mmyY in cultures of E. coli TOP10 transformed with CRISPR/Cas9-edited cosmids (A) 
Identification of C73_787/mmyR::apr cosmid lacking mmyQ (bands at ca. 400 bp). Copies of 
the original cosmid unedited by Cas9 are shown by bands appearing at ca. 1000 bp (B) 
Identification of C73_787/mmyR::apr cosmid lacking mmyY (bands at ca. 400 bp). Copies of 
the original cosmid unedited by Cas9 are shown by bands appearing at 850 bp. 
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the excision of mmyQ and mmyY on the cosmid while the flanking sequences remained 
intact, demonstrating the effectiveness of the CRISPR/Cas9 system in targeting only 
the intended DNA segment. 
2.7 Transfer of the ∆mmyQ and ∆mmyY constructs to S. coelicolor M145 and LC-MS 
analysis of extracts from cultures of the resulting transconjugants 
To examine whether MmyQ and MmyY are essential for the biosynthesis of the 
methylenomycin antibiotics, the Cas9-generated constructs, named pGI001 (for 
C73_787/mmyR::apr/∆mmyQ) and pGI002 (for C73_787/mmyR::apr/∆mmyY), were 
used to transform the non-methylating E. coli ET12567/pUZ8002. This was 
subsequently conjugated with S. coelicolor M145 to give W314 and W315 strains, 
lacking mmyQ and mmyY respectively. PCR analysis of the ∆mmyQ and ∆mmyY 
transconjugant colonies produced bands for mmyD (Fig. 2.20), encoding for the 
butenolide synthase essential for the methylenomycin pathway, thereby confirming 
the integration of the constructs into the M145 genome.  
                                         
Fig. 2.20: gel from agarose electrophoresis separation following PCR amplification of mmyD 
in W314 (S. coelicolor/pGI001) and W315 (S. coelicolor/pGI002). 1- W314, 2- W315, 3- S. 
coelicolor M145, lacking the C73_787 cosmid. DNA size markers are in bp. 
W314 and W315 strains were then fermented on SMMS and extracted with ethyl 
acetate. LC-ESI-HRMS analysis of extracts from the strains showed that only 
methylenomycin furan compounds could be detected in the extracts, while the 
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production of methylenomycin compounds was completely abolished (Fig. 2.21). 
Similar results were obtained with S. albus J1074 transformed with pGI001 and 
pGI002 (strains W316 and W317 respectively). The results suggest that both MmyQ 
and MmyY may play as yet unidentified roles in the biosynthesis of the 
methylenomycins. Indeed, possible steps involved in producing the methylemycin 
compounds from the putative butenolide intermediate (proposed in the concluding 
section 4.1.3) require the reduction of double bonds, and MmyQ, which is the only 
reductase encoded in the mmy cluster, may be required for these reductions. However, 
no methylenomycin-related intermediates were found to accumulate in the mutant 
strains, thus no further insight into their roles could be gained in the current study 
Fig. 2.21: EIC for m/z = 167.0700 corresponding to [M + H+] for methylenomycin C (17) and 
m/z = 195.0800 corresponding to [M + H+ - H2O] for MMF3 (21), following LC-ESI-MS 
analysis of the culture extracts of S. coelicolor W314 (M145/pGI001), W315 (M145/pGI001), 
M145 and W89 (mmyR only mutant). 
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study.  More work will be needed to demonstrate the role played by MmyQ in the 
biosynthesis of the methylenomycins, and that of MmyY (a nuclear transport protein) 
in the biosynthesis and/or regulation of the production of the methylenomy-cin 
antibiotics.  
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CHAPTER THREE 
3. ANTIMICROBIAL ACTIVITIES AND MODE OF ACTION OF 
METHYLENOMYCINS AND INTERMEDIATES 
3.1 Antimicrobial activities of the methylenomycins and intermediates 
Methylenomycin A (MmA, 16) had long been shown to exhibit activity against many 
Gram-positive bacterial strains and some Gram-negative ones, particularly the 
Proteus genus.171 Efforts towards investigating the biosynthesis of this compound has 
led to the accumulation, in various S. coelicolor mutant strains, of intermediates and 
shunt products of the methylenomycin pathway. These include pre-methylenomycin 
C (P-MmC, 26), pre-methylenomycin C lactone (P-MmCl, 27), methylenomycin D1 
(MmD1, 28) and methylenomycin D2 (MmD2, 29) (Fig. 3.1). As the biological 
activities of these newly characterised compounds had not been assessed, their 
antimicrobial properties were investigated as part of the current study. The 
penultimate compound of the pathway, methylenomycin C (MmC, 17), was also 
investigated. The purification 26 and 27 is described in the methods section 5.14.3; 
purification of 28 and 29 is also described in section 5.14.4. Isolation of 17 was 
discussed in section 2.1.3 of chapter 2.                                                                   
Activities of 17 and 26 – 29 were determined relative to the activity of MmA (16) 
against a range of Gram-positive and Gram-negative strains. The minimum inhibitory 
concentration (MIC) of each compound leading to no visible growth of the test strains 
was determined by a broth microdilution method in 96-well microtiter plates 
according to the Clinical and Laboratory Standards Institute (CLSI) guidelines 
(section 5.16.1).205 
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To determine the minimum bactericidal concentrations (MBC), a fluorescence-based 
microplate assay with AlamarBlueTM dye was employed.206 Viable bacterial cells, due 
to the reducing environment maintained within their cytosols, irreversibly convert a 
non-fluorescent blue compound called resazurin (the active component of the 
AlamarBlueTM) to a reduced and highly fluorescent red form, resorufin (Scheme 
3.1).207  The fluorescence generated is a measure of the amount of resorufin produced, 
which in turn depends on the population of viable cells in the culture. Incubation of 
test strains with increasing concentrations of an antimicrobial agent and addition of 
the AlamarBlueTM dye resulted in MBC values that correspond to a sharp drop in the 
Fluorescence-concentration curve. Fig. 3.2 exemplifies the plots obtained from 
AlamarBlueTM MBC assay for some Gram-positive strains and Candida albicans. 
Where necessary, additional tests were carried out within narrower concentration 
ranges. Complete killing of the strains was further confirmed by sub-culturing onto 
antibiotic-free agar plates and incubating for three days with no visible growth.  
     
Scheme 3.1:Conversion of resazurin (the active component of AlamarBlueTM dye) to resorufin 
by viable cells. 
Fig. 3.1: Structures of methylenomycin A and intermediate/shunt products of the pathway 
investigated for their antimicrobial activities. 
 
MmA (16)         MmC (17)       P-MmC (26)     P-MmCl (27)   MmD1 (28)    MmD2 (29) 
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Fig. 3.2:  MBC determination assays with AlamarBlueTM dye. The plots show dosage-
dependent decrease in fluorescence due to cell death in test strains incubated with 
methylenomycin-related compounds. Vertical axis shows fluorescence values as % of drug-
free controls; compound concentrations are in μg/ml. Data shown are representative of 12 
replicates from 3 independent experiments. 
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Table 3.1 provides a summary of the final MIC and MBC values for all the compounds 
and strains investigated. Like MmA, all the intermediate/shunt compounds showed no 
activity against wild-type E. coli, Pseudomonas, Klebsiella, and other Gram-negative 
strains tested. MmD1 and MmD2 also showed no detectable antimicrobial activities 
up to a maximum of 512 μg/ml tested against the Gram-positive strains. However, 
MmC, not previously reported to have antibiotic activity, showed comparable efficacy 
to MmA in most of the Gram-positive strains, although both compounds only showed 
modest activity. Interestingly, the recently discovered intermediates, P-MmCl and P-
MmC, showed much improved activities 
Table 3.1: Activities of isolated methylenomycin intermediates/shunts compared to MmA 
 MIC (MBC) in μg/ml    
 Organism 
MmA  
(16) 
MmC  
(17) 
P-MmCl       
(27) 
P-MmC      
(26) 
MmD1 
(28) 
MmD2 
(29) 
Gram-positive        
S. aureus DSM21979 (MRSA) 256(256)  512(512)  1(1) 16(16) ˣ ˣ 
S. aureus R34 256(256)  256(256)  2(2) 16(16)      ˣ ˣ 
B. subtilis MarburgT 192(192)  192(192)  1(1)   9.8(9.8) ˣ ˣ 
S. coelicolor M145 64(64)   64(64)  1(1) 8(8) ˣ ˣ 
S. albus J1074 256(256)  128(128) 0.5 (0.5) 0.5 (0.5) ˣ ˣ 
E. faecium U0317 256(256)  512(512)  2(2)   32(64) ˣ ˣ 
E. faecium  64/3 ˣ        ˣ 2(2) 8(16) ˣ ˣ 
       
Yeast       
C. albicans SC 5314 256(256) 384(384)  9.8(64)  9.8(64) ˣ ˣ 
       
Gram-negative        
E. coli SY327 - - - - -  - 
P. aeruginosa DSM29239 - - - - - - 
K. pneumoniae DSM26371  -  - -  -  - - 
S. plymuthica RVH1    -  -  -  -  - - 
R. mannitolilytica BCC1391   -  -  -   -  -  - 
B. metallica DSM23519   -   -  -   -  -  - 
B. ambifaria DSM16087    -         -  -   -  -  - 
x (no activity up to 512μg/ml), - (no activity up to 128µg/ml) 
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compared to MmA and MmC. Whereas MmA and MmC were inactive against the 
methicillin-resistant S. aureus (MRSA) until a concentration of 256 and 512 µg/ml 
respectively, P-MmCl and P-MmC gave respective MICs of 1 μg/ml and 16 μg/ml 
against this pathogenic strain. P-MmCl and P-MmC are also very active against 
Enterococci strains, particularly the E. faecium strain 64/3 where these compounds 
gave MICs of 2 and 8 µg/ml respectively, representing at least 256 and 64 fold 
improved activities over MmA and MmC. Similar differences in potency between 
these two metabolites and MmA/MmC were also observed for the other Gram-
positive strains and the yeast (Candida albicans). 
The results indicate that P-MmCl is by far the most active of all methylenomycin-
related compounds isolated to date. This compound showed greater potency against 
Enteroccoci species than vancomycin, an antibiotic that has been widely used for the 
treatment of enterococcal infections.208 Whereas vancomycin only becomes 
bactericidal against Enterococcus faecium 64/3 and Enterococcus faecium U0317 at 
concentrations of 128 µg/ml (86 µM) and 64 µg/ml (43 µM) respectively, P-MmCl 
displayed MBC of 2 µg/ml (12 µM) against these two strains, representing up to a 7-
fold improved activity compared to vancomycin. In addition, sequential passage of E. 
faecium 64/3 through increasing concentrations of vancomycin and P-MmCl over a 
period of 28 consecutive days (methods section 5.16.2) led to the generation of mutant 
colonies less susceptible to vancomycin (MIC 32 µg/ml), compared to the wild-type 
E. faecium 64/3 which is inhibited by vancomycin at 4 µg/ml. The same effect was 
not observed with P-MmCl where E. faecium 64/3 was still susceptible to 2 µg/ml 
after 28 days. The inability of the E. faecium 64/3 strain to develop resistance against 
P-MmCl over such a period of passage suggests a potential for this compound in the 
treatment of enterococcal infections.  
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However, tests of the activities of P-MmCl and P-MmC against ovarian cancer cells, 
shown by the dose-response plots in figure 3.3, reveal that P-MmCl gave IC50 
corresponding to a final concentration of 4 µg/ml, while P-MmC gave IC50 
corresponding to a final concentration of 12 µg/ml. The IC50 value for P-MmCl is 
very close to the concentrations at which the compound inhibits the pathogenic bacte- 
             
            
Fig. 3.3: Dose-response curves of activities of pre-methylenomycin C lactone (27) and pre-
methylenomycin C (26) against ovarian cancer cell line. The concentration at which only 50% 
of the cells survive, IC50 (shown by broken lines), corresponds to a final concentration of 4 
µg/ml for 27 (A) and 12 µg/ml for 26 (B) (Data kindly recorded by Isolda Canelon). 
P-MmCl (27) 
P-MmC (26) 
(10-1 mg/ml) 
(10-1 mg/ml) 
(A) 
(B) 
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-rial strains. The IC50 for P-MmC is also within the range of concentrations at which 
the compound kills the Gram-positive strains. These results thus suggest that both P-
MmCl and P-MmC may be cytotoxic at about the same concentrations as they are 
bactericidal. 
3.2 Does mmr expression confer resistance against pre-methylenomycin C (26) 
and pre-methylenomycin C lactone (27)? 
Antibiotic resistance genes present in antibiotic-producing strains can be transferred 
to other bacteria via horizontal gene transfer, HGT, often leading to the development 
of antibiotic resistance by otherwise susceptible pathogenic strains.209, 210 As 
discussed in chapter 2 (section 2.1.2), expression of the methylenomycin resistance 
gene, mmr, was shown to confer resistance in the S. coelicolor M145 strain, enabling 
feeding experiment to be conducted with methylenomycin C (17), consequently 
leading to its  turnover to MmA (16). Given the much improved antimicrobial activity 
of P-MmC (26) and P-MmCl (27), it was interesting to investigate whether mmr could 
confer resistance against these potent methylenomycin derivatives.  
Antibiotic activities of 26 and 27, alongside those of 16 and 17, were therefore 
investigated on S. coelicolor strains expressing multiple copies of mmr per cell and 
on strains expressing a single copy of the determinant, present on a cosmid integrated 
into the genome of S. coelicolor M145. W302 (M145/pIJ86/mmr) is a 
methylenomycin-resistant strain constructed by transforming S. coelicolor M145 
(SCP1-) with the construct pIJ86/mmr, in which the resistance gene is carried on the 
multicopy plasmid under the control of a strong constitutive promoter, ermE* (section 
2.1.1). W102 is an S. coelicolor M145 strain carrying the entire methylenomycin gene 
cluster except the transcriptional repressor gene, mmyR, and the putative kinase gene, 
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mmyX. While the lack of mmyX in W102 strain causes the abolition of 
methylenomycin production (as shown in section 2.3), it offers an S. coelicolor M145 
strain with only one copy of the mmr gene per cell. The three strains M145, W102 
(M145/C73_787/∆mmyX/mmyR::apr) and W302 (M145/pIJ86/mmr) were therefore 
incubated overnight in Mueller-Hinton broth and diluted in the same medium to 
approximately 105 CFU/ml. The minimum concentration of 16, 17, 26, and 27 
required to kill each of the strains was then determined using the Alamar BlueTM 
assay. 
Figure 3.4 (A to D respectively) shows fluorescence data obtained as a function of 
increasing concentrations of 16, 17, 27 and 26 incubated with the three S. coelicolor 
strains M145, W102 and W302. As expected, the data show that resistance is 
conferred against MmA (16) and MmC (17) in the S. coelicolor strains harbouring 
either the single copy or the multiple copies of the resistance gene. The MBC of 16 
increased from 64 µg/ml in the wild type M145 to 256 µg/ml in W102 
(M145/C73_787/∆mmyX) and 512 µg/ml in W302 (M145/pIJ86/mmr) (Fig. 3.4A). In 
the case of 17, the MBC only increased slightly from 64 µg/ml in M145 to 128 µg/ml 
in both the strains expressing mmr (Fig. 3.4B). Interestingly, however, neither strain 
M145/pIJ86mmr nor M145/C73_787/∆mmyX required concentration of P-MmCl (27) 
and P-MmC (26) above that which killed the wild type strain M145 - both the 
transconjugant strains carrying the resistance determinant as well as the wild type S. 
coelicolor M145 were killed at approximately 0.5 µg/ml by 27 and at 8 µg/ml by 26 
(Fig. 3.4C and D). The results indicate that mmr expression confers greater resistance 
against 16 than against 17, while it has no effect on the activities of 26 and 27.  
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Fig. 3.4: Effect of expression of methylenomycin resistant determinant (mmr) on the activities 
of 16, 17, 27 and 26. MBCs of 16 were raised significantly in strains harbouring mmr, 
compared to the wild type M145 (A); MBCs of 17 only increased slightly (B). MBC values 
of 27 and 26 were unaffected by mmr expression (C and D respectively). Data shown are 
averages of 9 replicates from 3 independent experiments. Error bars represent standard 
deviation values.  
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The indication that Mmr significantly reduced the antibiotic effect of 16 but only 
modestly affect the activity of 17 may probably explain why 17 is rapidly metabolised 
(via the saturation of the double bond at C-2) to the mixture of inactive 
diastereosiomers (MmD1, 28 and MmD2, 29). Although 16 also possesses the same 
exomethylene function at C-2, no similar reduced compounds analogous to 28 and 29 
(derived from 17) were present in the extracts of the S. coelicolor strains 
overproducing 16. Thus, the conversion of 17 to 28 and 29 may be an additional 
mechanism to prevent the antimicrobial effect of 17, while Mmr may be sufficient to 
protect the strain against the activity of 16, the final metabolite of the pathway. 
These results appear to be corroborated by a recent study within the group. It was 
previously proposed that MmyJ, an ArsR-like protein encoded within the 
methylenomycin cluster, could bind to the intergenic DNA sequence between mmyJ 
and mmr (containing the promoter region for the two genes), thereby preventing the 
transcription of mmr.157, 159 Matt Lougher, a former PhD student in the Corre group, 
recently showed that MmyJ did bind to this intergenic region as envisaged. In 
addition, it was shown via electrophoretic mobility shift assay (EMSA) that 16 caused 
the full release of MmyJ from the MmyJ-DNA complex, and 17 caused partial release, 
while 27 had no effect on the MmyJ-DNA complex.158 The study concluded that 16 
was the main ligand sensed by MmyJ, indicating that the onset of production of 16 in 
S. coelicolor causes MmyJ to be released from the DNA (promoter region of mmr), 
eliciting expression of the methylenomycin resistance determinant to trigger the self-
resistance mechanism of the producing strain.158 The fact that 17 only causes partial 
release of MmyJ from DNA (i.e. not able to trigger the full expression of mmr) may 
be consistent with the result shown here which indicates that Mmr only confers partial 
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resistance against 17. The results obtained with the strain carrying the construct 
pIJ86/mmr, where mmyJ is lacking, also suggest that the efflux protein, MmR, might 
bind and transport more specifically MmA (16) than MmC (17), while it does not 
transport P-MmC (26) and P-MmCl (27). 
The complete inability of 27 to release MmyJ from DNA and cause the concomitant 
expression of mmr implies that the expression of this gene may not be the mechanism 
by which the producing strain protects itself against 27 (and probably 26), explaining 
why Mmr could not confer resistance against 26 and 27 in the current study. Since 26 
accumulates in isolable amounts in S. coelicolor (M145/C73_787/ 
∆mmyE/mmyR::apr) and the strain is not killed in the process, the above results 
suggest that an alternative mechanism might be present in the producing strain to 
avoid suicide from the antibiotic effect of 26 (27 is a semisynthetic derivative of 26 
generated by treatment with acid).  
More interestingly, the results suggest that a possible acquisition of the mmr gene by 
other bacterial strains, for instance via HGT, is not likely to confer resistance on them 
against these two potent methylenomycin-derived compounds. This was further 
demonstrated by transforming the wild type S. albus J1074 with the constructs 
pIJ86/mmr and C73_787/∆mmyX, to give strain W319 (S. albus J1074/pIJ86/mmr), 
expressing multiple copies of the resistance gene, and W320 (S. albus J1074/C73_ 
787/∆mmyX), expressing a single copy of the gene per cell, respectively. 
Determination of MBCs of 16, 17, 26 and 27 on the strains revealed that the MBC of 
16 was raised in the S. albus derivative strain expressing either multiple or single copy 
of the resistance gene, while that of 17 was raised only in the W319 strain 
(S.albus/pIJ86/mmr), expressing many copies of the gene (Fig. 3.5 (A) and (B)). In  
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Fig. 3.5: Minimum bactericidal concentration (MBC) determinations for 16 (A), 17 (B), 27 
(C) and 26 (D) against the wild-type S. albus J1074 and its derivative strains, W319 (S. 
albus/pIJ86/mmr) and W320 (S. albus/C73_ 787/∆mmyX). 
both cases, the result confirms that the expression of mmr conferred resistance against 
16 and 17 on the otherwise susceptible S. albus J1074 strain, particularly in the 
derivative strain expressing multiple copies of the gene under the strong ermE* 
promoter. However, the MBC of P-MmC (26) and P-MmCl (27) remained the same 
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(at 0.5 µg/ml) against the two derivative strains, as for the wild type S. albus J1074 
(Fig. 3.5 (C) and (D)). These results demonstrate that the methylenomycin resistance 
protein, Mmr, has no effect on the antimicrobial activities of 26 and 27, and strongly 
indicate that a possible acquisition of the corresponding gene by pathogenic bacteria 
may not confer immunity on them, against these two potent methylenomycin 
analogues. 
3.3 Investigations into the mode of action of methylenomycin antibiotics  
Despite its discovery over four decades ago, the mechanism of action of MmA (16) 
has not been investigated. Knowledge of the mode of action of antibiotics is generally 
desirable in view of rational drug design in which multi-hurdle drugs (incorporating 
moieties killing bacteria using different strategies) are developed, and in 
combinatorial therapies in which an auxiliary drug (acting differently from a main 
drug) is administered to enhance the effectiveness of a major drug.213 
MmA was proposed to act as a DNA-alkylating agent, by forming covalent bonds to 
nitrogen or oxygen atoms in DNA bases, thereby inhibiting DNA replication in 
bacteria.252 However, there is no experimental evidence to support this hypothesis. It 
is also inconsistent with the results from the current study (section 3.1) which have 
shown that MmC (17), pre-MmC (26) and pre-MmCl (27), all possess antimicrobial 
activities, despite lacking the epoxide functionality which may be critical to DNA 
binding in MmA (16). Thus, it was considered necessary to investigate the mode of 
action of 16, along with those of the intermediates in the pathway which have shown 
antimicrobial activities in the current study. The mode of action study was carried out 
with two sets of promoter-reporter fusion strains: the first uses firefly luciferase as the 
reporter gene while the second incorporates a β-galactosidase gene. Further insights 
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were then obtained by testing the methylenomycin-related compounds against E. coli 
strains defective in the outer membrane permeability and in the efflux pump system. 
3.3.1 Mode of action studies with firefly luciferase reporter strains 
There are at least five major targets for antibacterial agents and they form the basis 
for the broad classification of the mechanism of action of antibiotics. These essential 
biosynthetic pathways/targets are DNA synthesis (or replication), RNA synthesis (or 
transcription), protein synthesis (or translation), cell wall biosynthesis and fatty acid 
biosynthesis.12,260  Using the so-called reference compendium of antibiotic-triggered 
mRNA expression profiles, Freiberg and co-workers 211, 212 have identified specific 
promoter regions in B. subtilis which are selectively induced by antibiotics killing 
bacteria by inhibiting these individual pathways. The promoters of the genes yorB, 
yvgS, yheI, ypuA, and fabHB were identified as being specifically induced by 
substances inhibiting DNA synthesis, RNA synthesis, protein synthesis (translation), 
cell wall (including cell envelope stress) and fatty acids biosynthesis respectively.211-
213 
By cloning each of the identified promoter regions in front of a firefly luciferase 
reporter gene, Freiberg and co-workers generated promoter-reporter fusion constructs 
which were transformed into Bacillus subtilis 1S34. Each of the resulting strains thus 
constituted a biosensor for antibiotics interfering with one of the targets.213 The 
biosensors have indeed been validated with a library of 14,000 compounds, including 
many antibiotics with well-defined mode of actions. Each biosensor was induced only 
by antibiotics that kill bacteria by inhibiting the respective pathway, while antibiotics 
with different mechanisms of action were not able to induce a given biosensor, or they 
generate signals below the set threshold.213  
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The methodology used followed the previously published assay procedure,213 with 
only slight modifications (96-well plates were used in this study instead of 384-well 
plates due to template compatibility for luminescence instrumentation). All the B. 
subtilis strains carrying the different promoter-reporter fusion constructs, except yheI, 
were grown in liquid LB medium containing 5 µg/ml erythromycin to an O.D at 600 
nm of 0.9 at 37 oC. The yheI biomarker was grown in Belitzky minimal medium 
(composition in section 5.6). The strains were then diluted to an O.D at 600 nm of 
0.01 (yorB), 0.02 (yvgS), 0.1 (yheI), 0.02 (ypuA) and 0.25 (fabHB) and were kept at 4 
oC overnight. Subsequently, 80 µl of each strain was incubated with 1 µl of 
methylenomycin compounds or 1 µl of a standard antibiotic, confirmed to be an 
inhibitor of the respective pathway and therefore serves as positive control for each 
strain. The standard antibiotics respectively inducing the yorB, yvgS, yheI, ypuA and 
fabHB were ciprofloxacin, rifampin, linezolid, vancomycin and cerulenin. Both the 
methylenomycin compounds and the standard compounds were dissolved in DMSO 
and were tested at three different sub-inhibitory concentration levels: 0.02, 0.08 and 
0.3 µg/ml. Each strain was also incubated at the same time with 1 µl DMSO as the 
non-induced control. Citrate buffer containing luciferin was then added to each well 
and luminescence was measured (see details in the methods section 5.16.3). Fig 3.6 
shows a sample of the plate used and the appearance of luminescence due to antibiotic-
induction of the promoter in one of the biosensor strains. 
The elicitation of luminescence in the assays may be explained by induction of the 
specific promoter in the biosensor strain (antibiotic-stress inducible), consequently 
leading to the strong expression of the firefly luciferase gene cloned downstream of 
each of the promoters. Once expressed, the resulting luciferase enzyme catalyses a 
reaction between molecular oxygen and luciferin, present in the citrate buffer, leading 
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Fig. 3.6: Annotation of a sample of  96-well plate showing the bioluminescence produced by 
the Bacillus subtilis strains carrying the promoter-luciferase fusion constructs. Three samples 
in the column labelled 4 (B4, D4, F4) were non-induced controls, with only DMSO added to 
a biosensor strain. A methylenomycin compound (Mm) and a standard antibiotic were added 
respectively to the columns labelled 6 and 8 to give the final sub-inhibitory concentrations 
shown in the figure. 
to the formation of a luciferin dioxetanone intermediate. This intermediate is highly 
energetic and unstable, due to the presence of a strained four-membered ring and a 
weak peroxide bond (scheme 3.2). Cleavage of this ring thus occurs spontaneously, 
with the release of energy which is efficiently directed towards the production of an 
electronically excited state in the resulting product, oxyluciferin.253 Subsequent rapid 
relaxation of the excited state oxyluciferin to the ground state is accompanied  by the 
release of excess energy as light photons, which is detected and measured in the assay.  
The greater a compound is able to induce a promoter, the more the luciferase enzyme 
is expressed, the more the amount of the energetic dioxetanone intermediate 
generated, and subsequently the higher the luminescence signal observed. 
0.30 µg/ml 
0.08 µg/ml 
0.02 µg/ml 
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Scheme 3.2: Luciferase-catalysed reaction between molecular oxygen and luciferin, 
ultimately leading to the emission of light photons. (*) denotes an electronic excited state. 
 
The decision of which of the major pathways (or biosensors) is ultimately inhibited 
by a test compound depends on comparison of the luminescence produced by the 
compound to that generated by standard antibiotics. Based on the assay development, 
a minimum signal of 250%, 200%, 200%, 170%, and 280% above the drug-free 
control is required respectively for yorB, yvgS, yheI, ypuA, and fabHB biosensors, in 
order for a test compound to be adjudged as an inhibitor of the given pathway.213,214  
Luminescence data obtained with methylenomycin antimicrobial compounds and the 
standard antibiotics are presented in Figure 3.7. The data show that there is no 
significant induction of the fabHB and yorB biosensors by any of the four compounds, 
indicating that they do not inhibit fatty acid biosynthesis, or DNA replication as 
previously conceived. Three of the compounds (MmA, P-MmC and P-Mmcl) gene- 
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Fig. 3.7: Induction of the pathway-specific luciferase biosensors by MmA (A), MmC (B), P-
MmC (C) and P-MmCl (D), compared with induction by the standard antibiotic for each 
pathway. Data shown are averages of 5 independent measurements calculated as % of the 
non-induced signal of the drug-free control. Black horizontal line cutting across each standard 
represents the minimum threshold that must be met by a test compound. (RLU – Relative 
Light Unit). Note: No data could be obtained for the yvgs promoter; the corresponding 
biosensor did not generate any response, even with the positive control. 
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rated signals in the yheI biosensor (marker of protein synthesis inhibition) above the 
200% minimum threshold for a compound believed to be interfering with translation. 
However, the induction of the yheI biosensor by the compounds is far below that 
elicited by linezolid, the positive control for yheI inducers. Interestingly, the ypuA 
biosensor (marker of cell wall inhibition) was significantly induced by all the four 
compounds above the 170% threshold. The more potent P-MmC (26) and PMmCl 
(27) induced the promoter even more than vancomycin (the standard antibiotic for 
ypuA biosensor), suggesting that these compounds inhibit cell wall biosynthesis in 
bacteria.  
In an attempt to further validate the results obtained with the bioactive 
methylenomycin compounds, further experiments were carried out with MmD1 which 
lacks antimicrobial activity. The result (shown in Fig. 3.8) revealed that MmD1 gave 
signal only approximately 180% above the drug-free control in yheI biosensor and 
100% above the drug-free control in ypuA biosensor, compared to the required 
threshold of 200% and 170% respectively for these markers. The compound also did 
not induce the yorB and the fabHB markers up to the required minimum level.  
The results thus indicate that the induction of yheI promoter (biosensor for protein 
synthesis inhibitors) and ypuA promoter (biosensor for cell wall biosynthesis 
inhibitors) by the active methylenomycin compounds is indeed a result of their 
antimicrobial effect. Further assays were then carried out as detailed in the next 
section. 
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Fig. 3.8: Assay of methylenomycin D1 (MmD1) with the luciferase reporter strains. Signal 
generated in all the biosensors was below the minimum threshold. Data represent average of 
4 independent measurements; error bars are standard deviation values associated with the 
measurements. 
3.3.2 Mode of action studies with β-galactosidase reporter strains  
β-galactosidase is a glycoside hydrolase enzyme that catalyses the cleavage of a β-
glycosidic bond between a galactose and an organic moiety. This enzyme is normally 
present in cells where it functions to hydrolyse the disaccharide, lactose, into its 
component monosaccharides – glucose and galactose.215,216 The β-galactosidase 
reporter strains used in this study contain the β-galactosidase gene (lacZ) cloned 
downstream of each of the promoter region of yvgS, yheH, ypuA, yvgI and yjaX, and 
are indicators for substances inhibiting RNA synthesis, translation, cell wall 
biosynthesis, lipid II biosynthesis, and fatty acid biosynthesis respectively. 
The assay relies on the ability of the β-galactosidase to hydrolyse X-gal, a substrate 
consisting of a substituted indole moiety linked by a β-glycosidic bond to a galactose 
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(Scheme 3.3). β-galactosidase cleaves galactose off X-gal, leaving the remainder of 
the molecule which spontaneously dimerises, and is subsequently oxidised to give an 
insoluble blue product.217 This only occurs in the assay if any of the pathway-specific 
promoters is induced by an antibiotic interacting with that pathway. Induction of a 
promoter causes β-galactosidase expression, consequently leading to the hydrolysis 
of X-gal present in the medium.  
        
Scheme 3.3: Structure of X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) and the 
insoluble dimer resulting from its hydrolysis by β-galactosidase. 
Experiments were carried out by adding Bacillus subtilis strains carrying the different 
promoter-reporter fusion constructs to 1% nutrient agar containing X-gal (see 
experimental section 5.16.4 for details). A solution of a standard antibiotic or a 
methylenomycin compound (10 µl) was then placed on a filter in the middle of the 
plates, which were then incubated for 48 hours. 
Figure 3.9 shows the plates with the standard antibiotics placed on the filters. As 
expected, a blue colouration is seen in each of the plates, indicating the induction of 
the respective promoters by the standard antibiotics. Figure 3.10 shows the results of 
the assay with methylenomcin antibiotics. As observed in the experiments with the 
luciferase reporter strains (section 3.3.1), the ypuA promoter (indicator of cell wall 
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Fig 3.9: Induction of β-galactosidase in B. subtilis reporter strains by standard antibiotics: 
yvgS by rifampicin, yheH by chloramphenicol, ypuA by vancomycin, yvgI by bacitracin, and 
yjaX by triclosan. 
biosynthesis inhibition) was induced by all the methylenomycin compounds. In 
addition, the yvgI promoter (marker of lipid II pathway inhibition) and the yjaX 
promoter (marker for fatty acid biosynthesis inhibition) were both induced by the 
methylenomycin compounds. While no connection is immediately apparent between 
cell wall biosynthesis and fatty acid biosynthesis, there is a direct relationship between 
cell wall biosynthesis and the lipid II pathway in bacteria. A key component of the 
cell wall is the polymer substance called peptidoglycan or murein, consisting of 
repeating units of N-acetyl-glucosamine (GlcNAc) and N-acetyl muramic acid 
(MurNAc), which are cross-linked by short peptides.54 Peptidoglycan biosynthesis 
proceeds via a multi-step pathway starting with the enzymatic conversion of UDP-
GlcNAc to UDP-MurNAc. The UDP-MurNAc is then modified by the successive 
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(Figure continued overleaf) 
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(D) 
 
Fig. 3.10: Induction of β-galactosidase pathway-specific promoters by methylenomycin 
antibiotics: MmA (A), MmC (B), P-MmC (C), and P-MmCl (D). 
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addition of L-Ala, D-Glu, Dmp, D-Ala and D-Ala, catalysed respectively by ligase 
enzymes MurC, MurD, MurE and MurF.56, 57 The resulting product, UDP-MurNAc 
pentapeptide, is then linked to a lipid carrier (C55, undecaprenyl) by MraY to form 
lipid I (undecaprenyl-diphosphoryl-N-acetylmuramoyl-pentapeptide).57 The so-called 
lipid II pathway is the conversion of lipid I via linkage to GlcNAc by MurG (a 
membrane-associated glycosyl transferase) to give undecaprenyl-diphosphoryl-N-
acetylmuramoyl-(pentapeptide)-N-acetylglucosamine (lipid II, Fig. 3.11). This full 
monomer of the peptidoglycan is flipped out of the cell membrane and polymerised 
severally to form the linear chain of the peptidoglycan. The linear chains are then 
cross-linked with adjacent chains and into the existing murein network (see section 
1.3.1, Scheme 1.1).57-59  It is thus clear from the foregoing that the lipid II pathway is 
an integral part of the peptidoglycan biosynthesis. Hence, the induction of yvgI 
promoter (indicator for lipid II pathway inhibition) by methylenomycin compounds  
      
Fig.3.11: Structure of lipid II (undecaprenyl-diphosphoryl-N-acetylmuramoyl-
(pentapeptide)-N-acetyl-glucosamine). X is the pentapeptide: L-Ala-D-Glu-Dmp-D-Ala-D-
Ala. 
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is fully consistent with the observed  induction of the ypuA promoters (indicator for 
cell wall biosynthesis inhibition) in both the luciferase and the β-galactosidase 
reporter systems.  
Experiments performed with MmD1 (lacking antibiotic activity) showed that none of 
the pathway-specific promoters was induced (Fig. 3.12), indicating that the induction 
of the promoters observed for the active methylenomycin compounds was indeed due 
to their antibiotic effect. These results suggest that the methylenomycin antibiotics 
may act by inhibiting cell wall peptidoglycan biosynthesis in bacteria. This conclusion 
was further corroborated by results presented in the next section. 
 
 
 
 
 
 
Fig. 3.12: Assay of β-galactosidase reporter strains with MmD1.  
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3.3.3 Activity of methylenomycin antibiotics against E. coli strains defective in 
outer membrane and in efflux pump system 
Gram-negative bacterial strains are generally less susceptible to antimicrobial attacks 
compared to their Gram-positive counterparts.218 This is due partly to the possession 
of an outer membrane which serves as the first line of defence and greatly limits the 
entrance of potentially harmful agents into the cell.219,230 Given that the outer 
membrane is not able to completely exclude the intrusion of potentially harmful 
compounds,220 the Gram-negative strains possess an additional defence mechanism in 
the efflux pump (Fig. 3.13), a system that expels harmful molecules such as antibiotics 
from the cell directly into the surrounding environment.221,222 The final intracellular 
concentration of any harmful substance in Gram-negative strains is therefore 
determined by the net balance between the actions of the outer membrane which limits 
inflow and the efflux pump system which throws them out.223 Thus, any defects in the 
functioning of the outer membrane and/or the efflux pump system may lead to a 
greater accumulation of harmful compounds in the cells, thereby causing increased 
sensitivity and cell death. A particular efflux pump in E. coli has been recognised to 
play a major role in the multiple-antibiotic-resistance (Mar) phenotype shown by the 
                     
 
Fig. 3.13: Schematic representation of the Gram-negative cell envelope showing the 
protective outer membrane (OM) and efflux pump components (AcrA, AcrB and TolC). PE 
– periplasm; IM – inner membrane; CYT – cytoplasm. Adapted from Silhavy et al.230 
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organism.224,225 This efflux pump comprises three important proteins: AcrA, AcrB 
and TolC.226 
Methylenomycin compounds were shown to exert no antibiotic effect against an E. 
coli strain up to a concentration of 128 µg/ml (section 3.1). In order to further 
demonstrate that the methylenomycins act by inhibiting cell wall peptidoglycan 
biosynthesis as suggested by experiments with pathway-specific reporter strains 
(section 3.3.1 and 3.3.2), the compounds were tested against three E. coli strains, 
including strains with defects in the outer membrane barrier and in the efflux pump 
system. The first of the strains, N43, contains a mutation which prevents the 
expression of acrA, and is therefore defective in the efflux pump system.227 The 
second strain, D22, contains mutation in the lpxC gene,228 the product of which 
catalyses a key step in the biosynthesis of lipid A,229 a crucial part of the outer 
membrane. The third strain (E. coli K-12) is a wild type strain and it is the parent for 
both N43 and D22. This strain has no known mutations and thus served as control for 
the experiment. 
Given that N43 and D22 strains contain mutations which presumably compromise 
their defence mechanisms, it was expected that the methylenomycin compounds 
would exhibit improved potency against both N43 and D22, while having poor 
activity against the parent strain K-12. The minimum inhibitory concentrations 
(MICs) of methylenomycin antibiotics were therefore determined. MICs of 
vancomycin, chloramphenicol and triclosan were also determined in parallel. 
Table 3.2 shows the results of the MICs determined against the three E. coli strains. 
As expected, all the methylenomycin compounds showed no activity against the wild 
type (K-12) up to a concentration of 128 µg/ml. The compounds were also not active 
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Table 3.2: Activities of methylenomycins and standard antibiotics against the wild 
type E. coli K-12 and its derivative mutant strains N43 and D22 
Compound   MIC (µg/ml)
*     
    E. coli K-12 E. coli N43 E. coli D22 
MmA (16)  ˃ 128      ˃ 128 16 
MmC (17)  ˃ 128 ˃ 128 64 
P-MmC (26)  ˃ 128 ˃ 128 16 
P-MmCl (27)  ˃ 128 ˃ 128 8 
Vancomycin  ˃ 128 ˃ 128 8 
Chloramphenicol  8 0.25 0.25 
Triclosan   1 0.0625 0.0625 
     
   *Four independent determinations were carried out 
against the mutant E. coli strain N43 up to 128 µg/ml, but all showed activity against 
E. coli D22 when compared to the parent strain K-12. These results were not 
anticipated as methylenomycin antibiotics were initially expected to show improved 
activity against both the strain N43 (defective in the efflux pump system) and D22 
(defective in the outer membrane structure). The results therefore prompted some 
literature review into the organisation of cell envelopes in Gram-negative bacteria, 
and into the efflux pump mechanism, in particular with respect to the LpxC and the 
AcrA proteins which have been mutated in D22 and N43 strains respectively. 
The cell envelope in Gram-negative organisms consists of three principal layers; the 
outer membrane, the periplasm containing a thin peptidoglycan layer, and the 
cytoplasmic or inner membrane, in the stated order.230 The protective outer membrane 
is a distinguishing feature of the Gram-negative organisms and it is absent in the 
Gram-positive strains. The main component of the outer membrane which allows it to 
perform the protective function is a highly ordered and tightly bound structural 
material called lipopolysaccharide (LPS), present on the outermost leaflet of the 
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membrane.231,232 The LPS is attached to the inner part of the outer membrane by a 
molecule called lipid A, consisting of a repeating disaccharide backbone, decorated 
with several fatty acid side chains (Fig. 3.14). The lipophilic fatty acid side chains of 
lipid A are actually responsible for anchoring the LPS to the inner part of the outer 
membrane.229,233 The inner leaflet of the outer membrane are made of phospholipids 
which offer no protection to the cell. LpxC is required to catalyse an important step 
in lipid A biosynthesis (Scheme 3.4), but is non-functional in the E. coli D22 strain; 
lipid A production is therefore blocked in the strain, implying that the outer membrane 
is largely defective due to the lack of the protective LPS layer. This allowed 
methylenomycin compounds to gain access to the next layer in the cell envelope, the 
peptidoglycan, accounting for why they showed a much improved potency on the D22 
strain.  
                  
Fig. 3.14: Structure of E. coli lipid A. 
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Scheme 3.4: Early steps in the biosynthesis of lipid A: LpxC catalyses the deacetylation of 
UDP-3-O-acyl-GlcNAc (36) to give the amine compound (37) which is subsequently N-
acylated by LpxD. UDP-D-GlcNAc (35) is a common precursor for biosynthesis of lipid A, 
lipopolysaccharides and peptidoglycan, all part of the Gram-negative cell envelope.  
E. coli strain N43, on the other hand, has the outer membrane fully intact and the 
methylenomycin compounds could not gain access to the peptidoglycan layer. The 
only component of the Gram-negative defence cascade mutated in N43 is acrA, the 
product of which functions in the efflux pump system. Review into the mechanism of 
operation of the efflux pump system revealed that AcrA is an accessory protein 
located in the periplasm and serves as a bridge to allow the passage of harmful 
intruders from the cytoplasm to the outer membrane, from where they are 
subsequently ejected.225,234   
The two other components of the efflux pump are acrB and tolC, and are not mutated 
in the N43 strain. AcrB is located in the cytoplasmic membrane and it is the actual 
efflux transporter removing unwanted substances from the cytoplasm. TolC is a small 
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outer membrane protein which provides the pore or an outlet through which inhibitors 
are finally extruded into the surrounding environment.234 - 236 Given that TolC is the 
only component of the efflux pump located on the outer membrane, and has not been 
mutated in E. coli N43, the outer membrane remains intact in this strain. Thus, 
methylenomycin compounds were not able to gain access to the peptidoglycan layer, 
explaining why they showed no activity against the N43 strain. The same reason 
accounts for why vancomycin, an antibiotic targeting a peptidoglycan precursor, 
showed no activity against the N43 strain.  
The results showed that both chloramphenicol and triclosan, antibiotics inhibiting 
translation and fatty acid biosynthesis respectively, showed increased activity on both 
E. coli strains N43 and D22, relative to the wild-type strain K-12. Defects in the outer 
membrane of strain D22 allowed these two antibiotics unhindered passage into the 
cell, leading to the increased potency which was observed. Mutation in acrA (i.e. lack 
of a functional perisplasmic bridge) in strain N43 also prevented the compounds from 
being extruded from the cell, leading to higher intracellular concentration of these 
compounds and the subsequent greater potency on the strain.  
The results indicate that chloramphenicol and triclosan are able to infiltrate the outer 
membrane into the cytoplasm where they attack their target sites without being thrown 
out of the cell, whereas methylenomycins and vancomycins are not able to reach their 
target sites (peptidoglycan) in N43, as they were barred by the protective outer 
membrane which remained intact in this strain. Lack of a proper outer membrane in 
D22 allowed the methylenomycins and vancomycin access to the peptidoglycan layer, 
where they exert their antibiotic effects. 
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3.3.4 Final comments on the mode of action study  
Antibiotic-induced cell death often occurs via inhibition of one of the key cellular 
functions as a primary mode of action. Methylenomycin antibiotics induced the ypuA 
and yheI promoters in the luciferase pathway-specific biosensors. These promoters 
are indicative of substances inhibiting cell wall biosynthesis and translation 
respectively. Experiments with the β-galactosidase reporter system also revealed that 
the compounds all induced the promoter for ypuA, as well as yvgI (indicative of lipid 
II biosynthesis inhibition) and yjaX (indicative of fatty acid biosynthesis inhibition). 
Induction of the ypuA promoter (for cell wall biosynthesis) by methylenomycin 
antibiotics is consistent in both the luciferase and the β-galactosidase reporter systems. 
The results are also consistent with the observed induction of the biosensor for lipid 
II pathway, an intrinsic part of the peptidoglycan biosynthetic pathway. These results 
strongly suggest that the compounds may act by inhibiting cell wall peptidoglycan 
biosynthesis. This is in consonance with the activities of the methylenomycin 
compounds mainly against the Gram-positive bacterial strains (as demonstrated in 
section 3.1, table 3.1) and in agreement with previous reports that polyprenyl-coupled 
cell wall precursors, such as lipid II, are readily accessible on the outside of the Gram-
positive bacteria, and represent an easy target for antibiotics.238 The Gram-negative 
strains possess an outer membrane which serves as a protective layer for the cell, by 
preventing access to the peptidoglycan layer or precursors.101 When the 
methylenomycin antibiotics were tested against E. coli strain D22 in which the 
protective outer membrane has been compromised, (due to mutation in the lpxC, 
essential for the biosynthesis of lipid A which serves as an anchor for LPS in the outer 
membrane), all methylenomycin compounds showed activity against the E. coli strain, 
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but not against the parent wild type strain containing an intact outer membrane. The 
result indicate that the lack of an integral outer membrane component in D22 allowed 
methylenomycin compounds access to the peptidoglycan, leading to the observed 
potency on the strain, in contrast to the wild type (K-12) in which the outer membrane 
was not defective. Interestingly, similar results as for the methylenomycin compounds 
were obtained for vancomycin (inhibiting cell wall peptidoglycan biosynthesis) 
against the various E. coli strains, but not for chloramphenicol and triclosan, 
antibiotics inhibiting translation and fatty acid biosynthesis respectively. 
Vancomycin and the methylenomycin antibiotics showed no potency against E. coli 
strain N43, possessing an intact outer membrane but defective in the AcrA component 
of the efflux pump system which removes antibiotics from inside the cell.  The lack 
of activity against E. coli N43 implies that the compounds did not affect the 
cytoplasmic content of the cells; hence, the lack of a functional efflux pump system 
in the strain did not, in any way, predispose or make the strain more susceptible to 
attack by vancomycin and the methylenomycin antibiotics. This is consistent with 
previous work which has shown that increased susceptibility of E. coli strains lacking 
acrA or acrB to antibiotics occurred due to the inability of the strains to expel the 
compounds, rather than by an increased permeability of the outer membrane 227(which 
would have allowed access to the inner parts of the cells starting with the 
peptidoglycan layer). In contrast to methylenomycins and vancomycin, the impaired 
efflux pump in the current study resulted in much improved potency of 
chloramphenicol and triclosan on strain N43 compared with the wild type K-12, 
indicating that these compounds indeed reached the cytoplasm but were not able to be 
pumped out. The foregoing strongly indicate that the primary site of action of the 
methylenomycin antibiotics in bacteria is the peptidoglycan and that the compounds 
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do not need to enter the cytoplasm in order to exert their antibiotic effects. Although 
the yeast cell envelope does not contain peptidoglycan, one of the main components 
of the cell wall is chitin, made up of polymers of N-acetyl-glucosamine 
(GlcNAc).254,255 GlcNAc is also one of the two component monomers of the 
peptidoglycan in bacteria.54 Thus, the chitin in yeast may represent the target for the 
methylenomycin metabolites, accounting for why they showed activity against the 
yeast, Candida albicans.  
The above conclusions notwithstanding, the induction of promoters indicative of 
protein synthesis inhibition and fatty acid biosynthesis inhibition by methylenomycin 
compounds may not be totally discarded. This is because it is possible for antibiotics 
to interfere with other cellular functions in addition to their primary targets. For 
example, ciprofloxacin causes cell death primarily by inhibiting replication through 
the trapping of DNA-gyrase.70,71 However, there have also been indications that the 
same compound may also disrupt cell membrane as a secondary mode of action.239 
The rifamycin group of antibiotics are also known to act primarily by inhibiting RNA 
synthesis via binding to RNA polymerase.78,79 However, it has been observed that 
their hydroquinone moiety simultaneously interacts with DNA, thereby causing DNA 
damage.240,241 The fact that the methylenomycin-related metabolites also inhibit 
mammalian (ovarian cancer) cells, which lack structures similar to the peptidoglycan 
in bacteria or the chitin in yeast,256,257 suggests that there is an additional as yet 
unidentified target for these compounds in mammalian cells, which is responsible for 
their activity against ovarian cancer cell line.  
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CHAPTER FOUR 
4. CONCLUSIONS AND FUTURE WORK 
4.1 Conclusions 
4.1.1 MmyO and MmyF both play roles in the epoxidation of methylenomycin C 
(17) to give methylenomycin A (16)  
The last step in the biosynthesis of methylenomycin A (16), the epoxidation of 
methylenomycin C (17), has been investigated in detail. Bioinformatic analyses of the 
various proteins encoded in the mmy cluster had implicated MmyO and MmyF in the 
epoxidation step. Individual deletion of either mmyO or mmyF from the mmy gene 
cluster also led to the accumulation of 17 in the mutant strains, 174 further 
corroborating the hypothesis that the product of these two genes might be responsible 
for the epoxidation reaction.  
That hypothesis was investigated by transforming an S. coelicolor strain expressing 
both mmyO and mmyF with a multicopy plasmid carrying the methylenomycin 
resistance determinant (mmr); enabling feeding of methylenomycin C to the otherwise 
sensitive strain. Analysis of extract from the fed strain confirmed that 
methylenomycin C was converted to methylenomycin A as hypothesised, leading to 
a proposed mechanism for the epoxidation step. MmyO and MmyF showed sequence 
similarities to a monooxygenase and a flavin reductase (NADPH-dependent) 
respectively. MmyF could catalyse the reduction of FAD to FADH2, which reacts with 
molecular oxygen to give flavin hydroperoxide. The flavin hydroperoxide is 
deprotonated to give a nucleophilic peroxide which attacks the C-5 position in 17 to 
ultimately furnish methylenomycin A (16) (see chapter 2, scheme 2.1).  
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Investigations into the substrate flexibility of the epoxidation reaction was also carried 
out. The result revealed that MmyO and MmyF were able to epoxidize 
methylenomycin C (17) and its putative precursor, pre-methylenomycin C (26), but 
not other methylenomycin-derived metabolites (27, 28 and 29) which possess the 
same cyclopentenone structure. Simple synthetic analogues such as 2-cyclopentenone 
and 2-cyclohexenone were also not epoxidized, indicating that MmyO is highly 
specific for 17 and 26. 
4.1.2 Many mmy genes implicated in methylenomycin biosynthesis may not be 
essential to the pathway 
LC-MS analyses of extracts of transconjugant S. coelicolor strains containing the 
entire mmy cluster but lacking the transcriptional repressor gene, mmyR, and a gene 
from a set of putative biosynthetic genes (mmyP, mmyK, mmyT, mmyG, mmyX, 
mmyQ, mmyY) were carried out. The results revealed that methylenomycin production 
was retained in the mutant strains lacking mmyP, mmyK, mmyT, or mmyG; indicating 
that the proteins encoded by these genes are not essential for methylenomycins 
biosynthesis. The results suggest the possibility of similar proteins from the mmy gene 
cluster, the pathway of another secondary metabolite in the host strain or the primary 
metabolic pathway (particularly the fatty acid synthase), acting in place of the mmy 
enzymes, accounting for why methylenomycin production was sustained in the 
mutants (see discussions in section 2.3) 
Conversely, methylenomycin production was completely abolished in the 
transconjugant mutant strains lacking either of mmyX or mmyQ, indicating that MmyX 
and MmyQ are both essential for the biosynthesis. This points to a need for some 
phosphorylation and reduction steps in the methylenomycin pathway (MmyX and 
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MmyQ bear sequence similarities to a kinase and a reductase respectively). The fact 
that MmyK, also a kinase, is not required for methylenomycin biosynthesis may mean 
that MmyX is sufficient and able to do any required phosphorylation in the pathway, 
explaining why production was retained in the strain lacking mmyK, but containing 
mmyX. 
While no new intermediates were found accumulating in isolable amounts in the 
mutant strains, the results provide an indication of the essential enzymes of the 
methylenomycin pathway i.e. the minimum required to biosynthesize 
methylenomycin A (16). These are likely to be the acyl carrier protein (MmyA), the 
ketoacyl synthase III (MmyC), the butenolide synthase (MmyD), the kinase (MmyX), 
the reductase (MmyQ), the enoyl reductase (MmyE), the flavin reductase (MmyF) 
and the monooxygenase (MmyO),  in that order.  
Although methylenomycins production was also abolished in the mmyY mutant, 
generated via CRISPR/Cas9 deletion in the current work, previous studies conducted 
with jadX,258,259 a homologue of mmyY in S. venezuelae,  suggest that the nuclear 
transport factor (NTF 2) proteins encoded by these genes may play as yet unidentified 
roles in transcriptional regulation or transport of intermediates (moieties), rather than 
catalysing enzymatic steps in the biosynthetic pathways.  
4.1.3 Putative butenolide intermediate (25) in the methylenomycin pathway was 
identified in some S. coelicolor transconjugant strains 
MmyD, encoded within the methylenomycin cluster, shows 47% similarity to AvrD 
over 333 amino acids. AvrD catalyses the formation of a butenolide intermediate in 
the biosynthesis of syringolides.189 The level of similarity between these proteins, 
coupled with the encoding of an ACP (MmyA) and a KAS III (MmyC) within mmy 
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cluster, that could facilitate the formation of a betaketothioester-ACP,  led to the 
hypothesis that MmyD could catalyse the formation of a butenolide intermediate in 
the methylenomycin pathway, analogous to that formed by AvrD in the syringolides 
pathway.173 
A compound consistent with the proposed butenolide (25) for the methylenomycin 
pathway has now been identified in some of the S. coelicolor transconjugants carrying 
the mmy cluster (section 2.4). Feeding of [U-13C]D-ribose to the strains led to the 
incorporation of labelled 2-, 3-, 4- ,5- and 7-carbon units into the putative butenolide 
(25), and subsequently into methylenomycin C (17). While the details of the 
incorporation of labelled 3- and 5- carbon precursors were previously described for 
the methylenomycins,173 pathways leading to the separate incorporation of a labelled 
2-carbon precursor derived from acetyl-CoA and a 4-carbon precursor derived from 
two units of acetyl CoA have been proposed in this study for 25 and 17. [U-13C]D-
ribose is metabolised in the cells to [U-13C]ribose-5-phosphate, which is isomerised 
via the pentose-phosphate pathway to [U-13C]ribulose-5-phosphate, also in 
equilibrium with its epimer, [U-13C]xylulose-5-phosphate (Xu5P). The labelled Xu5P 
can then generate [U-13C]glyceraldehyde-3-phosphate (G3P) via transketolase 
reactions of the pentose-phosphate pathway. The fully labelled G3P can enter 
glycolytic pathway where it is converted to [U-13C]pyruvate, which is subsequently 
broken down aerobically to give [U-13C]acetyl CoA, with the release of 13CO2. The 
KAS III, MmyC, can then catalyse the decarboxylative condensation of [U-13C]acetyl 
CoA with unlabelled malonyl-MmyA, to furnish acetoacetyl-MmyA, labelled only at 
two of the carbon positions (see chapter 2, scheme 2.5). MmyD-catalysed 
condensation of the partly labelled acetoacetyl-MmyA with a pentulose will furnish 
the putative butenolide (25) and subsequently methylenomycin C (17), both labelled 
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only at two corresponding carbon atoms. Incorporation of a labelled 4-carbon 
precursor into 25 and 17 results when the acetoacetyl-MmyA  is fully labelled. This 
may proceed via conversion of [U-13C]acetyl CoA to [U-13C]malonyl CoA, catalysed 
by acetyl CoA carboxylase, using H2
13CO3 generated from the liberated 
13CO2 as the 
carbon source. MmyA and MmyC-mediated condensation of the [U-13C]malonyl CoA 
and [U-13C]acetyl CoA will then produce the fully labelled [U-13C]acetoacetyl-
MmyA, which is condensed with a pentulose by MmyD to give 25 and 17, both 
labelled with four 13C atoms as observed.  
 
Scheme 4.1: Pathway proposed for methylenomycin A(16) biosynthesis prior to this study 
The similar incorporation patterns observed for the putative butenolide (25) and 
methylenomycin C (17) indicate that the methylenomycins could indeed derive from 
25. Possible reactions to convert 25 to the more structurally-characterised advanced 
intermediates of the pathway (27 and 26) have therefore been proposed, leading to a 
revised pathway for methylenomycin A biosynthesis in S. coelicolor (Scheme 4.2, 
compared to scheme 4.1).  Given that the deletion of mmyX, encoding a putative 
kinase, led to the complete abolition of methylenomycins biosynthesis (pointing to a 
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need for some phosphorylation in the pathway), the C-4’ and C-5’ hydroxyl groups of 
the butenolide (25) may be phosphorylated by MmyX. This would pave the way for 
loss water molecules, leading to an unsaturated intermediate (34), which would need 
Scheme 4.2: A revised pathway for methylenomycin A (16) biosynthesis in S. coelicolor. 
Evidence was obtained for the butenolide (25) in this study. Possible reactions leading from 
25 to 27 and 26 are proposed based on insights obtained from this study. The conversion of 
16 to 17 by MmyO and MmyF has also been demonstrated unambiguously in this study. 
to undergo reduction reactions. Again, mmyQ encodes a putative coenzyme F420-
dependent reductase. The deletion of this gene, achieved via CRISPR/Cas9 excision 
in this study, also led to the complete abolition of methylenomycins production. Thus, 
MmyQ could possibly catalyse the reduction of the double bonds in 34, using 
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hydrogen atoms derived from the reduced cofactor F420H2. Intramolecular aldol 
condensation in the resulting intermediate, followed by the loss of a molecule of 
water, possibly mediated by MmyX, would afford pre-methylenomycin C (26) and 
the related lactone (27). Dehydration of 26 is proposed to give methylenomycin C 
(17), which is then epoxidized by MmyF and MmyO to give methylenomycin A (16), 
the final product of the pathway. 
Expression of mmyD alone in E. coli was not sufficient to produce the butenolide 
intermediate in the methylenomycin pathway (25), unlike the expression of its 
homologue, avrD, which led to the production of syringolide compounds.189 The 
results (discussed in section 2.5) suggest that the ketoacyl synthase III, MmyC, 
required for the formation of the diketide, acetoacete, is essential to the 
methylenomycin pathway and its action may not be substituted by other KAS III from 
E. coli fatty acid synthase. 
4.1.4 Pre-methylenomycin C (26) and pre-methylenomycin C lactone (27) are 
much more potent antimicrobial agents than methylenomycin A 
Investigations into the antimicrobial potentials of intermediates in methylenomycin 
pathway revealed that methylenomycin C, pre-methylenomycin C and pre-
methylenomycin C lactone, all possess antimicrobial activities. While the activity of 
methylenomycin C compares with that of methylenomycin A (both only moderately 
potent), pre-methylenomycin C and pre-methylenomycin C lactone showed much 
improved activity against Gram-positive strains and yeast (Candida albicans), with 
the pre-methylenomycin C lactone being the most active of all the methylenomycin-
related compounds.  
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Experiments investigating the effect of the methylenomycin resistance protein, Mmr, 
on the activities of these compounds revealed it to be most profound on the activity 
of methylenomycin A, and to a lesser extent on methylenomycin C (17). The results 
suggest an explanation for why 17 is rapidly metabolised to the mixture of inactive 
diastereoisomers (methylenomycin D1 (28) and methylenomycin D2, 29), probably 
as an additional mechanism to resist the antimicrobial effect of methylenomycin C. 
Although methylenomycin A possesses the same exomethylene function which is 
saturated in methylenomycin C to give 28 and 29, no reduced products analogous to 
28 and 29 were found in the strains overproducing methylenomycin A, indicating that 
the methylenomycin resistance protein, Mmr, is sufficient to protect S. coelicolor 
against this metabolite. The potency of pre-methylenomycin C (26) and pre-
methylenomycin C lactone (27) were not in any way reduced by mmr expression in S. 
coelicolor and S. albus strains. The results suggest that the likely acquisition of mmr 
by pathogenic strains, possibly via horizontal gene transfer, may not confer resistance 
on them against 26 and 27.  
Both pre-methylenomycin C (26) and pre-methylenomycin C lactone (27) were active 
against ovarian cancer cells at concentrations close to those at which they exert 
bactericidal effects on pathogenic Gram-positive strains, suggesting that these 
compounds might also be cytotoxic. This notwithstanding, the work demonstrated 
another example in which deletion of a gene within a biosynthetic gene cluster led to 
the production of analogues of an antibiotic with much improved potency.  
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4.1.5 Methylenomycin antibiotics may target cell wall peptidoglycan biosynthesis 
in bacteria 
The mechanism of action of methylenomycin antibiotics, previously unknown, was 
investigated in the current study with two sets of B. subtilis inducible promoter-
reporter systems which reveal the ability of antibiotics to interfere with specific 
essential pathways in bacteria.213,214 Methylenomycin compounds induced the 
promoters indicative of inhibition of cell wall biosynthesis, lipid II biosynthesis, 
translation and fatty acid biosynthesis. While the induction of translation and fatty 
acid biosynthesis may not be entirely ruled out (since antibiotics sometimes interfere 
with more than one targets), only the induction of the promoter indicative of cell wall 
biosynthesis inhibition was consistent in the two promoter-reporter systems 
employed. This is also consistent with the induction of the promoter for the lipid II 
pathway, an integral part of the cell wall peptidoplycan biosynthesis,54-57 and with the 
activities of the compounds mainly against the Gram-positive bacterial strains. 
Methylenomycin antibiotics mostly behaved like vancomycin, an antibiotic targeting 
the D-alanyl-D-alanine end of the pentapeptide precursor of the cell wall 
peptidoglycan,64,65 suggesting they might similarly inhibit peptidoglycan 
biosynthesis.  
Further evidence that methylenomycin-related metabolites target the peptidoglycan 
was obtained when the compounds showed activity against an E. coli strain with a 
defective outer membrane, indicating that they were able to gain access to the 
peptidoglycan layer. This is in contrast to the results obtained with the wild type E. 
coli strain, having the outer membrane intact, and to which the methylenomycin 
compounds showed no potency. Activity against the yeast, C. albicans, is likely due 
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to the presence of chitin, a key cell wall component biosynthesised from N-acetyl-
glucosamine (GlcNAc),254,255 which is also a precursor to the peptidoglycan in 
bacteria.54 This is the first study to report the mode of action of methylenomycin 
antibiotics produced by Streptomyces coelicolor A 3(2). 
4.2 Recommendations for future work  
4.2.1 Role of MmyX and MmyQ in the biosynthesis of methylenomycins 
Work presented herein suggests that both MmyX (a kinase) and MmyQ (a reductase) 
may play catalytic roles in the biosynthesis of methylenomycin compounds. However, 
no intermediates of the pathway were found accumulating in the mutant strains and 
further insights into their roles could not be gained in this study. It is therefore 
necessary to demonstrate the proposed roles for MmyX and MmyQ in the biosynthesis 
of methylenomycin antibiotics.  
The corresponding genes may be cloned and overproduced in E. coli to possibly purify 
the recombinant proteins. Potential substrates from the methylenomycin pathway may 
then be chemically synthesised and incubated with these proteins to possibly establish 
their roles in the biosynthesis.  
4.2.2 Chemical derivatisation of methylenomycins and intermediates  
Efforts at investigating the biosynthesis of methylenomycin A (16) has recently 
uncovered putative intermediates: pre-methylenomycin C (26), pre-methylenomycin 
C lactone (27), methylenomycin D1 (28) and methylenomycin D2 (29),174 all of which 
possess reactive functional groups (double bonds, ketones and carboxylic acid / 
lactone). As well as methylenomycin A and methylenomycin C, the reactivities of 
these compounds should be explored to generate novel semisynthetic derivatives, 
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which may then be investigated for possible biological activities. This might also lead 
to alteration or elimination of undesirable properties in the bioactive methylenomycin 
compounds, for instance, the cytotoxic nature of 26 and 27. The S. coelicolor 
transconjugant strains producing the putative butenolide compound (25) may be 
cultured on media containing N-acetyl-cysteine, to possibly facilitate the isolation of 
this intermediate for further spectroscopic characterisation. 
4.2.3 Chemical Synthesis of pre-methylenomycin C (26) and pre-
methylenomycin C lactone (27) 
While this is the first study to demonstrate the antimicrobial activities of 26 and 27, a 
previous study has synthesized similar structures as intermediates in the attempted 
total synthesis of methylenomycin A.242 It is worth synthesizing these compounds 
chemically to determine if they have the same strereochemistry as 26 and 27, purified 
from the mmyE deletion mutant in this study. This may be interesting if the synthetic 
route proves to be simple, thereby providing a cheaper and faster source of these 
compounds. The potentials of 26 and 27 as anticancer agents should also be 
investigated and explored. 
4.2.4 Mode of action of methylenomycin antibiotics 
Experiments with B. subtilis promoter-reporter fusion strains and activities of the 
methylenomycins against the outer-membrane defective E. coli strain have strongly 
indicated that the compounds inhibit bacterial peptidoglycan biosynthesis. However, 
the final target in the biosynthesis is not yet known. For instance, vancomycin and 
bacitracin are two antibiotics inhibiting cell wall peptidoglycan biosynthesis: while 
the former binds to the pentapeptide terminus of the peptidoglycan precursor,64,65 the 
later acts by inhibiting the enzyme required to dephosphorylate the undecaprenyl 
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diphosphate (C55-PP) during peptidoglycan biosynthesis,
69  thereby blocking lipid I 
and subsequently lipid II production.  
Methylenomycin compounds may therefore be incubated with reactions at different 
stages of the in vitro reconstituted peptidoglycan pathway. This would reveal the 
step/s or enzyme/s of the pathway that are inhibited by the methylenomycin 
antibiotics. The possible antagonisation of the activities of methylenomycin 
compounds by peptidoglycan precursors such as UDP-MurNAc-pentapeptide, lipid I 
and lipid II should also be investigated. This would reveal whether methylenomycin 
antibiotics inhibit peptidoglycan biosynthesis by binding directly to peptidoglycan 
intermediates, thereby blocking their conversion to the subsequent intermediates of 
the pathway. A possible combination of enzyme inhibition and precursor binding  in 
the peptidoglycan biosynthesis may also not be ruled out.
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CHAPTER FIVE 
5. MATERIALS AND METHODS 
5.1 General materials and equipment 
Isolation of plasmid DNA from E. coli was performed with a GeneJet Plasmid 
Miniprep Kit (Thermo Scientific) following the manufacturer’s instructions. 
Purification of DNA following agarose gel electrophoresis was performed with a 
GeneJet gel extraction kit (Thermo Scientific) according to the manufacturer’s 
instructions. Polymerase chain reactions were performed using Taq polymerase from 
Fermentas (Lithuania) or High fidelity DNA polymerase from Roche (Germany), 
except where stated otherwise. Quick PCR screening of E. coli colonies were carried 
out with One Taq® Quick load® Master Mix PCR (New England Biolabs). All 
oligonucleotides were purchased from Sigma Aldrich.  
E. coli strains were grown in Luria-Bertani (LB) medium obtained from Fisher 
BioReagents, unless where otherwise stated. Specialised media for Streptomyces 
cultures were prepared following published procedures,9 and using reagents 
purchased from Difco and Becton, Dickinson and Co.  
Erythromycin and chloramphenicol (from Duchefa Biochemie, Netherlands); 
rifampin (from Fischer Scientific); linezolid and triclosan (from Sigma Aldrich); 
ciprofloxacin, vancomycin, bacitracin and cerulenin (from VWR), were all used in 
microbiological assays. D-luciferin was purchased from Sigma Aldrich and X-gal was 
purchased from Applichem PanReac, Spain.  
Optical density was measured using Biomate 3 spectrophotometer (Thermo Electron 
Corp.) and luminescence was measured using a charge-coupled device camera-based 
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luminescence detector (available in Life Sciences). A Bio-Rad Gene Pulser II with the 
Bio-Rad Pulse controller Plus was used for electroporation. An Eppendorf 
Mastercycler nexus GX2 or Eppendorf Mastercycler Personal was used for the PCR 
reactions. Centrifugation of samples was performed with Eppendorf Centrifuge 
5804R or benchtop Eppendorf centrifuge 5424 (for 1.5ml samples). Concentration of 
DNA and RNA was measured on a NanoDrop ND-1000 spectrometer 
All organic solvents were used as supplied (VWR or Sigma Aldrich). Solvents were 
evaporated from culture extracts using a Buchi Rotavapor R-200 equipped with a 
Buchi Vacuubrand pump. Flash column chromatography was performed with silica 
gel (pore size 60 Ǻ, particle size 40-63 µm)(Sigma Aldrich). Thin layer 
chromatography was carried out on aluminium plates pre-coated with Merck silica gel 
60 F254 and visualised by UV light or potassium permanganate.  
NMR spectra were recorded using Bruker DPX 300, 400 or 500MHz spectrometer 
and chemical shifts (δ) are reported in ppm with reference to the residual solvent peak. 
5.2 Methods for HPLC and LC-MS analysis  
5.2.1 Preparative HPLC 
Methylenomycin compounds were separated from crude extracts of Streptomyces 
cultures by preparative HPLC, except where otherwise stated. Multiple injections of 
100 µl solution of the crude extracts were performed, with water containing 0.1 % 
formic acid (solvent A) and acetonitrile/methanol containing 0.1% formic acid 
(solvent B) as eluents. The flow rate was maintained at 20 ml/min at a pressure of 400 
atm. The elution program is as shown in Table 5.1. Fig. 5.1 also shows typical HPLC 
traces obtained from multiple runs during the purification of methylenomycin 
  Chapter Five - Materials & methods 
142 
 
compounds from extracts of S. coelicolor strains expressing the mmy gene cluster. 
Fractions collected for each compound were pooled, to give the purified compound in 
a mixture of water and acetonitrile/methanol containing 0.1% formic acid. The 
organic solvent was evaporated on a rotary evaporator and the left-over water was 
extracted with ethyl acetate. Alternatively, the mixture of water and organic solvent 
was evaporated completely and the flask was rinsed with ethyl acetate. The ethyl 
acetate was then evaporated and the residue was dried under high vacuum before 
further characterisations were carried out. 
Table 5.1: Elution gradient for HPLC purification of methylenomycin compounds 
Time (mins) Solvent A (%) Solvent B (%) 
0 95 5 
30 0 100 
35 0 100 
40 95 5 
   
 
 
Fig. 5.1: HPLC traces from the purification of P-MmCl (27) from S. coelicolor W86 extract. 
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5.2.2 LC-MS analysis 
Liquid Chromatography – Mass Spectrometric analyses were carried out using a 
reverse phase column (Agilent C18, 100 x 2.1 mm, 1.8 µm) connected to a Thermo 
Scientific Ultimate 3000 UHPLC+. Samples (5 µl)  were injected while the mobile 
phase flow rate was maintained at 0.2 ml/min at an operating pressure of 
approximately 350 atm. Separation of the metabolites was achieved using water 
containing 0.1% formic acid (solvent A)  and acetonitrile or methanol containing 0.1% 
formic acid (solvent B) whilst in positive mode. For analysis in negative mode, 
ammonium hydroxide was added to the mobile phase solvents instead of formic acid. 
The method used is shown in Table 5.2. The outflow was routed to a Bruker (MaXisTM 
Impact) High Resolution-Mass Spectrometer fitted with an electrospray ionisation 
(ESI) source operating in positive or negative mode. A scan of m/z range 50 to 1,500 
was used in all analyses. 
Table 5.2: Method for the separation of compounds during LC-MS analysis 
Time (mins) Solvent A (%) Solvent B (%) 
0 95 5 
5 95 5 
17 0 100 
22 0 100 
25 95 5 
33 95 5 
   
   
5.3 Culture conditions and sample preparation for analysis 
S. coelicolor, S. lividans and S. albus wild-type strains and those expressing genes for 
methylenomycin production were cultured on Supplemented Minimal Medium Solid 
(SMMS) agar and were incubated at 30 oC for six days. The plates were frozen 
overnight, defrosted and the agar with the mycelia were transferred into syringes 
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plugged with cotton wool. The syringes were held tightly, through carefully cut-out 
portions on the lids, into plastic falcon tubes and were centrifuged at 2500 rpm for 10 
minutes. 50 µl of the resulting filtrate samples were made up to 1 ml with methanol 
and desalted by passing through filters at 6000 rpm prior to analysing by LC-MS.  
Alternatively, the SMMS culture plates were adjusted to pH 2 with 2M HCl and left 
for about 30 mins. Equal volume of ethyl acetate was then added and the mixture was 
shaken for 1 hour before filtering. The filtrate was dried over magnesium sulphate and 
the solvent removed on a rotary evaporator. The dried residue was diluted 
appropriately with methanol, filtered as above and analysed by LC-MS.  
5.4 Strains and Plasmids 
5.4.1 Escherichia coli strains 
E. coli strains used in this study are listed in Table 5.3  
Table 5.3: Escherichia coli strains 
 
5.4.2 Streptomyces strains  
Streptomyces strains used in this study are provided in Table 5.4 
   
Name Property Source/Ref 
ET12567/pUZ8002 Non- methylating host for the  transfer of DNA Gust et al.243 
  into Streptomyces species   
K-12 Wild type E. coli having no known mutations EGSC 
N43 acrA mutant of K-12 strain Ma et al.227 
D22 lpxC mutant of K-12 strain SN et al. 228 
BL21* F- ompT hsdSB (rB-mB-) gal dcm rne131 (DE3) Invitrogen 
TOP10 F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 Invitrogen 
  ΔlacΧ74 recA1 araD139Δ(ara-leu)7697 galU galK    
  rpsL (StrR) endA1 nupG   
   
  Chapter Five - Materials & methods 
145 
 
Table 5.4: Streptomyces Strains 
   
Strains Properties Source/Reference 
M145 S. coelicolor SCP1 minus , SCP2 minus Kieser et al.9 
W89 M145/C73_787/mmyR::apr C. Corre 
W86 M145/C73_787/ΔmmyE/mmyR::apr C. Corre 
W95 M145/C73_787/ΔmmyD/mmyR::apr C. Corre 
W108 M145/C73_787/ΔmmyF/mmyR::apr C. Corre 
W100 M145/C73_787/ΔmmyO/mmyR::apr C. Corre 
W102 M145/C73_787/ΔmmyX/mmyR::apr C. Corre 
W104 M145/C73_787/ΔmmyG/mmyR::apr C. Corre 
W105 M145/C73_787/ΔmmyK/mmyR::apr C. Corre 
W106 M145/C73_787/ΔmmyP/mmyR::apr C. Corre 
W107 M145/C73_787/ΔmmyT/mmyR::apr C. Corre 
W114 M145/pOSV556/mmyE C. Corre 
W117 M145/pOSV556/mmyD C.Corre 
W110 M145/pOSV556/mmyOF C. Corre 
W301  W110/pIJ86/mmr This study 
W302 M145/pIJ86/mmr This study 
W318 S. albus/pOSV556/mmyOF/pIJ86/mmr This study 
W319 S. albus/pIJ86/mmr This study 
W311 S. albus/pOSV556/mmyE This study 
W305 S. albus/pOSV556/mmyD This study 
W303 S. albus/C73_787/mmyR::apr This study 
W320 S. albus/C73_787/ ΔmmyX/mmyR ::apr This study 
W304 S. lividans/C73_787/mmyR::apr This study 
W314 M145/C73_787/ΔmmyQ/mmyR::apr This study 
W315 M145/C73_787/ΔmmyY/mmyR::apr This study 
W316 S. albus/C73_787/ΔmmyQ/mmyR::apr This study 
W317 S. albus/C73_787/ΔmmyY/mmyR::apr This study 
   
 
5.4.3 Cosmids and plasmids 
Table 5.5: Cosmids and plasmids used in this study 
   
Plasmids/Constructs properties source 
C73_787  Integrative cosmid containing the full  Gust et al.175 
  methylenomycin gene cluster   
C73_787/mmyR::apr Construct to overexpress mmy genes C. Corre 
pGI001 C73_787/ΔmmyQ/mmyR::apr This study 
pGI002 C73_787/ΔmmyY/mmyR::apr This study 
pIJ86/mmr    Methylenomycin resistance determinant C. Corre 
pGI003 pET151/mmyD This study 
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5.5 Primers  
The primers used in this study are listed in Table 5.6.  
Table 5.6: Primers  
  
Primer Sequence 
mmr-fwd 5’ATGACCACTGTCCGAACAGG 3’ 
mmr-rev 5’TCAGGTGGCCGCCGTGACGG  3’ 
mmyQ-sgRNA-1 
5’GATCACTAATACGACTCACTATAGGGACGTACTGGTGTTGGTCAT 
GTTTTAGAGCTAGAAATAGC 3’ 
mmyQ-sgRNA-2 
5’GATCACTAATACGACTCACTATAGGGTCGGCCGGAGTGAACATGTG 
GTTTTAGAGCTAGAAATAGC 3’ 
mmyY-sgRNA-1 
5’GATCACTAATACGACTCACTATAGGGAGCTGTGCACCCGCATGGCG 
GTTTTAGAGCTAGAAATAGC 3’ 
mmyY-sgRNA-2 
5’GATCACTAATACGACTCACTATAGGGCCGACGGGAACCGCCACATC 
GTTTTAGAGCTAGAAATAGC 3’ 
sgRNA-rev 
5’AAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAG 
CCTTATTTTAACTTGCTAT 3’ 
mmyQ-scrn-fwd  5’TGCGGCTGGTGCCAGCTGAC 3’ 
mmyQ-scrn-rev  5’CCGGTTCTCCAGCGCCAGTG 3’ 
mmyY-scrn-fwd  5’CGTAACGGAGAGTTAAACCGG 3’ 
mmyY-scrn-rev  5’AGGGACACGGAAGCGAAGG 3’ 
mmyD-fwd 5’CACCATGCCAGTCAGCGGTTCCCTAT 3’ 
mmyD-rev  5’TCAAGGCAGGCGGTGGGCGAC 3’ 
T7-fwd 5´TAATACGACTCACTATAGGG-3´ 
T7-rev 5´TAGTTATTGCTCAGCGGTGG-3´ 
  
 
5.6 Culture Media 
Unless ortherwise stated, all media were autoclaved after addition of all components. 
5.6.1 SFM medium 
Bacto agar    20 g/L 
Mannitol   20 g/L 
Soya Flour   20 g/L 
Tap Water   to make up to 1 Litre 
5.6.2 SMMS medium 
Bacto agar   20 g/L 
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MgSO4   5 mM 
L-Alanine   30 mM 
TES buffer pH 7.0  25 mM 
Distilled Water  to make up to 1 Litre 
Mixture of the above components was first autoclaved before the following were 
added: 
Glucose   10 g/L (from 50 % stock) 
NaH2PO4   5 mM 
K2HPO4   5 mM 
Trace elements  1 ml/L 
Trace elements solution was made up of: 
ZnSO4.7H2O   0.1 g/L 
FeSO4.7H2O   0.1 g/L 
MnSO4.4H2O   0.1 g/L 
CaCl2.2H2O   0.1 g/L 
NaCl    0.1 g/L  
5.6.3 LB medium 
Bacto agar   15 g/L 
Tryptone   10 g/L 
Yeast extract   5 g/L 
NaCl    10 g/L 
Water    to make up to 1 Litre 
5.6.4 AlaMM medium (pH 5.0) 
Bacto agar   15 g/L 
L-Alanine   30 mM 
K2HPO4   5 mM 
MgSO4   5 mM 
Tap Water   to make up to 1 Litre 
Glycerol   10 g/L (from 50% sterile stock) 
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Adjusted to pH 5.0 with 35% HCl 
5.6.5 Belitzky minimal medium (BMM) 
(NH4)2SO4   15 mM 
MgSO4.7H2O   8 mM 
KCl    27 mM 
Tris Base   50 mM 
Final pH adjusted to 7.5 with conc. HCl 
5.6.6 Nutrient Agar medium 
Beef Extract   3 g/L 
Peptone   5 g/L 
Agar    15 g/L 
Made up with distilled water 
5.6.7 Mueller Hinton Broth (MHB) 
Casein acid hydrolysate 17.5 g/L 
Beef extract   3.0 g/L 
Starch    1.5 g/L 
5.6.8 M92 medium 
Trypticase Soy broth  30 g/L 
Yeast Extract    3 g/L 
Agar (When necessary) 15 g/L 
Distilled water to make up to 1 litre  
5.6.9 M9 medium  
M9 salts (5x)    200 ml 
Glucose (20%)  20 ml 
MgSO4 (1M)   2 ml 
CaCl2 (1M)   100 µl 
Distilled water  to make up to 1 litre 
M9 salts (5x) was made up of: 
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Na2HPO4.7H2O  64.0 g 
KH2PO4    15.0 g 
NaCl    2.5 g 
NH4Cl    5.0 g 
Dissolved and made up to 1L with distilled water 
 
5.7 Stock solutions 
Table 5.7 lists the stock solutions used in this study. 
Table 5.7: Stock solutions  
   
stock solutions components solvent 
TBE (1000 ml, 5x) Tris base - 53.00 g Water 
 Boric acid - 27.59 g  
 EDTA - 10 mM, pH 8  
Fast screening 
Lysis Sucrose - 5.00 g Water 
buffer KCl - 0.23 g  
 NaOH - 200 mM (2.5 ml of 2 M)  
 
SDS - 0.5 % (1.25 ml of 10 % 
stock)   
Citrate buffer Citric acid - 2.10 g Water 
 Sodium citrate - 2.94 g  
   
 
5.8 Agarose gel electrophoretic analysis 
Agarose gel electrophoresis was performed on Bio-Rad Power Pac 300. Except where 
stated otherwise, 100 ml of 1% agarose gel was prepared in 1x TBE buffer and 2 µl 
of GelRed DNA stain was added. Electrophoresis was carried out on 3 to 40 µl of 
PCR products for 50 minutes under 90 V. GeneRulerTM 1 kb and/or middle range 
DNA ladder was used to provide size markers and allowed for the estimation of PCR 
products size when visualised under UV (BioDoc-ItTM 2UV Transilluminator) at 365 
nm.  
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5.9 Spore stock preparation 
Spores of S. coelicolor, S. albus, and S. lividans strains were propagated by 
inoculation on SFM agar containing 50 µg/ml apramycin or hygromycin, depending 
on the resistance marker carried by each strain. Following incubation for 7 days, 5 ml 
of sterile distilled water was added to each plate and a sterile spreader was used to 
scrape off the bacterial spores. The bacteria–laden water was filtered through glass 
wool, centrifuged at 4000 rpm for 10 mins and the supernatant was discarded. 400 µl 
of sterile distilled water and 600 µl of sterile 50 % glycerol were added and the content 
was mixed thoroughly before transferring into a sterile cryotube for storage at -80 oC.  
5.10 Preparation of electrocompetent E. coli cells  
E. coli TOP10 was used in this study for maintaining and propagating plasmids and 
constructs, while E. coli ET12567/pUZ8002 (ET) served as the non-methylating host 
mediating the transfer of the constructs into Streptomyces by conjugation. 100 µl of 
the TOP10 or ET cells from – 80 oC was used to inoculate 10 ml of LB (supplemented 
with 50 µg/ml kanamycin and 25 µg/ml chloramphenicol in the case of E. coli ET) ) 
and were incubated overnight in a 37 oC shaker. The cells were refreshed the next day 
by inoculating 10ml LB with 100 µl of the overnight culture and incubating to an O.D 
600 of 0.4. The cells were pelleted by centrifuging at 4,000 rpm for 5 mins and the 
supernatant was discarded. The pellets were then washed twice with 10 ml ice-cold 
10 % glycerol and the supernatant discarded each time. The pellets were finally 
suspended in 100 µl 10 % glycerol and transferred into cryovials for storage at -80 oC 
pending their use for electroporation.   
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5.11 Construction of S. coelicolor strains W301 and W302, respective 
methylenomycin-resistant derivatives of W110 and M145 strains 
5.11.1 Purification of the plasmid pIJ86 carrying mmr gene 
100 µl of E. coli TOP10 (carrying the DNA construct pIJ86/mmr) from a glycerol 
stock was added to 5ml of LB medium containing 50 µg/ml apramycin and was 
incubated at 37 oC, 180 rpm overnight. Plasmid DNA was purified from the cells and 
the presence of the methylenomyin resistance gene mmr was confirmed by PCR 
amplification using mmr-fwd and mmr-rev primers provided in Table 5.6 and the 
components and conditions outlined below. The PCR product was analysed by  
Table 5.8: PCR mixture for amplifying mmr 
  
Component of PCR Volume (µl) 
Purified plasmid DNA 2.0 
Buffer with MgCl2 5.0 
dNTPs (10mM) 1.0 
mmr-fwd (10µM) 1.5 
mmr-rev (10µM) 1.5 
Taq DNA polymerase 0.5 
DMSO 5.0 
Distilled water 33.5 
TOTAL  50.0 
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Initial denaturation       94 oC     5 min 
Denaturation              94 oC     1 min 
Annealing     55 oC     1 min 33x 
Extension     72 oC     1.5 min 
Final extension   72 oC    10 min 
End and storage    4 oC 
 
agarose gel electrophoresis, which showed a single band corresponding to the 1.4 kb 
mmr. The construct was kept at – 20 oC pending further use.  
5.11.2 Transformation of E. coli ET12567/pUZ8002 
Purified plasmid pIJ86/mmr (2 µl) was added to 100 µl of electrocompetent E. coli 
ET12567/pUZ8002 cells and mixed gently before being transferred to an 
electroporation cuvette where 1.8 V was applied. 1 ml of ice-cold liquid LB medium 
was added and the mixture was incubated at 37 oC, 180 rpm for 1 hour. It was 
thereafter spread over solid LB plates containing apramycin (50 µg/ml), kanamycin 
(50 µg/ml) and chloramphenicol (25 µg/ml). The plates were incubated at 37 oC for 
18 hours to generate individual colonies.  
Transformation of the E. coli ET12567/pUZ8002 and E. coli TOP10 by the cosmid 
C73_787/mmyR::apr and its various mutated derivatives were also carried out in a 
similar manner. The selective plates however contained only apramycin in the case of 
TOP10 transformation.  
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5.11.3 Conjugation of E. coli ET12567/pUZ8002 with Streptomyces species 
The procedure described here was used to conjugate ET12567/pUZ8002 (ET) 
carrying pIJ86/mmr (from section 5.11.2) with S. coelicolor strains W110, M145 and 
S. albus J1074, and also for the conjugation of the ET carrying the cosmid 
C73_787/mmyR::apr or any of its mutated derivatives with S. coelicolor, S. albus or 
S. lividans as required. 
Single colonies of the E. coli ET12567/pUZ8002 carrying the required construct was 
inoculated into 5 ml LB medium containing kanamycin, chloramphenicol and 
apramycin. The culture was incubated overnight at 37 oC,  and 100 µl was added to 
10 ml LB containing the antibiotics and incubated for 5 hours (O.D600 approximately 
0.4). The cells were collected by centrifuging at 3000 rpm for 10 minutes, washed 
twice with liquid LB medium containing no antibiotics, and suspended in 400 µl of 
LB medium.  
400µl of liquid LB medium was added to a 50 µl spore stock of each of the 
Streptomyces strains from -80 oC glycerol stocks. The cells were then heat-shocked at 
55 oC for 10 minutes and were immediately transferred to an ice bath for 5 minutes. 
They were then mixed with the fresh cells of E. coli ET12567/pUZ8002 carrying the 
required construct. The mixture was centrifuged for 2 minutes at 10,000 rpm, half of 
the supernatant discarded, and the cells were resuspended in the remaining liquid. The 
resulting suspension was spread over three 25 ml solid SFM plates containing 100µl 
of 2.5 M MgCl2 and incubated overnight at 30 
oC. The plates were overlayed in the 
morning with 1ml of sterile water containing 25 µl of apramycin and 20 µl of nalidixic 
acid. The plates were then incubated at 30 oC for an additional 5 days. 
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Single colonies of the resulting Streptomyces transconjugants were picked and 
cultured on SFM plates containing apramycin and nalidixic acid. The inclusion of 
nalidixic acid ensured any residual E. coli that might be picked with the Streptomyces 
colonies were all eliminated. The plates were then incubated for 7 days and the spore 
stocks were generated. Strains W110 and M145 carrying the pIJ86/mmr construct 
were named W301 and W302 respectively. Table 5.3 provides the names of 
Streptomyces transconjugants carrying the cosmid C73_787 or its derivatives. 
Integration of the cosmid into these Streptomyces species was confirmed by LC-MS 
analysis of the resulting transconjugants which showed that they produced 
methylenomycin antibiotics and/or the methylenomycin furans relative to their 
respective wild type strains. Genetic confirmation was obtained for strains W301 and 
W302 as detailed in section 5.11.4. 
5.11.4 Colony PCR to confirm the presence of mmr in W301 and W302 
W301 and W302 strains were inoculated on SFM agar plates and were incubated at 
30 oC for 4 days. Wild type S. coelicolor M145 was also grown in parallel under the 
same conditions. Colonies of each of the strains were lysed using the following 
procedure: 1 loop of the spores was scrapped from the plates and 30 µl of fast 
screening lysis buffer was added. The mixture was incubated at 37 oC for 2 hours 
before adjusting to pH 8 with 1M HCl. The content was cooled on ice for 10 minutes 
and centrifuged at 13,200 rpm for 10 minutes. 20 µl of the resulting supernatant was 
diluted to 100 µl with sterile distilled water. 2 µl of this solution was analysed by PCR 
using the same primers and conditions outlined in section 5.11.1. The PCR products 
were analysed by agarose gel electrophoresis. 
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5.12 CRISPR/Cas9 deletion of mmyQ and mmyY 
5.12.1 Generation of the synthetic guide sequence as DNA 
sgRNA sequences required to delete mmyQ and mmyY were designed by searching 
for PAM (NGG) sequences near the beginning and the end of each gene. The CRISPR 
design tool at http://crispr.mit.edu was employed for the search and PAM sequences 
were selected that would lead to in-frame deletion of the genes. The 20 bp 
immediately upstream of the identified PAM sequences were then incorporated into 
the design of a primer which also contains the sequence for the T7 RNA promoter. 
The pairs of primers designed to respectively delete mmyQ and mmyY were mmyQ-
sgRNA-1/mmyQ-sgRNA-2 and mmyY-sgRNA-1/mmyY-sgRNA-2 (Table 5.5), with 
the 20 bp guide sequence underlined in each case. Each of the primers served as the 
forward primer in the initial extension PCR to amplify the full synthetic RNA 
sequence as DNA templates. The reverse primer for each of the PCR reaction was  
Table 5.9: PCR mixture and conditions for the generation of synthetic guide DNA 
templates for transcription to sgRNAs 
 
 
 
 
 
 
 
 
   
   
Component of PCR Volume (µl)  
pCRISPOmyces 2 DNA 0.5  
Forward primer (10µM) 2.0  
Reverse primer (10µM) 2.0  
Phusion® high-fidelity PCR mix 
(M0532S) 
25.0 
 
DMSO 1.5  
RNAse-free water 19.0  
   
   
TOTAL  50.0  
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Initial denaturation       98 oC     1 min 
Denaturation              98 oC     5 secs 
Annealing     58 oC     5 secs 35x 
Extension     72 oC     8 secs 
Final extension    72 oC    8 mins  
End and storage      4 oC 
 
sgRNA-rev (Table 5.5), while the plasmid DNA pCRISPomyces 2 served as the 
template.192 The conditions for the reaction are as detailed in Table 5.9. To confirm 
the presence of the expected synthetic guide sequence bands following the extension 
PCR, 1 µl of loading dye was added to 3 µl of the PCR products and were run on 2 % 
agarose gel at 90 V for 40 mins in TBE buffer and with super low range DNA ladder 
(50 bp) as marker.  
5.12.2 In vitro transcription of the synthetic DNA templates to mRNA (sgRNA) 
The PCR products from section 5.12.1 were purified directly with a GeneJet Gel 
extraction kit, omitting the steps for solubilising the gel, and the purified DNA was 
dissolved in 20 µl of RNAse/DNAse-free water. The transcription reaction was then 
set up as shown in Table 5.10 with HiScribeTM T7 high yield RNA synthesis kit (New 
England Biolabs) and incubated overnight at 37 oC. 
The RNA generated was purified with MEGAclearTM RNA purification kit 
(Invitrogen) and eluted with 20 µl of RNAse/DNAse-free water to yield: mmyQ-
sgRNA-1 (1,617 ng/µl), mmyQ-sgRNA-2 (1,467 ng/µl), mmyY-sgRNA-1 (719 ng/µl) 
and mmyY-sgRNA-2 (1,153 ng/µl). 
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Table 5.10 Reaction mixture for the transcription of synthetic guide DNA to RNA 
 
 
 
 
 
 
5.12.3 Phenol/Chloroform purification of cosmid DNA for CRISPR/Cas9 work 
E. coli TOP10 was transformed with the construct C73_787/mmyR::apr and 6 
colonies were selected following overnight incubation at 37 oC on LB agar 
supplemented with 50 µg/ml apramycin. The selected colonies were transferred into 
liquid LB containing apramycin and grown overnight at 37 oC. The cosmid DNA was 
isolated from each overnight culture by miniprep and eluted with 20 µl of 
RNAse/DNAse-free water, then combined to give 120 µl crude cosmid. 80 µl of 
phenol-chloroform mix (Acros Organics) was added, and the mixture was shaken for 
1 minute before centrifuging at 13,000 rpm for 5 mins. The supernatant (containing 
the cosmid DNA) was carefully transferred into a fresh tube and 50 µl of chloroform 
was added. The mixture was again shaken and centrifuged at 13,000 rpm for 5 
minutes. 55 µl of the supernatant was transferred into a fresh tube, 33 µl of isopropanol 
was added, and the mixture was left on ice for about 10 mins to precipitate DNA. The 
mixture was then centrifuged as before and the supernatant was discarded. 200 µl of  
70 % ethanol was added to the precipitate, and the mixture was shaken, centrifuged, 
and the supernatant discarded. The precipitate was allowed to dry in a flow hood for 
  
Reaction component Volume (µl) 
RNAse/DNAse-free water 2 
Reaction buffer (10x) 3 
UTP (100mM) 3 
ATP (100mM) 3 
GTP (100mM) 3 
CTP (100mM) 3 
DNA template (66 – 100 ng/µl) 10 
T7 RNA polymerase 3 
    
TOTAL 30 
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2 hours before 20 µl of pre-warmed (50 oC) RNAse/DNAse-free water was added to 
dissolve the DNA. 
 
5.12.4 Excision of mmyQ and mmyY by Cas9 nuclease 
In vitro CRISPR/Cas9-mediated reactions to delete mmyQ and mmyY were performed 
with Cas9 nuclease (New England Biolabs), and the prepared sgRNAs and the cosmid 
DNA, C73_787/mmyR::apr. The reactions were set up as detailed in Table 5.11. All 
components of the reaction (except the cosmid DNA) were first mixed and incubated 
at 26 oC for 10 mins before the cosmid DNA was added. The reaction was then 
incubated at 37 oC overnight. 
The edited DNA was ethanol precipitated the next day by adding 5 µl of 3M sodium 
acetate and 150 µl of absolute ethanol. The mixture was kept on ice for 1 hour before 
centrifuging at 13,500 rpm for 15 mins. The supernatant was discarded and the 
precipitated DNA was washed with 150 µl of 70% ethanol and again centrifuged for 
15mins. The DNA pellet was left to air dry for 3 hours and dissolved in 20 µl of water.  
 
Table 5.11: Reaction components for CRISPR/Cas9 excision of mmyQ and mmyY 
  
mmyQ                            mmyY 
mmyQ-sgRNA-1                4.0 µl (6,468 ng) mmyY-sgRNA-1                  6.5 µl (4,674 ng) 
mmyQ-sgRNA-2                4.5 µl (6,604 ng) mmyY-sgRNA-2                  4.0 µl (4,615 ng) 
Cas9 nuclease                       2.0 µl Cas9 nuclease                        2.0 µl 
Cas9 buffer                           3.0 µl Cas9 buffer                            3.0 µl 
RNAse/DNAse-free water   14.5 µl RNAse/DNAse-free water    12.5 µl 
Cosmid DNA                        2.0 µl (500ng) Cosmid DNA                         2.0 µl (500ng) 
    
TOTAL                                30.0 µl TOTAL                                  30.0 µl 
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5.12.5 End repair and ligation of Cas9-editted cosmid C73_787/mmyR::apr  
Since the SpCas9 nuclease has been shown to have exonuclease activity which trims 
the non-complementary strand following the double strand cleavage,198,200 the cosmid 
DNA from the Cas9 reaction was repaired at the cleaved ends. To each of the 20 µl 
DNA solutions, 0.3 µl of dNTPs (10 mM), 3 µl of Buffer 2.1 (10x, New England 
biolabs), 6.2 µl of water and 0.5 µl of T4 DNA polymerase (New England biolabs) 
were added. The mixture was incubated at 12 oC for 15 mins and the polymerase was 
inactivated by heating at 75 oC for 20 mins. 
The cosmid was then ligated directly by adding 3.3 µl of T4 DNA ligase buffer and 
1.5 µl of T4 DNA ligase (New England biolabs) to the mixture. The content was 
incubated overnight at 16 oC and terminated at 65 oC for 10 mins. 
5.12.6 Screening to identify mmyQ and mmY-mutated cosmids 
50 µl electrocompetent TOP 10 E. coli cells were transformed with 13 µl of the 
mixture from ligation and colonies were selected on LB agar plates supplemented with 
50 µg/ml apramycin following overnight incubation at 37 oC. Several individual 
colonies were picked and transferred into 100 µl of LB liquid (containing apramycin) 
in 96 well plates and incubated overnight in a 37 oC shaker. 2 µl of culture from cloudy 
wells (where the cells have grown actively) was used as template in the screening 
PCR reaction set up as shown in Table. 5.12. The screening primers for mmyQ 
mutation and mmyY mutation are the primers annealing 150 to 200 bp outside of the 
coding sequence for each gene and designated as mmyQ-scrn-fwd/mmyQ-scrn-rev and 
mmyY-scrn-fwd/mmyY-scrn-rev respectively (sequences provided in Table 5.5) 
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Table 5.12: PCR mixture and conditions for screening for ∆mmyQ and ∆mmyY 
constructs 
 
 
 
 
 
Initial denaturation       95 oC     4 mins 
Denaturation              95 oC     30 secs 
Annealing     58 oC     30 secs 35x 
Extension     72 oC     1 min 
Final extension    72 oC    10 mins 
End and storage      4 oC 
The remaining culture from wells which gave the expected bands after agarose gel 
electrophoretic analysis of the PCR products was transferred into 10ml LB containing 
apramycin and grown overnight at 37 oC. The mutated constructs were then isolated 
from the overnight cultures by miniprep. The PCR was repeated using the isolated 
constructs directly as templates, followed by sequencing using the PCR screening 
primers for mmyQ and mmyY to confirm gene deletion. 
E.coli ET 12567/pUZ8002 was transformed with the mutated constructs for onward 
transfer to Streptomyces spp. via conjugation (see section 5.11.3). 
 
   
Component of PCR Volume (µl)  
Template (E. coli culture or pure cosmid) 2   
Forward primer (10µM) 1  
Reverse primer (10µM) 1  
One-taq® Quick load® PCR (NEB) 10  
water 6  
  
 
TOTAL  20  
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5.13 Cloning and expression of mmyD in E. coli BL21* 
mmyD was amplified from the construct C73_787/mmyR::apr using Phusion high 
fidelity DNA polymerase and primers mmyD-fwd and mmyD-rev in Table 5.5. It was 
ligated into pET151 vector following guidelines provided in the ChampionTM pET 
TOPO® Expression manual.244 5 µl of the mixture from ligation was used to 
transform electrocompetent TOP10 E. coli cells and selection was done on LB plates 
supplemented with 100 µg/ml ampicillin. Colonies were grown overnight in liquid 
LB containing ampicillin and were screened by PCR using the mmyD-fwd primer and 
the T7 reverse primer (Table 5.5). Plasmid DNA was purified by miniprep from 
overnight cultures which gave the expected band in the PCR screening. The purified 
DNA was sequenced to confirm the presence of the cloned gene in the right 
orientation. The resulting construct pET151/mmyD was named pGI003. 
E.coli BL21* was transformed with pGI003, single colonies were selected with 
ampicillin on LB plates, and passed through liquid LB overnight at 37 oC. 2 ml of the 
overnight culture was used to inoculate 100 ml of M9 medium and the mixture 
incubated at 37 oC until O.D of 0.7 at 600 nm. IPTG was then added to a final 
concentration of 0.5 mM to induce mmyD expression. The culture was further 
incubated overnight at 15 oC, centrifuged at 10,000 rpm for 10 mins and the 
supernatant was adjusted to pH 3 with concentrated HCl. The supernatant was 
extracted with 150 ml ethyl acetate, then dried and dissolved in methanol for LC-MS 
analysis. The wild type E. coli BL21* was grown simultaneously in M9 medium 
containing 0.5 mM IPTG and the extract analysed by LC-MS for comparison with the 
E.coli BL21*/pGI003 culture extract. 
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5.14 Purification of compounds 
5.14.1 Purification of methylenomycin C (17) 
Fourteen square petri plates, each containing 50 ml of SMMS medium, were 
inoculated with spore suspensions of S. coelicolor W108 (M145 with 
C73_787/mmyR::apr/∆mmyF) and were incubated for 36 hours at 30 oC. The plates 
were then combined and acidified to pH 2 with 2M HCl solution prior to extraction 
with 800ml ethyl acetate. The organic extract was separated from the agar by filtration 
and was dried over magnesium sulphate. The solvent was removed under vacuum and 
the residue was dissolved in 2 ml of methanol. Methylenomycin C was purified from 
this solution by preparative HPLC (section 5.2.1). The retention time (RT) was 6.5 
minutes. 1H and COSY NMR were consistent with those previously assigned for 
methylenomycin C (17).173 
δH (400 MHz, CDCl3), 1.84 (s, 3H, H-8), 2.14 (s, 3H, H-9), 4.10 (s, 1H, H-1), 5.67 (d, 
1H, H-7b, J = 1.9 Hz), 6.22 (d, 1H, H-7a, J = 1.9 Hz) ppm; observed LC-HR-MS 
(positive mode) m/z = 167.0708 as [M + H]+  (Calculated for [C9H11O3]
+: 167.0703).  
5.14.2 Purification of methylenomycin A (16) from strain W303  
W303 (S. albus/C73_787 mmyR::apr) was inoculated on 18 plates of SMMS, each 
containing ca. 50 ml of the medium. The plates were incubated at 30 oC for 6 days, 
combined and acidified to pH 3 with 2M HCl before extraction with 1 litre of ethyl 
acetate. The agar was separated by filtration and the resulting organic extract was 
dried over magnesium sulphate. Ethyl acetate was then removed on a rotary 
evaporator and methylenomycin A (20 mg) was purified from the residue by flash 
column chromatography, Rf = 0.32 (silica, toluene/acetic acid 9:1). The purified 
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product was confirmed by 1H and COSY NMR analysis and data obtained were 
consistent with methylenomycin A (16) as determined previously.173 
δH (400 MHz, CDCl3), 1.43 (s, 3H, H-8), 1.52 (s, 3H, H-9), 3.77 (s, 1H, H-1), 5.60 (d, 
1H, H-7a, J = 1.5 Hz), 6.20 (d, 1H, H-7b, J = 1.5 Hz) ppm; observed LC-HR-MS 
(positive mode) m/z = 183.0650 as [M + H]+  (Calculated for [C9H11O4]
+: 183.0652). 
5.14.3 Purification of pre-methylenomycin C lactone (27) and conversion to pre-
methylenomycin C (26) 
Pre-methylenomycin C lactone (27) was purified by flash column chromatography, 
Rf = 0.42 (silica, toluene/ethanol  9:1), from a 1-Litre SMMS culture of S. coelicolor 
strain W86 (M145 with C73_787/mmyR::apr/∆mmyE), following the same procedure 
used to overproduce and purify methylenomycin A.  Alternatively, the compound was 
purified from the crude extract by preparative HPLC method (Rt = 6.2 minutes). 
The pre-methylenomycin C lactone was dissolved in CDCl3 and 
1H and 2D-NMR 
experiments were performed. Data obtained were fully consistent with the the 
structure of 27 as assigned previously.174 
δH (400 MHz, CDCl3), 1.73 (s, 3H, H-8), 2.26 (s, 3H, H-9), 3.34 (d, 1H, H-2, J = 7.27 
Hz), 3.66 (d, 1H, H-1, J = 7.28 Hz), 4.42 (dd, 1H, H-7b, J = 3.29 Hz), 4.57 (t, 1H, H-
7a, J = 9.68 Hz) ppm, observed LC-HR-MS (positive mode) m/z = 167.0700 as [M + 
H]+  (Calculated for [C9H11O3]
+: 167.0703). 
A 4 mg portion of the purified compound was dissolved in 1ml THF and hydrolysed 
to the free acid with 1ml of 10mM NaOH by stirring the mixture overnight at room 
temperature. The THF was evaporated and the remaining aqueous mixture was placed 
under high vacuum for several hours until all the liquid was removed to leave a 
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colourless residue of pre-methylenomycin C (26). The residue was dissolved in D2O 
and 1H and 2D-NMR experiments were carried out. Data obtained were fully 
consistent with those previously assigned for 26. 174 
                              
δH (400 MHz, D2O), 1.62 (s, 3H, H-8), 2.01 (s, 3H, H-9), 2.80 (q, 1H, H-2, J= 6.6 Hz), 
3.67 (d, 1H, H-1, J = 6.6 Hz), 3.79 (dd, 1H, H-7b, J= 5.90 Hz), 3.89 (dd, 1H, H-7a, J 
= 12.59 Hz) ppm, observed LC-HR-MS (positive mode) m/z = 167.0701 as [M + H - 
H2O]
+  and 207.0629 as [M + Na]+ (Calculated for [C9H11O3]
+: 167.0703 and 
[C9H12O4Na]
+: 207.0630 respectively )   
5.14.4 Purification of methylenomycin D1 (28) and methylenomycin D2 (29) 
Crude extract was obtained from S. coelicolor strain W108 (M145 with 
C73_787/mmyR::apr/∆mmyF) following the same procedure as for methylenomycin C 
purification (section 5.14.1), with the exception that incubation was continued for 7 
days. Methylenomycin D1 and D2 were first separated from the crude extract by flash 
column chromatography (silica, toluene/acetic acid 9:1). The solvent was evaporated 
under vacuum and the mixture of diastereoisomers was re-dissolved in 1.5 ml of 
methanol. The two compounds were thereafter separated by preparative HPLC 
(section 5.2.1). 
Methylenomycin D1(28) eluted from the column at 5.9 minutes while 
methylenomycin D2 (29) eluted at 6.7 minutes. 2mg of methylenomycin D1 was 
finally obtained while methylenomycin D2 was 4mg. The compounds were dissolved 
in CDCl3 and confirmed by NMR analysis as previously reported.
174 
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Methylenomycin D1 (28): δH (400 MHz, CDCl3), 1.25 (d, 3H, H-7, J = 7.48 Hz), 1.78 
(s, 3H, H-8), 2.07 (s, 3H, H-9), 2.72 (m, 1H, H-2), 3.79 (d, 1H, H-1, J = 7.28 Hz) ppm; 
LC-HR-MS (positive mode) m/z = 169.0862 as [M + H]+  (Calculated for [C9H13O3]
+: 
169.0859). 
Methylenomycin D2 (29): δH (400 MHz, CDCl3), 1.27 (d, 3H, H-7, J = 7.42 Hz), 1.78 
(s, 3H, H-9), 2.11 (s, 3H, H-9), 2.66 (m, 1H, H-2), 3.21 (s, 1H, H-1) ppm; LC-HR-
MS (positive mode) m/z = 169.0860 as [M + H]+  (Calculated for [C9H13O3]
+: 
169.0859)  
5.15 Feeding experiments 
5.15.1 Feeding of methylenomycin C (17) to W301 and W302 
70 µl each of S. coelicolor strains W301 (M145/pOSV556/mmyOF/pIJ86mmr) and 
W302 (M145/pIJ86mmr) from glycerol stock were used to inoculate Alamm (pH 5) 
plates containing sterile semi-permeable membrane. After 48 hours of incubation at 
30 oC, 200 µl of a solution of methylenomycin C in DMSO (1 mg/ml) was fed in drops 
to each strain using a pipette. The plates were further incubated for 4 days before the 
cells were scrapped off the membrane and suspended in 20 ml of methanol in conical 
flasks. These were left for about 2 hours with intermittent shaking to dissolve 
compounds. 1ml of the extract was taken in each case and was passed through column 
centrifuge filters at 8,000 rpm prior analysis by LC-MS.  
Feeding experiments with other methylenomycin C analogues/intermediates and 
strains were carried out similarly. 
5.15.2 Feeding of 13C-labelled D-ribose to Streptomyces coelicolor strains 
expressing mmy gene cluster 
[U-13C]-D-ribose was purchased from Cambridge Isotope Laboratories (Andover, 
USA). The supplemented minimal medium was modified for the feeding experiment 
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in order to observe significant incorporation of the labelled precursor: D-Glucose was 
reduced from 1 % to 0.2 % (w/v) and 0.2 % casamino acids was used instead of 0.25 
% (w/v) L-Alanine.  
25 ml of the modified SMM medium was inoculated separately with 100 µl of strain 
W108 (M145/C73_787/mmyR::apr/∆mmyF) and W100 (M145/C73_787/mmyR:: 
apr/∆mmyO), as well as the heterologous host M145, both directly from -80 oC 
glycerol stocks. After incubation at 30 oC for 6 hours in a 180 rpm shaker, 1ml of 
sterile water containing 25 mg of [U-13C]-D-ribose was added to each flask. 
Incubation was continued for an additional 72 hours before the cultures were filtered 
and the filtrate adjusted to pH 3 with 2 M HCl. The filtrates were then extracted with 
an equal volume of ethyl acetate, dried on a rotary evaporator and dissolved in an 
appropriate amount of methanol for analysis by LC-MS. 
5.16 Microbiological assays 
5.16.1 Determination of the minimum inhibitory/bactericidal concentration 
(MIC/ MBC)  
The minimum inhibitory concentrations (MICs) of methylenomycin compounds 
against Gram-positive and Gram-negative strains were determined by broth 
microdilution in 96-well microtiter plates according to the CLSI guidelines.101,245 
Cells growing in exponential phase were diluted to ca. 105 CFU/ml into cation-
adjusted Mueller-Hinton broth (MHB) before addition of methylenomycin 
compounds to final concentrations ranging from 0.5 to 512 µg/ml in 100 µl culture 
aliquots. 50 times concentrated stocks of methylenomycin compounds to give the final 
concentrations upon dilution were prepared in DMSO and control experiments with 
only DMSO added to the wells were carried out in all cases. Enterococci strains were 
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grown and diluted with Medium 92. Strains were incubated for 20 hours (or up to 48 
hours in the case of Streptomyces spp. and yeast) before visual inspection for growth.  
Minimum bactericidal concentrations (MBCs) were determined with the 
AlamarBlueTM fluorescence assay. 10 µl of the AlamarBlueTM dye was added to each 
well from the MIC plates and were further incubated for 2 hours. Fluorescence 
measurements were recorded at excitation wavelength (530 nm) and emission 
wavelength (590 nm) on a BioTek Synergy HT multi-detection microplate reader. 
MBCs correspond to the point at which sudden fall in the fluorescence-concentration 
curve was observed, and were further confirmed by sub-culturing wells at such 
concentration levels onto antibiotic-free agar plates and incubating for up to 3 days 
with no visible growth.  
5.16.2 Development of resistant strains of Enterococcus faecium (64/3) via the 
sequential method 
In order to investigate whether E. faecium (64/3) could develop resistance to pre-
methylenomycin C and pre-methylenomycin C lactone, this strain was passed 
sequentially through increasing levels of the antibiotics beginning from sub-lethal 
concentrations. Vancomycin, an antibiotic to which Enterococcus strains often 
develop resistance, 246,247 was used as the control in a parallel experiment. The MICs 
of these compounds against E. faecium 64/3 were first determined as detailed in 
section 5.16.1. MIC-type assays were then set up with 0.25 x MIC, 0.5 x MIC, 1 x 
MIC, 2 x MIC and 4 x MIC final concentrations of the three compounds and incubated 
overnight.101 Culture medium containing the highest concentration of each compound 
that allowed active growth of the bacterial cells was diluted 100 times with fresh M92 
medium and the diluted cultures were used to re-set up the experiment which were 
again incubated overnight. This procedure continued for 28 consecutive days while 
  Chapter Five - Materials & methods 
168 
 
the concentration of compounds in the assay was consistently increased in instances 
where the strain was already able to survive the initial highest concentration of 4 x 
MIC.  
At every 4 days during the 28-day lifetime of the run, 10 µl of culture from the highest 
concentration well which allows growth was streaked onto antibiotic-free M92 agar 
plates and grown overnight. 5 colonies were then selected from each plate, grown 
overnight in M92 broth and MIC of the strains was determined by the normal single 
step standard procedure. This was used to confirm whether the selected colonies had 
MICs above the parent E. faecium strain (resistance acquired).  
5.16.3 Bioluminescence experiment with the luciferase reporter strains 
Bacillus subtilis strains carrying the promoter regions of yorB, yvgS, yheI, ypuA, and 
fabHB, each fused to a firefly luciferase (reporter) gene, were originally constructed 
by Urban et al.213 Erythromycin is used for routine growing of the strains while 
ciprofloxacin, rifampin, linezolid, vancomycin, and cerulenin are the standard 
antibiotics known to induce the yorB, yvgS, yheI, ypuA, and fabHB promoters 
respectively.  
All methylenomycin compounds used for the assay were purified as detailed in the 
previous sections. Solutions of methylenomycin compounds and the standard 
antibiotics were prepared by dilution from an initial 1 mg/ml stock of each compound 
in DMSO. 
The strains were incubated at 37 oC in liquid LB medium containing 5 µg/ml 
erythromycin to an O.D600 of 0.9; only the yheI biosensor strain was grown in Belitzky 
minimal media (BMM) containing 5 µg/ml erythromycin to the same O.D value. The 
strains were then diluted with either LB or BMM as applicable to different O.D600 
  Chapter Five - Materials & methods 
169 
 
values: 0.01, 0.02, 0.1, 0.02 and 0.25 for yorB, yvgS, yheI, ypuA and fabHB 
respectively, and were kept at 4 oC overnight. The following morning, 80 µl of each 
strain was incubated in a 96-well plate at 37 oC with 1 µl solution of methylenomycin 
compounds or the standard antibiotics from stock solutions of 25 µg/ml, 6.25 µg/ml 
and 1.56 µg/ml. Incubation times differ for the different strains and they were: 1 hr 
(ypuA), 1.5 hrs (yvgS), 3 hrs (yorB and fabHB) and 4 hrs (yheI).213,214 
After incubation, 50 µl of 0.1M Citrate buffer containing 2 mM luciferin was added 
to each well and the plate was swirled gently before measuring Luminescence for 30 
seconds.  
5.16.4 Assay with the β-galactosidase reporter strains 
β-galactosidase Bacillus reporter strains in which the promoter regions of yvgS, yheH, 
yvgI, ypuA, and yjaX were fused to the β-galactosidase gene were obtained from 
Demuris Limited, Newcastle, UK. Erythromycin antibiotic was used for routine 
growing and selection of the strains, while rifampicin, chloramphenicol, bacitracin, 
vancomycin and triclosan were used as the positive control antibiotics inducing the 
yvgS, yheH, yvgI, ypuA, and yjaX promoters respectively. 
To carry out the assay, 1 % nutrient agar was prepared and supplemented with 
erythromycin and X-gal to 50 µg/ml and 100 µg/ml final concentrations respectively. 
25 µl of each reporter strain was used to inoculate 25 ml of the nutrient agar while 
still warm, and the mixture was poured into petri dishes and allowed to solidify. A 
sterile filter was placed in the middle of each plate and 10 µl of a 3 mg/ml solution of 
a standard antibiotic or a methylenomycin compound (dissolved in DMSO) was 
placed on the filter. Control experiments with only DMSO placed on the filters were 
also set up simultaneously for each reporter strain. The plates were incubated for 48 
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hours at 27 oC. A zone of inhibition with blue colouration around the circumference 
of inhibition indicated an induction of a given promoter.
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Appendices 
Appendix 1: Data from sequencing of constructs pGI001 (C73_787/mmyR::apr/ ∆mmyQ) 
and pGI002 (C73_787/mmyR::apr/∆mmyY) 
Appendix 2: NMR spectra of purified methylenomycin compounds 
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Appendix 1 
 
Fig. A1: Sequence alignment of the mutated construct C73_787/mmyR::apr/∆mmyQ (Query) 
against the complete sequence of the C73_787/mmyR::apr cosmid (Subject). The missing 
nucleotides on the query sequence correspond to the 603 bp sequence of mmyQ which has 
been deleted by Cas9 editing.  
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Fig. A2: Sequence alignment of the mutated construct C73_787/mmyR::apr/∆mmyY (Query) 
against the complete sequence of the C73_787/mmyR::apr cosmid (Subject). The missing 
nucleotides on the query sequence correspond to the 375 bp sequence of mmyY which have 
been deleted by Cas9 editing.  
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Appendix 2: NMR spectra of purified methylenomycin compounds 
 
 
 
 
     Fig. A3: 1H NMR spectra of methylenomycin A (16) 
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     Fig. A4: COSY NMR spectra of methylenomycin A (16) 
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 Fig. A5: 1H NMR spectra of methylenomycin C (17) 
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     Fig. A6: COSY NMR spectra of methylenomycin C (17) 
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     Fig. A7: 1H NMR spectra of pre-methylenomycin C (26) 
 
 
 
 
  Appendices 
197 
 
 
 
 
 
     Fig. A8: COSY NMR spectra of pre-methylenomycin C (26) 
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     Fig. A9: 1H NMR spectra of pre-methylenomycin C lactone (27) 
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     Fig. A10: COSY NMR spectra of pre-methylenomycin C lactone (27) 
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     Fig. A11: 1H NMR spectra of methylenomycin D1 (28) 
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  Fig. A12: COSY NMR spectra of methylenomycin D1 (28) 
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     Fig. A13: 1H NMR spectra of methylenomycin D2 (29) 
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     Fig. A14: COSY NMR spectra of methylenomycin D2 (29) 
 
 
